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Abstract 
Coronary Heart Disease risk: family history and gene-environment interaction. 
Ph.D. thesis. Agricultural University Wageningen and the National Institute of Public Health and 
the Environment, Bilthoven, the Netherlands. 
Jolanda MA Boer 
The first part of this thesis describes research into lifestyle, genetic, and biological factors that 
may underlie the increased risk for coronary heart disease (CHD) in individuals with a family 
history of this disorder. The second part of this thesis describes whether levels of plasma lipids 
and lipoproteins - which are among the major CHD risk factors - are influenced by the interaction 
between common gene polymorphisms and lifestyle-related factors. A large cohort study was 
used to evaluate the association between family history and CHD mortality. The association of 
family history with gene polymorphisms, lifestyle-related and biological CHD risk factors, as well 
as gene-environment interactions were studied cross-sectionally. For this purpose subsamples 
from a large population-based project (the Cardiovascular Disease Risk Factor Monitoring 
Project) and the European Atherosclerosis Research Study (EARS) were used. 
Family history increased the risk for CHD death in men and women. Only a small part was 
mediated through known CHD risk factors. The most pronounced characteristics of individuals 
with a family history were the higher levels of total cholesterol and apolipoprotein (apo) B as 
compared to subjects without a family history. The contribution of lifestyle-related (i.e. 
modifiable) factors to higher apo B levels in individuals with a family history was small; most of it 
seemed to be genetically determined. The apo E polymorphism is probably one of the most 
important genetic factors involved. Besides the apo E4 isoform, the D9N mutation and the 
N291S mutation in lipoprotein lipase (LPL) were more frequent among subjects with a parental 
history of premature myocardial infarction. Other gene polymorphisms (LPL S447X, CETP TaqlB 
and apo Clll Sstl) proved to be non-informative. 
Like family history, genotypes cannot be modified. However, the effect of some 
polymorphisms clearly depended on lifestyle-related factors. A significant interaction between 
the apo E2 isoform and body mass index was found in EARS as well as in the population-based 
sample of Dutch origin. Surprisingly, in EARS the association between BMI and apo B levels 
was more pronounced in E2-carriers compared to subjects with other phenotypes, while in the 
Dutch sample the association was weaker in apo E2-carriers. Further, a strong interaction 
between the LPL D9N mutation and physical activity became apparent. Physically inactive 
carriers of the mutation (n=5) had considerably higher total cholesterol and apo B levels 
compared to non-carriers, whereas their HDL-cholesterol concentrations were lower. This was 
not the case for physically active carriers of this mutation (n=10). Our studies also showed that 
only among moderate alcohol consumers, subjects with the CETP B2B2 genotype presented 
with higher mean HDL-cholesterol levels compared to subjects with other genotypes. 
Furthermore, smokers with the apo Clll S1S2 genotype had higher levels of triglycerides and 
apo B and somewhat lower levels of HDL-cholesterol, as compared to smokers with the S1S1 
genotype. This was not observed among non-smokers. 
It is firstly concluded that the underlying mechanisms for the increased risk in individuals with 
a family history of CHD remain unclear. The risk of CHD is highest in individuals with a family 
history and unfavorable levels of other CHD risk factors. Therefore, assessing family history is 
important for risk prediction and prevention, despite the fact that family history by itself cannot be 
changed. Since little is known about the most useful definition of a family history more large 
long-term prospective studies are needed. Secondly, gene-environment interaction implies that a 
genetic predisposition to unfavorable lipid levels, and consequently CHD risk, is not in all cases 
something of which the consequences cannot be influenced. However, our insights into specific 
gene-environment interactions is limited. More research is needed before knowledge about 
gene-environment interactions can be applied for better focusing preventive measures to 
subgroups in the population that are susceptible to CHD. 
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Background 
Coronary heart disease (CHD) is still the leading cause of death in the 
Netherlands and other western societies.13 Despite the 40-45% decrease in age-
adjusted CHD mortality between 1972 and 1994 in the Netherlands, there is an 
increase in the prevalence of coronary heart disease, especially in the age group of 
65 years and over.34 Trends in CHD mortality and hospitalization rates indicate that 
there is a strong shift from acute to more chronic forms of the disease.3 Taken this 
shift together with the future increase in population size and the proportion of elderly 
persons, the prevalence of CHD will even further increase. It is expected that the 
prevalence of CHD will increase from 154.400 cases in 1994 to about 224.000 
cases in 2015.3 Therefore CHD remains one of the most important public health 
problems. 
The etiology of coronary heart disease is multifactorial with many lifestyle, 
biological and genetic factors contributing to its development. Smoking, high intake 
of dietary saturated fat and cholesterol, and a lack of physical activity are known to 
increase the risk of CHD, while moderate alcohol consumption decreases the risk.5 
Overweight, high blood pressure, diabetes and lipid disorders are well known 
examples of biological risk factors.5 Furthermore, a genetic component in CHD 
development is generally acknowledged.6 Possibly, many genetic factors are 
involved, but only a few of them have been identified so far. Therefore, family history 
of coronary heart disease has often been used as a proxy for genetic susceptibility 
to the disease. 
Family history and coronary heart disease 
A positive association between family history and coronary heart disease has 
been observed in several prospective and case-control studies. Although these 
studies varied in their definition of family history as well as in the outcome measure, 
the results have been highly consistent. Prospective studies have shown that a 
parental history of CHD or myocardial infarction (Ml) is associated with a 1.3-2 fold 
increase in the risk of CHD or Ml.714 Estimates from case-control studies are of 
similar magnitude.1517 However, a sibling history of CHD may increase the risk two to 
more than five times.151719 More generally, CHD risk is especially increased in 
individuals with a family history when they or their affected relatives are 
young.791213171920 Assuming that family history is a good proxy for genetic 
susceptibility, these findings corroborate those of Marenberg et al. in a study among 
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Swedish twins.6 They suggested that premature CHD is more genetically determined 
than late-onset forms of the disease. 
Although the association between family history and coronary heart disease is 
clearly established, family history by itself provides little information about the 
mechanisms by which it contributes to the risk of disease. 
Explanations for the family history - CHD association 
Several mechanisms may underlie the positive association between family history 
and CHD risk (Figure 1). 
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Figure 1. Possible mechanisms underlying the association between family history 
and coronary heart disease. Clustering of genes and lifestyle in families influences A) 
levels of known biological risk factors and B) levels of unknown biological risk factors and 
consequently CHD risk. C) Subjects with a family history may be more susceptible to the 
unfavorable effects of risk factors on CHD. 
Besides genotypes, lifestyle factors, such as smoking and dietary habits, may 
cluster in families.21'23 These genetic and lifestyle factors may influence known 
biological CHD risk factors, which in their turn increase CHD risk (Figure 1, 
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mechanism A). Smoking, high blood pressure and high serum cholesterol levels are 
the three major risk factors for CHD.24 Furthermore, overweight and diabetes 
increase CHD risk.2527 It can be hypothesized that these risk factors explain most of 
the association between family history and coronary heart disease. Several 
investigators tested this hypothesis. However, after adjustment for these risk factors 
(smoking status, plasma total cholesterol, blood pressure, diabetes and body mass 
index) family history remained predictive for CHD.7911121415'2829 This implies that other 
lifestyle and biological risk factors for coronary heart disease, such as physical 
inactivity and thrombogenic factors5, may account for some of the increased risk in 
individuals with a family history of CHD. Moreover, genetic and lifestyle factors may 
affect other yet unknown risk factors and thereby CHD risk (Figure 1, mechanism B). 
In addition to these two mechanisms, subjects with a family history may be more 
susceptible to the unfavorable effects of risk factors on CHD (Figure 1, mechanism 
C). For example, the risk of CHD associated with cigarette smoking or 
hypercholesterolemia, may be higher for individuals with a family history of CHD 
than for those without a family history.2030 However, definite conclusions cannot be 
drawn, because the evidence sofar is contradictory.9,12'4,1529'31 The inconsistencies 
may in part be ascribed to methodological issues, such as differences in the 
methods of statistical interaction-testing. 
The role of lipid metabolism 
The underlying pathological condition for coronary heart disease is 
atherosclerosis.32 This paragraph describes the current state of knowledge about the 
atherosclerotic process and the role of lipid metabolism therein. One of the first 
steps in the atherosclerotic process is the collection of cholesterol-laden foam cells 
beneath the endothelium. These lesions may progress in size and complexity, 
resulting in lipid-rich plaques. Rupture or disruption of the lipid-rich plaque may lead 
to acute coronary occlusion with subsequent myocardial infarction, unstable angina 
or ischemic sudden death.3334 Alternatively, rupture of the lipid-rich plaque may result 
in the formation of mural thrombus, with a subsequent increase in stenosis, possibly 
resulting in angina. The atherosclerotic process may progress further, resulting in 
severely stenotic or occlusive plaques.34 There is broad consensus about the role of 
cholesterol in the atherosclerotic process. Epidemiological evidence shows that 
besides plasma cholesterol35, elevated plasma triglyceride levels are associated with 
an increased risk of CHD.36 
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Since cholesterol and triglycerides are hydrophobic compounds, they are 
transported throughout the body in lipoproteins. The metabolism of cholesterol and 
triglycerides - in which the liver is the central organ - can be subdivided into three 
parts: (1) the exogenous pathway, (2) the endogenous pathway and (3) reverse 
cholesterol transport (reviewed in 3739). With regard to exogenous lipid transport (left 
side of Figure 2), dietary cholesterol and triglycerides are processed in the intestinal 
lumen, absorbed and packaged into chylomicrons, which are secreted into the lymph 
and subsequently enter the circulation. The triglycerides in the core of the 
chylomicron particle are hydrolyzed by the enzyme lipoprotein lipase (LPL) with 
apolipoprotein (apo) Cll as a co-factor. The now cholesterol-enriched chylomicron 
remnants are efficiently cleared by hepatic remnant-receptors, which recognize apo 
E on their surface. 
Dietary cholesterol 
and triglycerides 
\ ; JpioBlOO 
Chylomicrons 
CM-remnants 
Figure 2. Schematic illustration of the exogenous and endogenous pathways of lipid 
metabolism. Apo: apolipoprotein, LPL: lipoprotein lipase, HL: hepatic lipase, VLDL: very 
low density lipoprotein, IDL: intermediate density lipoprotein, LDL: low density lipoprotein. 
The first step in the endogenous lipid pathway (right side of Figure 2) is the 
secretion of cholesterol and triglycerides in the form of very low density lipoproteins 
(VLDL) by the liver. Like in chylomicrons, triglycerides in VLDL are hydrolyzed by 
LPL, resulting in the formation of smaller intermediate density lipoprotein (IDL) 
particles. IDL can be cleared from the circulation by the remnant- or LDL-receptor 
and apo E serves as a ligand for this receptor-mediated uptake of IDL. The 
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triglycerides in IDL can also be further hydrolyzed by LPL or hepatic lipase (HL) to 
form low density lipoproteins (LDL) that are recognized and taken up by the LDL-
receptor on the liver and peripheral tissues via apo B-100. High plasma LDL 
concentrations will increase LDL concentrations in the intima and consequently the 
risk of foam cell formation.34 
receptor 
,kJ HDL2 TG-rich 9L°L 
nascent HDL 
aPo/f~\ 
^ ^ r * 
HDL 2 
CE-rich 
( j V L D L 
Extrahepatic tissue 
Figure 3. Schematic illustration of reverse cholesterol transport. Apo: apolipoprotein, 
CETP: cholesteryl ester transfer protein, LCAT: lecithin:cholesterol acyltransferase, VLDL: 
very low density lipoprotein, IDL: intermediate density lipoprotein, LDL: low density 
lipoprotein, HDL: high density lipoprotein. 
The transport of cholesterol from peripheral tissues back to the liver is known as 
'reverse cholesterol transport' (Figure 3) and the high density lipoprotein (HDL) 
particle plays a central role in this process.39 Nascent HDL, a disk-shaped particle 
that is produced in the intestine and liver, takes up free cholesterol from extrahepatic 
cells. This cholesterol is esterified by the enzyme lecithinxholesterol acyltransferase 
(LCAT), which utilizes apo Al as a co-factor. The more hydrophobic cholesteryl 
esters migrate to the core of the HDL particle, thereby changing its shape into a 
more spherical particle (HDL3). Further uptake of cholesterol and the action of LCAT 
will turn HDL3 into larger-sized cholesteryl ester-rich HDL2. Subsequently, cholesteryl 
esters are transferred to apo B containing lipoproteins (VLDL, IDL and LDL) in 
exchange for triglycerides by the action of cholesteryl ester transfer protein (CETP). 
This process results in triglyceride-rich HDL, and enables the hepatic uptake of 
16 Chapter 1 
cholesteryl esters via LDL and VLDL. A portion of HDL2 can be removed from the 
circulation by direct action of the HDL-receptor. Additionally, triglycerides in HDL, 
may be hydrolyzed by hepatic lipase, converting HDL, back to HDL3> which will again 
serve as acceptor of free cholesterol. Epidemiological studies have shown that high 
plasma HDL-cholesterol levels are associated with a reduced risk of CHD.40 
It should be clear that variation in the structure, function or activity of enzymes, 
receptors, and apolipoproteins - that act as ligands, cofactors or inhibitors of 
metabolic processes - may influence lipid metabolism and consequently plasma lipid 
and (apo)lipoprotein levels. In the search for candidate genes for dyslipidemias and 
coronary heart disease much attention has therefore been focused on the 
identification of mutations and polymorphisms in the genes that code for these key 
factors in lipid metabolism. 
Genes and lipid metabolism 
Several familial lipid disorders have been described.4"12 Only for a few of them, 
the underlying genetic defects are known. For example, familial defective apo B100 
is caused by a mutation (Arg3500 -> Gin) in the apo B gene, while familial 
hypercholesterolemia is caused by mutations at the LDL-receptor locus, resulting in 
fewer or defective LDL-receptors. Both disorders are associated with large increases 
in LDL-cholesterol and affect about 1 in 500 persons. Even rarer are familial 
disorders that result in severe HDL deficiency, such as LCAT defects or LPL 
deficiency. Since the underlying mutations are so rare, these mutations contribute 
little to the total variation in lipid and lipoprotein levels in the general population. 
Possibly, gene variants which have small effects but which are common account 
for most of the inter-individual variation in plasma lipid levels. Until now, the Apo E 
polymorphism is the most important common gene variant that has been described. 
It explains about 3-15% of the inter-individual variation in total cholesterol, LDL-
cholesterol and apo B levels.4346 Numerous polymorphisms have been detected in 
genes that code for the other apolipoproteins (for reviews see 4749). Some restriction 
fragment length polymorphisms (RFLP's) in the Apo B gene, such as those detected 
with restriction enzymes Xbal and ecoRI, have been associated with plasma apo B 
and cholesterol levels. However, they explain less of the inter-individual variation in 
plasma lipid levels in the general population than does the apo E polymorphism. 
Variation in the Apo AI-CIII-AIV gene cluster is more likely to affect HDL-cholesterol 
and triglyceride levels. The most consistent association found for a polymorphism in 
this gene cluster is probably the association of the apo Oil I Sstl RFLP with 
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hypertriglyceridemia. Furthermore, an A -> G transition in the apo Al promotor 
region has been associated with higher apo Al and HDL-cholesterol levels.4850 Most 
of these polymorphisms are caused by sequence changes outside the coding 
regions of the genes and therefore do not alter the amino acid sequences of the 
proteins. Possibly, they are in linkage disequilibrium with other mutations that are 
actually responsible for the effects on lipid metabolism. 
Besides apolipoproteins, also enzymes and transfer proteins that are involved in 
lipid metabolism have been studied. In addition to some missence mutations, at 
least four common functional mutations in the LPL gene have been described.51 Two 
of them (N291S and D9N), have been associated with elevated triglyceride and 
lowered HDL-cholesterol levels. For another mutation (-93 G-»T), which shows 
strong allelic association with the D9N mutation, associations with plasma lipids and 
lipoproteins have been less consistent.5152 Carrier frequencies for these mutations 
are rather low (2-5%). A C to T transversion that results in a truncated LPL protein 
(S447X), is much more common (20%) and has been associated with favorable 
effects on plasma HDL-cholesterol and triglyceride levels.51 Furthermore, 
heterogeneity at the CETP gene locus has been associated with variation in plasma 
HDL-cholesterol levels, and especially the TaqlB polymorphism has been frequently 
studied.53 Recently, an association between a common mutation in the gene coding 
for hepatic lipase and plasma lipid levels was descibed.5455 
The here described common gene variations have a rather small effect on plasma 
lipid levels. However, in combination with other factors, such as those related to 
lifestyle, their effects may be greater. 
Gene-environment interaction 
Although an important contribution of gene-environment interactions to inter-
individual variability in plasma lipid levels is generally acknowledged56, our current 
knowledge is limited. Most attention has focused on the evaluation of interactions 
between genes and diet, usually through intervention studies (for reviews see 57'60). 
However, it has not yet become general practice to take gene-environment 
interaction into account in observational genetic association studies. Moreover, little 
attention is given to factors that are not directly related to diet. Usually the role of 
specific gene-environment interactions is evaluated only when earlier studies have 
suggested that such interaction might exist. For example, in 1995, two research 
groups reported that the unfavorable effect of the LPL N291S mutation on plasma 
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triglyceride levels was more pronounced in individuals with a high body mass 
index.6162 Since then, most researchers evaluated the possible modulating effect of 
BMI when studying associations between LPL mutations and lipid traits. However, 
possible interactions with other lifestyle-related factors are generally ignored. 
General objectives 
The objectives of the research described in this thesis were twofold. The first 
objective was to identify genetic, lifestyle and biological factors that may explain the 
association between family history of myocardial infarction and coronary heart 
disease. Although this association is clearly established, the mechanisms behind it 
remain unclear. In particular, little is known about genetic factors that may underlie 
the increased risk of CHD in individuals with a family history. We studied several 
polymorphisms that are related to lipid metabolism. Initially, we included the apo E 
polymorphism and Lp(a), a lipoprotein that is for 90% genetically determined6364, in 
our investigations. These were likely candidates to start with, since the apo E 
polymorphism is the most important common genetic determinant of plasma 
cholesterol levels, and elevated Lp(a) levels are one of the most prevalent inherited 
risk factors for myocardial infarctions.6566 In addition, we had the opportunity to study 
three functional mutations in the LPL gene (N291S, D9N and S447X), and two 
restriction fragment length polymorphisms at the CETP (TaqlB) and apo OlII (Sstl) 
loci. 
Since little is known about the role of gene-environment interactions in relation to 
plasma levels of lipids and lipoproteins, our second objective was to evaluate how 
the gene polymorphisms that we investigated interact with lifestyle-related factors. 
For this purpose we studied interactions with body mass index, fat distribution, 
smoking, physical activity, alcohol consumption and the plasma cholesteryl ester 
linoleate-to-oleate ratio (used as a biomarker of the polyunsaturated-to-saturated 
fatty acid composition of the diet). All these factors are known to influence lipid 
metabolism themselves. 
Outline of the thesis 
Several parts of the mechanisms that may underlie the association between 
family history and CHD risk were studied. The results have been described in the 
first part of this thesis (Chapter 2-5). Whether known lifestyle and biological risk 
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factors explain the association between family history of Ml and 12-year CHD 
mortality is described in Chapter 2. The study population consisted of more than 
45.000 men and women who participated in the Consultation Bureau Heart Project. 
In this chapter, also the hypothesis that individuals with a family history are more 
susceptible to the unfavorable effects of other risk factors on CHD was tested. 
For other studies described in the first part of this thesis {Chapter 3-5), information 
and blood samples were used that were gathered as part of the Monitoring Project 
on Cardiovascular Disease Risk Factors, a large monitoring project in the 
Netherlands. In this monitoring project, parental history of myocardial infarction was 
assessed based on questionnaire information provided by the participants. However, 
self-reported information is subject to error and misclassification might lead to bias. 
A study was undertaken to assess the validity and reproducibility of parental history 
of myocardial infarction and the results are described in Chapter 3. 
In Chapter 4 differences in plasma lipid and lipoprotein levels according to 
parental history of premature myocardial infarction are described. This chapter 
mostly focuses on the extent to which lifestyle factors and polymorphisms involved in 
lipid metabolism (the apo E polymorphism, LPL N291S, D9N and S447X, CETP 
TaqlB and apo Clll Sstl) may account for the observed differences. 
The association of lifestyle factors and the apo E polymorphism with lipid profiles 
reflecting low, intermediate and high risk of myocardial infarction was studied in 
another sample and described in Chapter 5. Although this study was not directly 
related to family history, the studied associations are part of the mechanisms 
described in Figure 1. 
The second part of this thesis will further address the association between genetic 
factors and lipid traits, but focuses on gene-environment interaction. Whether the 
apo E polymorphism modulates associations between plasma lipid traits and 
lifestyle-related factors was studied in two different populations. The first study was 
conducted with data of the European Atherosclerosis Research Study (EARS), a 
multi-center study among students in 11 countries throughout Europe (Chapter 6). 
The second study, described in Chapter 7, uses the sample that was originally 
selected to assess the association between parental history of Ml and 
polymorphisms (see chapter 4). Chapters 8 and 9 describe how in the latter sample 
the effects of three other gene polymorphisms (LPL D9N, CETP TaqlB and apo Clll 
Sstl) on plasma lipid levels were modulated by factors that are related to lifestyle. 
A general reflection on our results and a general conclusion based on these 
results will be given in the General Discussion {Chapter 10). 
Chapter 2 
FAMILY HISTORY OF MYOCARDIAL INFARCTION AND 12-YEAR 
CORONARY HEART DISEASE MORTALITY 
Based on: Boer JMA, Feskens EJM, Verschuren WMM, Seidell JC, Kromhout D. The joint impact of 
family history of myocardial infarction and other risk factors on 12-year coronary heart disease 
mortality. Submitted for publication. 
Family history and CHD mortality 23 
Abstract 
We investigated the joint impact of a family history of myocardial infarction and other 
cardiovascular risk factors on coronary heart disease (CHD) mortality in a large Dutch 
cohort study with a mean follow-up of 12 years. Family history increased the risk for CHD 
death in men (RR 1.70, 95%-CI 1.26-2.30) and women (2.31, 1.21-4.41). Body mass index, 
systolic blood pressure, serum total cholesterol, smoking and physical activity could explain 
only a small part of this association. Individuals with a family history together with 
unfavorable risk factor levels had the highest absolute risk for CHD death. In men the risk 
was as expected under the assumption of additivity. The risk among women with a family 
history in combination with other risk factors was somewhat higher than expected from their 
separate effects. This was most pronounced for smoking. The risk in female smokers with a 
family history was higher (RR: 5.6, 2.3-13.7) than expected (2.0) from the additive effects of 
family history and smoking. Among these women 65% (95%-CI: 4-88%) of the cases were 
attributable to the interaction. Because of the small number of CHD deaths among women, 
confidence intervals for the etiologic fraction due to interaction were, however, wide. 
Our results provide limited evidence for the hypothesis that individuals with a family 
history are more susceptible to the unfavorable effect of other risk factors. Nevertheless, 
special attention for risk factor modification is warranted in individuals with a family history, 
since they have the highest absolute risk for dying of coronary heart disease when other risk 
factors are also present. Moreover, women may be more susceptible to the unfavorable 
effects of smoking. 
Introduction 
Several prospective studies have demonstrated that a family history of coronary 
heart disease (CHD) is associated with an increased risk for this disorder.7'143067 
Family history by itself provides little information about the mechanisms by which it 
contributes to the risk of disease. The increased risk for CHD among relatives of 
CHD patients could be a consequence of common genetic and environmental 
factors that act through known risk factors, such as high blood cholesterol, high 
blood pressure and obesity. Most of the prospective studies, however, have 
demonstrated that a family history of CHD remains a risk factor after adjustment for 
other major risk factors.7312143067 Therefore, the increased risk in subjects with a 
family history cannot be fully explained this way. 
Additionally, detrimental effects of risk factors may be more potent in persons with 
a family history of CHD. So far, this hypothesis is investigated in a small number of 
prospective studies, but the results were inconclusive.912143068 In these studies 
interaction between risk factors was evaluated on a multiplicative scale. However, 
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while relative risks are similar across strata (absence of interaction on the 
multiplicative scale), the absolute excess risks may differ considerably. Therefore, 
we share the opinion that it is more appropriate to evaluate interaction on an additive 
scale.69 Furthermore, little information is available on the risk for CHD that is 
associated with the joint presence of a family history and other risk factors.1230 
We therefore studied the joint impact of family history of myocardial infarction and 
some other major risk factors on coronary heart disease mortality in the Netherlands 
Consultation Bureau Project on Cardiovascular Diseases, a prospective study with a 
mean follow-up of 12 years, including more than 49,000 men and women. We also 
tried to further elucidate whether individuals with a family history are more 
susceptible to the detrimental effects of some other classical risk factors on CHD. 
Methods 
Data collection 
From 1974 to 1980 a total of 50,887 men and women, from five towns in the 
Netherlands were examined as part of the Consultation Bureau Project on 
Cardiovascular Diseases.70 The response rate varied from 70 to 80%. The age range 
of the population was 30-54 years, with about 75% of the respondents aged 35 to 
45. A more detailed description of the study is given by Verschuren et al.71 In brief, 
questionnaire information about smoking habits, leisure time physical activity and 
(family) history of cardiovascular disease, hypertension and diabetes mellitus was 
obtained. A family history of myocardial infarction was considered present if the 
participant reported that at least one parent or sibling had suffered from a 
myocardial infarction. No information on the age at the time of the event was 
available. Participants were asked how they rated their physical activity during 
leisure time (little exercise/ exercise for at least 4 hours a week/ regular exercise/ 
regular strenuous exercise). Subjects were considered to be inactive when they 
reported little exercise, while the remainder was considered to be physically active. 
A non-fasting blood sample was taken. Serum total cholesterol was determined 
according to a direct Liebermann-Burchard method.72 Total cholesterol values were 
converted to enzymatic values as described previously7', and values > 5.2 mmol/l 
were considered to be high. 
Height was measured to the nearest cm, while weight was measured to the 
nearest 0.1 kg in subjects wearing indoor clothing and no shoes, after they had 
emptied their pockets. Body Mass Index (BMI) was calculated as weight/height2 
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(kg/m2), whereas overweight was defined as a BMI > 25 kg/m2. Blood pressure was 
measured once on the right arm with a random zero sphygmomanometer, while 
subjects were seated. Hypertension was defined as a systolic blood pressure > 140 
mmHg and/or diastolic blood pressure > 90 mmHg and/or the use of 
antihypertensive medication. 
Mortality follow-up 
Mortality follow-up was started in 1986 and completed in 1993.71 For 49,018 
subjects (96.3%) mortality follow-up was successfully completed. The proportion 
loss to follow-up was similar in subjects with and without a family history of 
myocardial infarction. Mean duration of follow-up was 12.0 ± 2.2 years (mean ± SD). 
For deceased subjects the cause of death was obtained from 'Statistics 
Netherlands'. For 30 subjects such information could not be obtained, since they 
had died outside the Netherlands. 
Causes of death were coded according to the 9th revision of the International 
Classification of Diseases (ICD-9).73 ICD-codes 410-414 were classified as CHD 
deaths. For deaths that had occurred before January 1st 1979 (n=89), the 8th 
revision was used. For CHD, codes remained in the same category when defined 
according to ICD-9. 
Statistical analyses 
Only subjects for whom all data on family history, possible intermediate factors 
and mortality (n=46,356) were available were included in the analyses. At baseline, 
prevalence of myocardial infarction was low (1.5% in men and 1.2% in women). Only 
few of the subjects with a personal history of myocardial infarction had died during 
follow-up (5.7% of the male and 3.4% of the female cases). Most of them (85%) had 
no family history. We included them in the analyses, and find it unlikely that this had 
appreciable impact on our results. Because men and women differ considerably in 
risk factor levels as well as absolute CHD risk, we analyzed them separately. All 
analyses were carried out using SAS statistical software (SAS, Cary, version 6.08). 
Cox proportional hazards (survival) analysis was used to estimate age-adjusted 
relative risks. To evaluate whether lifestyle factors and intermediate biological traits 
explained associations between family history and mortality, additional adjustments 
were made for smoking habits (no, ex or current smoking), leisure time physical 
activity (yes/no), body mass index, systolic blood pressure and serum total 
cholesterol. 
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To estimate the joint impact of a family history and other risk factors, subjects 
were classified according to family history and the presence of unfavorable risk 
factor levels (overweight, hypertension, high cholesterol, current smoking and 
physical inactivity). Within the risk factor strata, the mean levels for the underlying 
traits (BMI, systolic and diastolic blood pressure, total cholesterol, amount and 
duration of smoking) were similar in individuals with and without a family history, 
excluding the possibility of residual confounding. Relative risks were calculated 
using individuals without a family history and normal risk factor levels as the 
reference category. Adjustments were made for age and all other risk factors than 
the one under investigation. BMI, total cholesterol and systolic blood pressure were 
included as continuous variables, smoking in 3 categories (no, ex and current 
smoking). Interaction was evaluated by comparing the risk in the group with both a 
family history and a given unfavorable risk factor level with the risk expected from 
the additive effects of family history and the risk factor alone, as suggested by 
Rothman.69 The proportion of cases among individuals with a family history and a 
high risk factor level that was attributable to their interaction was estimated with the 
method of Walker.74 
Results 
A family history of myocardial infarction was reported by 24.2% of the male and 
26.1% of the female participants. At baseline, men and women with and without a 
family history were fairly similar in age, BMI, blood pressure, smoking habits and 
physical activity (Table 1). Hypertension and high cholesterol levels were, however, 
slightly more prevalent among participants with a family history. Few participants 
reported diabetes mellitus (1.4%) and this percentage was independent of family 
history. Therefore we did not consider this risk factor for CHD further. 
During follow-up 789 men and 487 women died, of which 186 men (23.6%) and 
37 women (7.6%) died from CHD. These figures are as expected for this age group 
in the Netherlands.3 Family history of myocardial infarction was associated with a 1.7 
times greater risk of CHD death in men, while it more than doubled the risk in 
women. Adjustment for smoking habits, physical inactivity, BMI, serum total 
cholesterol levels and systolic blood pressure resulted in relative risks that were only 
slightly lower. Therefore, these lifestyle and biological factors explained only a small 
part of the association. In men, a family history also resulted in an increased risk for 
all-cause mortality, while this was not the case in women, due to the small 
contribution of CHD to total mortality (Table 2). 
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Table 1 . Baseline characteristics 
MEN 
Age (years) 
Body mass index (kg/m2) 
Overweight" (%) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Hypertension" (%) 
Total cholesterol (mmol/l) 
High cholesterol0 (%) 
Diabetes mellitus (%) 
Smokers (%) 
Ex- smokers (%) 
Physical inactivity" (%) 
WOMEN 
Age (years) 
Body mass index (kg/m2) 
Overweight3 (%) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Hypertension" (%) 
Total cholesterol (mmol/l) 
High cholesterol" (%) 
Diabetes mellitus (%) 
Smokers (%) 
Ex- smokers (%) 
Physical inactivity" (%) 
according to family history of myocardial infarction 
Family history 
Without 
n=16,753 
39.1 ± 4.4 
24.4 ± 3.0 
39.3 
132.6 ±16.2 
80.9 ±11.3 
32.5 
5.51 ±1.10 
59.8 
1.4 
65.2 
19.6 
14.2 
n=17,916 
39.2 ± 4.5 
23.7 ± 3.7 
29.1 
126.3 ±17.6 
77.5 ±11.0 
22.9 
5.15 ±0.99 
44.9 
1.3 
46.4 
12.6 
11.1 
With 
n=5,348 
39.4 ± 4.3 
24.5 ± 3.1 
40.5 
133.7 ±16.5 
81.9±11.4 
36.2 
5.67 ±1.10 
65.6 
1.4 
66.8 
19.5 
13.8 
n=6,339 
39.8 ± 4.4 
23.9 ± 3.7 
31.4 
127.9 ±18.1 
78.6 ±11.1 
27.1 
5.28 ± 1.03 
49.7 
1.4 
48.1 
12.0 
11.1 
Values are presented as mean ± SD or percentages, a. Body Mass Index > 25 kg/m . b. Systolic blood 
pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg and/or the use of antihypertensive 
medication, c. Serum total cholesterol > 5.2 mmol/l. d. Reporting little leisure time exercise. 
Table 3 shows the relative risk for CHD death according to family history and 
other risk factors for men. The highest risk was found in men with a family history 
together with unfavorable risk factor levels, but their risk did not differ considerably 
from the risk expected under the assumption of additivity. As a result, the proportion 
of cased among them that was due to interaction was rather low (9-27%). 
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Table 2. Coronary heart disease (ICD9: 410-414) and all-cause mortality according to family 
history of myocardial infarction. The CB-Project. 
Men 
CHD 
All-cause 
Women 
CHD 
All-cause 
Family history 
Without 
Rate* (n) 
n=16,753 
5.99(120) 
27.97 (560) 
n=17,916 
0.92 (20) 
15.83(346) 
of myocardial infarction 
With 
Rate (n) 
n=5,348 
10.51 (66) 
36.46 (229) 
n=6,339 
2.22(17) 
18.39(141) 
RRf 
1.70(1.26-2.30) 
1.28(1.10-1.49) 
2.31 (1.21-4.41) 
1.12(0.92-1.36) 
RR* 
1.58(1.17-2.13) 
1.22(1.05-1.42) 
2.12(1.11-4.05) 
1.09 (0.89-1.32) 
* Crude mortality rate per 10,000 person-years (number of deaths), t Age-adjusted relative risk (95%-
confidence interval). The group without a family history is taken as the reference category. $ Adjusted 
for age, smoking habits, leisure time physical activity, body mass index, systolic blood pressure and 
serum total cholesterol. 
Except for high cholesterol, the risk for CHD mortality in women with a family 
history together with an unfavorable level of a given other risk factor was double that 
expected from the additive effects (Table 4). However, confidence intervals for the 
proportion of cases due to interaction were wide, as a result of the small number of 
CHD deaths among women. Nevertheless, women with a family history seemed to 
be more susceptible to the unfavorable effect of smoking. In female smokers with a 
family history the observed relative risk was 5.6, while a relative risk of two was 
expected. Sixty-five percent of the cases among female smokers with a family 
history were attributable to the interaction between smoking and family history. 
Discussion 
Our results contribute to the large body of evidence from other prospective 
studies that the relation between a family history of myocardial infarction and 
coronary heart disease cannot be fully explained by the major classical risk 
factors.79'2143067 This is not unexpected, since other, unmeasured, predictors of CHD, 
such as HDL-cholesterol, triglycerides, alcohol consumption and hemostatic 
variables, were not available for inclusion in our models. Furthermore, not much 
support is found for the hypothesis that individuals with a family history may be more 
susceptible to the detrimental effects of other CHD risk factors. However, women 
with a family history seemed to be more susceptible to the effects of smoking. 
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Table 3. Coronary heart disease mortality (ICD9: 410-414) according to family history of 
myocardial infarction and categories of other risk factors in men. 
Family Risk Relative Risk* Proportion due 
history factor Rate*H Observed§ Expectedf to interaction^: 
Overweight" 
-
+ 
+ 
+ + 
Hypertension" 
-
+ 
+ 
+ + 
High cholesterol0 
-
+ 
+ 
+ + 
Current Smoking 
-
+ 
+ 
+ + 
Physical inactivity" 
-
+ 
+ 
+ + 
4.27 (52) 
5.91 (68) 
7.88 (33) 
8.12(33) 
3.99 (54) 
7.59 (66) 
5.76 (25) 
12.82(41) 
2.62(21) 
5.77 (99) 
4.37(10) 
9.19(56) 
2.88 (20) 
7.01 (100) 
4.64(11) 
11.08 (55) 
5.83(100) 
5.22 (20) 
8.99 (55) 
9.25(11) 
1.00 (reference) 
1.38 (0.96-2.00) 
1.84(1.19-2.85) 
1.90(1.22-2.96) 
1.00 (reference) 
1.90(1.32-2.76) 
1.45 (0.90-2.32) 
3.21 (2.12-4.87) 
1.00 (reference) 
2.20(1.37-3.53) 
1.66(0.78-3.54) 
3.50(2.11-5.81) 
1.00 (reference) 
2.43(1.50-3.94) 
1.61 (0.77-3.36) 
3.85 (2.30-6.43) 
1.00 (reference) 
0.90(0.55-1.45) 
1.54(1.11-2.14) 
1.59 (0.85-2.96) 
2.2 
2.4 
2.9 
3.0 
1.4 
-17 (-90,28) 
27 (-15, 53) 
18 (-34, 50) 
21 (-26, 50) 
9 (-87, 56) 
* Adjusted for age, and the other risk factors, e.g. results for overweight are adjusted for systolic blood 
pressure, total cholesterol, smoking (no, ex-, current) and physical inactivity. ^ Mortality rate per 
10,000 person-years (number of deaths). § Relative risk (95%-confidence interval), t Expected under 
the assumption of additivity of effects, t Proportion of cases among those with a family history 
together with an unfavorable risk factor that was due to their interaction (95%-confidence interval).7" 
a. Body Mass Index > 25 kg/m2. b. Systolic blood pressure > 140 mmHg and/or diastolic blood 
pressure > 90 mmHg and/or the use of antihypertensive medication, c. Serum total cholesterol > 5.2 
mmol/l. d. Reporting little leisure time exercise. 
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Table 4. Coronary heart disease mortality (ICD9: 410-414) according to family history of 
myocardial infarction and categories of other risk factors in women. 
Family 
history 
Risk 
factor Ra te l 
Relative Risk Proportion due 
Observed§ Expectedt to interaction^ 
Overweight3 
-
+ 
+ 
+ + 
Hypertension" 
-
+ 
+ 
+ + 
High cholesterol" 
-
+ 
+ 
+ + 
Current smoking 
-
+ 
+ 
+ + 
Physical inactivity" 
-
+ 
+ 
+ + 
0.71 (11) 
0.83 (9) 
0.99 (6) 
2.48(11) 
0.65(11) 
1.07 (9) 
0.97 (6) 
3.07(11) 
0.33 (4) 
1.12(16) 
0.96 (4) 
2.17(13) 
0.68 (8) 
1.34(12) 
0.67 (3) 
3.85(14) 
0.93(18) 
0.49 (2) 
1.52(12) 
3.27 (5) 
1.00 (reference) 
1.17(0.46-2.94) 
1.39(0.51-3.77) 
3.49(1.46-8.37) 
1.00 (reference) 
1.63(0.64-4.19) 
1.48 (0.55-4.00) 
4.69(1.93-11.4) 
1.00 (reference) 
3.36(1.11-10.2) 
2.88(0.72-11.5) 
6.53(2.10-20.4) 
1.00 (reference) 
1.97(0.79-4.91) 
0.98 (0.26-3.69) 
5.63(2.32-13.7) 
1.00 (reference) 
0.53(0.12-2.43) 
1.64(0.79-3.41) 
3.52 (1.26-9.87) 
1.6 
2.1 
5.2 
2.0 
1.2 
55 (-36, 85) 
55 (-22, 83) 
20 (-88, 66) 
65 (4, 88) 
67 (-34, 92) 
* Adjusted for age, and the other risk factors, e.g. results for overweight are adjusted for systolic blood 
pressure, total cholesterol, smoking (no, ex-, current) and physical inactivity. 1j Mortality rate per 
10,000 person-years (number of deaths). § Relative risk (95%-confidence interval), t Expected under 
the assumption of additivity of effects, $ Proportion of cases among those with a family history 
together with an unfavorable risk factor that was due to their interaction (95%-confidence interval)." 
a. Body Mass Index > 25 kg/m2. b. Systolic blood pressure > 140 mmHg and/or diastolic blood 
pressure > 90 mmHg and/or the use of antihypertensive medication, c. Serum total cholesterol > 5.2 
mmol/l. d. Reporting little leisure time exercise. 
A common shortcoming of large prospective studies, such as ours, is that 
subjects were classified according to self-reported family history. Unfortunately, we 
did not have the possibility to validate the family history, but in general validity of 
such data is fairly good (sensitivity 60-80%, specificity 60-95%).147576 
Family history and CHD mortality 31 
Another disadvantage of our study is that the age of the affected relative at the 
time of the event was not recorded. Since premature CHD might be more strongly 
determined by genetic susceptibility then late-onset CHD6, such information could 
have been useful. We knew, however, if a family member died of a myocardial 
infarction before the age of 55 (yes/no). This was the case for 14% of the men and 
women with a family history (733 men and 866 women). Because of the small 
number of cases (n=2), the association between a family history of fatal premature 
myocardial infarction and CHD mortality could not be separately determined in 
women. In men, however, the risk was indeed more markedly increased (RR: 2.39, 
95%-CI: 1.35-4.24 versus 1.58, 1.17-2.13 see Table 2). Given the age range of our 
participants and the fact that death from CHD occurs mainly after the age of 45 in 
men and 65 in women3, we think that in our study the events were relatively 
premature, especially for women. Most of our female and a smaller part of our male 
cases, might therefore represent those genetically susceptible to the disease. This 
may explain why in women the association of family history with CHD mortality was 
stronger as compared to men. Additionally, interaction effects - if any - were more 
pronounced in women. We can therefore not exclude the possibility that individuals 
with a family history of premature myocardial infarction are indeed more susceptible 
to the effects of other risk factors. 
Hopkins was the first to demonstrate that the effect of smoking was more 
pronounced in families of subjects who died of CHD than in control families.20 Others 
also found that smoking was slightly more predictive of coronary or cardiovascular 
disease in women912'52968 or men68 with a family history. In some other studies, 
however, no interaction with smoking was found.1430 
A possible explanation for the increased risk for smoking in women with a family 
history is that more women without a family history stopped smoking after baseline 
examinations. This is unlikely, however, since at baseline the percentage of ex-
smokers did not differ according to family history. Another explanation might be that 
smoking potentiates an inherited predisposition to CHD. Cigarette smoking affects 
other risk factors for CHD, such as total, LDL- and HDL-cholesterol levels77 and 
hemostatic factors, a.o. PAI-178 and fibrinogen.79 Smoking may also enhance 
oxidative stress and could thus increase LDL oxidation.80 If smoking potentiates an 
inherited predisposition to low HDL-cholesterol levels or unfavorable levels of 
hemostatic factors and oxidized LDL, this might explain the more pronounced effect 
of smoking in subjects with a family history. It has been demonstrated that the effect 
of some gene mutations on HDL-cholesterol levels, hemostatic factors, as well as on 
CHD risk is indeed modulated by smoking.4981'83 HDL-cholesterol and hemostatic 
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factors were, however, not measured in our study. Therefore we could not 
investigate this hypothesis further. 
Only few studies evaluated the interaction between family history and risk factors 
other than smoking91268, mostly with negative results.912 Khaw and co-workers68 found 
that the effect of hypercholesterolemia on cardiovascular mortality was stronger in 
men without a family history compared to those with a family history. This was, 
however, not the case in women. When in the present study subjects were classified 
according to hypercholesterolemia (total cholesterol > 6.5 mmol/l) no interaction was 
detected in men. The risk for CHD mortality was, however, strongly increased in 
hypercholesterolemic women with a family history (RR: 10.1, 4.5-23), and not in 
those with hypercholesterolemia but no family history (2.1, 0.8-5.9). About 78% (33-
93%) of the cases among women with hypercholesterolemia and a family history 
were due to their interaction. Management of hypercholesterolemia might therefore 
reduce their risk for early CHD death considerably. 
We did not observe an interaction between family history and overweight in the 
present study. Although overweight (BMI > 25 kg/m2) was not strongly related to 
CHD mortality, more severe overweight (BMI > 30 kg/m2) has been shown to be 
associated with a three-fold increase in CHD risk in this population.25 Interactions 
may also be different at different levels of overweight, but the percentage obese 
subjects (about 5%) was too small to evaluate this further. 
Although not much evidence was found that individuals with a family history are 
more susceptible to the detrimental effects of other risk factors, assessing family 
history is important for risk prediction and prevention. This is because the highest 
CHD risk is observed in both men and women with a combination of a family history 
of myocardial infarction and other risk factors. Special efforts should therefore be 
made to persuade those with a positive family history to reduce the level of other risk 
factors. Moreover, women with a family history might be more susceptible to the 
detrimental effects of smoking, suggesting that for them smoking cessation may be 
even more effective. 
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RELIABILITY OF SELF-REPORTED 
PARENTAL HISTORY OF MYOCARDIAL INFARCTION 
The Monitoring Project on Cardiovascular Disease Risk Factors 
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Abstract 
Elsewhere in this thesis we described the association between self-reported parental 
history of myocardial infarction (Ml) and genetic factors using data from the Monitoring 
Project on Cardiovascular Disease Risk Factors. A study was conducted to evaluate both 
the validity and reproducibility of the parental history data. We selected 480 individuals who 
participated in the monitoring project in Maastricht. Questionnaires, asking about the 
occurrence of a myocardial infarction in their parents, were returned by 241 participants. We 
tried to validate parental history through general practitioners and death certificates. For 
32% of the fathers and 45% of the mothers, information could be obtained from their 
(former) general practitioner. For 69% of the deceased parents, the registration number of 
the death certificate could be obtained, but for only 15% of the deceased parents 
information from the general practitioner was also available. This was too limited to fully 
validate parental history data. The benefits of obtaining causes of death would therefore not 
balance the costs, and we decided not to do so. The reproducibility of parental history was 
good. For both a paternal and maternal history the general agreement was 85% or more, 
while the K-statistics were 0.80 and 0.73, respectively. The reproducibility of parental history 
of premature Ml was somewhat lower, since the reported age at the event was discordant 
(i.e. differed more than two years) in 31% of the cases. About 75% of the participants were 
classified into the same parental history group (no, one or two parents with a premature Ml) 
in the monitoring project and the reproducibility study. The lack of reproducibility may have 
led to an underestimation of true associations between parental history and coronary risk 
factors. 
In conclusion, the reproducibility of parental myocardial infarction as assessed in the 
Monitoring Project on Cardiovascular Disease Risk Factors was good, but information was 
too limited to fully evaluate its validity. Misclassification due to imperfect reproducibility may 
have led to bias towards the null. 
Introduction 
It is well known that a family history of myocardial infarction (Ml) increases the risk 
for coronary heart disease (CHD).712 Moreover, family history has often been 
associated with cardiovascular risk factors.8486 Most studies used self-reported 
information to assess family history. However, self-reports are subject to error and 
may therefore result in misclassification, which can bias the results.8788 Therefore, 
several investigators tried to validate self-reported family history data.1475,76,868992 Most 
of these studies only provided partial insights into the validity of family history. In 
some studies only positive, but not negative, family histories were verified. Others 
verified family history through living next-of kin only, while for the definition of family 
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history also deceased relatives were informative. Furthermore, for deceased 
relatives the occurrence of an event was usually verified against the cause of death 
only, ignoring non-fatal myocardial infarctions in individuals with other causes of 
death. Moreover, little is known about the reproducibility of family history data. We 
are aware of two studies in which reproducibility was determined, but only one of 
them reported the results explicitly for a family history of Ml.9394 
In the next chapter (Chapter 4) the association between self-reported parental 
history of Ml and genetic as well as non-genetic CHD risk factors is described. For 
that study, data from the Monitoring Project on Cardiovascular Disease Risk Factors 
- a large risk factor monitoring project carried out in three Dutch towns between 1987 
and 199195 - were used. The validity and reproducibility of the parental history data 
cannot be easily extrapolated from other studies. This is not simply because the 
other investigators conducted partial validations only, but also because other studies 
differ too much in the selection of subjects, the definitions of family history and the 
ways these family histories were obtained. Therefore, we tried to validate parental 
history of Ml through living parents, death certificates and medical records (for both 
living and deceased parents) and determined its reproducibility in a subsample of 
the monitoring project. During the study it became clear that we would not have 
enough information to fully validate the family history data. In this chapter our efforts 
with respect to the validation of family history as well as the results for the 
reproducibility are described. 
Methods 
The Monitoring Project on Cardiovascular Disease Risk Factors 
Between 1987 and 1991 more than 36,000 men and women participated in a 
large monitoring project of cardiovascular risk factors in the Netherlands. A detailed 
description of the monitoring project is given elsewhere.95 In brief, each year a new 
random sample of men and women, aged 20-59 years, was selected from the 
municipal registries of three Dutch towns (Amsterdam, Doetinchem and Maastricht) 
and invited to participate. The overall response rate was 50% for men and 57% for 
women. The examination included a physical examination at the Municipal Health 
Center and a self-administered questionnaire. 
The questionnaire provided information about the presence and (parental) history 
of cardiovascular diseases, history of other diseases, presence of some major 
lifestyle-related cardiovascular risk factors, etc. Parental history of myocardial 
infarction was ascertained using two questions: (1) Did your father ever have a 
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myocardial infarction? and (2) Did your mother ever have a myocardial infarction? If 
a myocardial infarction was reported, the parent's age at the time of the event was 
also requested. A myocardial infarction was considered to be premature if it 
occurred before the age of 61 in the father and before the age of 66 in the mother. 
These cut-off points correspond to the mean of the reported ages at the time of the 
event. 
Trained technicians who were all instructed by the same physician conducted the 
physical examinations. During the examination, height, weight and blood pressure 
were measured, while non-fasting blood samples were taken for the determination of 
total and HDL-cholesterol using previously described methods.9697 
Validation study 
For logistic reasons, the subsample for the validation study (n=480), consisted of 
participants from Maastricht only. All subjects who were in another subsample, i.e. of 
a study concerning parental history and variability in genes involved in lipid 
metabolism (Chapter 4), were included (n=204). Additionally, all remaining subjects 
who reported that both parents had had a premature Ml (n=29), a random sample 
(n=146) of the subjects without a parental history and a random sample (n=101) of 
the subjects with one affected parent were included. The resulting subsample 
comprised of 197 subjects without a parental history, 202 with one affected parent 
(father n=124, mother n=78) and 81 subjects who reported that both parents were 
affected. 
Data collection 
The validation study was started in 1995, after approval of the Medical Ethics 
Committee. Subjects who were still residing in the Maastricht area (n=459) received 
a letter from the Municipal Health Center, asking for permission to give their name 
and address to the investigators. Six subjects could not be reached because they 
passed away since baseline examinations (n=4) or because their current address 
was unknown (n=2). A total of 330 subjects gave permission to be approached by 
the investigators and gave information about the vital status of their parents. The 
remainder was not approached for the validation study because they refused 
permission (n=50) or because they did not respond to the letter of the Municipal 
Health Center or a reminder (n=73). 
Subjects who gave permission to be approached received a questionnaire asking 
about Ml, stroke and angina in their father and mother. If applicable, one or two 
similar questionnaires were included that had to be filled out by living parents. Two-
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hundred and forty-seven subjects returned the questionnaire, of which 6 had to be 
excluded from further analyses because they were adopted (n=2) or because - on 
closer inspection - it turned out that they were not the persons we intended to study 
(n=4). In summary, a total of 241 subjects (50.2% of all 480 subjects in the 
subsample) participated in the validation study. They all gave informed consent. An 
overview of the response is given in Table 1. 
Table 1 . Overview of the response in the validation study 
Total sample n=480 
Living outside the Maastricht area n= 21 ( 4.4%) 
Deceased n= 4 ( 0.8%) 
Address Unknown n= 2 ( 0.4%) 
Refused to participate n= 50 (10.4%) 
No response at all n= 73 (15.2%) 
To be approached n=330 (68.7%) 
Returned questionnaires n=247 (51.5%) 
Adopted n= 2 ( 0.4%) 
Wrong respondent n= 4 ( 0.8%) 
Included in the study n=241 (50.2%) 
For the validation of parental history we attempted to obtain information in two 
ways, i.e. through information from general practitioners and through death 
certificates. Living parents were asked to provide the name and address of their 
general practitioner (GP) and informed consent to contact him/her. For deceased 
parents we asked the participant to provide the name and address and informed 
consent. Additionally, we asked them to give informed consent to obtain causes of 
death from Statistics Netherlands. 
General practitioners received a short questionnaire, asking whether or not 
his/her patient ever had a myocardial infarction, the date of the first event, and the 
age at which the event occurred. Several GP's had handed their patients over to the 
care of another GP after retirement. In these cases the practicing GP was 
approached. Additionally, we planned to obtain causes of death for those deceased 
parents with a known date of birth who died before the baseline examinations. To 
obtain their initials, maiden name (for the mother), and the town they last resided in, 
participants were re-contacted. Subsequently, municipal registries were asked to 
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provide the date and town of death as well as the registration number of the death 
certificate. Since for only a small percentage of the parents all necessary information 
for the full validation of family history became available, we refrained from asking 
Statistics Netherlands about the causes of death. 
Statistical analyses 
Differences between responders and non-responders were tested using a 
Student's t-test for continuous variables and a x2-test or Fisher's exact test for 
categorical variables. The degree to which self-reported parental history of Ml could 
be confirmed by general practitioners was evaluated using the four measures that 
were described by Cicchetti and Feinstein9899: (1) the proportion general agreement, 
(2) the percentage positive agreement, (3) the percentage negative agreement and 
(4) the K-statistic. Reproducibility of parental history of myocardial infarction was 
evaluated, using the same four measures, by comparing the information that the 
participant gave in the monitoring project with the information that he/she gave in the 
reproducibility study. If in the reproducibility study parental history was 'unknown' or 
missing, answers were considered to be discordant. The age at the event was 
considered to be discordant if the difference in the reported age was more than two 
years. In the reproducibility study, some of the participants reported a paternal or 
maternal event that occurred after the examinations for the monitoring project. This 
implies that earlier no myocardial infarction had occurred and the participants was 
classified as having no paternal (or maternal) history in the reproducibility study. 
To evaluate the effects of imperfect reproducibility, we determined differences in 
coronary risk factors according to parental history of premature myocardial infarction 
(by analyses of variance and x2-tests), before and after exclusion of participants for 
whom parental history was discordant. 
Results 
Non-response 
Questionnaire information was available for 50.2% of the subjects (n=241). The 
percentage was slightly lower for subjects without a parental history of premature Ml 
(45%), compared to those with one (55%) or two affected parents (51%). 
Participants were about 2.5 years older and had a higher educational level 
compared to subjects for whom no questionnaire was available due to the reasons 
given in Table 1. They somewhat more often reported a personal history of Ml (3.8% 
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versus 1.3%, p=0.08) and were also more often treated for cardiac complaints by a 
physician (10.4% versus 4.2%, p=0.009). More specifically, almost all hypertensives 
who returned the questionnaire used anti-hypertensive medication (88.9%), in 
contrast to hypertensives who did not participate in this study (18.8%, p=0.0001). 
Despite these differences in treatment, differences in CHD risk factors were small 
and not statistically significant. 
Table 2. Overview of the validation through general practitioners 
Fathers Mothers 
Total number of parents 
No permission 
Unknown general practitioner 
Died before 1975 
Unknown date of birth 
n=241 n=241 
n=12 ( 5.0%) 
n=27 (11.2%) 
n=75 (31.3%) 
n=11 ( 4.6%) 
n= 6 ( 2.5%) 
n=28 (11.6%) 
n=30 (12.4%) 
n=11 ( 4.6%) 
Parents for whom GP was approached 
GP did not respond 
No medical records found 
n=116 (48.1%) 
n=14 (12.1%) 
n=26 (22.4%) 
n=166 (68.9%) 
n=18 (10.8%) 
n=40 (24.1%) 
Data available 
Living parents 
Deceased parents 
76 (31.5%) 
n=43 (72%)* 
n=33 (18%)* 
n=108 (44.8%) 
n=76 (67%)* 
n=32 (25%)* 
* Percentage of total number of living/deceased parents 
Validation of parental history of myocardial infarction 
For all living and deceased parents we wanted to validate self-reported parental 
history of Ml through general practitioners. However, not for all parents the (former) 
GP could be approached. No attempts to retrieve any information were made in 
case: (1) we did not get permission to do so, (2) the general practitioner was 
unknown, (3) the parent died before 1975 (files are in general destroyed 10 years 
after the death of a patient) and (4) the parents date of birth was unknown. Sixty-
eight GP's were approached for the retrieval of information on 116 fathers and 166 
mothers. Seven of them did not respond to our requests and to a reminder. In quite 
a large number of cases the GP could not find any medical records. In total, 
information was available for only 31.5% of the fathers and 44.8% of the mothers 
(see Table 2 for an overview). Especially for deceased parents it was hard to obtain 
information. 
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Whether or not the reported parental histories could be confirmed using 
information provided by the general practitioners is shown in Table 3. Although 25-
30% of the reported myocardial infarctions could not be confirmed, the general 
agreement and K-statistics were reasonable. These figures should, however, be 
interpreted with caution, since for the majority of parents no information could be 
obtained at all. 
Table 3. Verification of parental history of myocardial infarction by general practitioners 
Reported by GP 
Yes 
No 
Reported by the participant at the time of the monitoring project 
Ml in father 
Yes No 
21 5 
9 41 
General agreement 
Positive agreement 
Negative agreement 
K-statistic 
81.6% 
75.0% 
85.4% 
0.61 
Ml in mother 
Yes No 
25 6 
10 67 
General agreement 
Positive agreement 
Negative agreement 
K-statistic: 
85.2% 
75.8% 
89.3% 
0.65 
GP: General practitioner 
In addition to the validation of family history through general practitioners, we 
wanted to obtain causes of death from Statistics Netherlands for deceased parents 
(180 fathers and 128 mothers). However, no attempts were made in case: (1) no 
permission was given to obtain causes of death, (2) the parent died after 
examinations as part of the monitoring project, (3) the parent's date of birth was 
unknown. For 69% of the deceased parents the date and place of death and the 
registration number of the death certificate could be obtained from municipal 
registries (Table 4). However, complete information to fully validate parental history 
(i.e. both information from general practitioners and death certificates) was lacking 
for the majority of the deceased parents (85%). Probably, the benefits of obtaining 
causes of death would not counterbalance the efforts and costs, and we decided not 
to do so. 
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Table 4. Overview of the validation through death certificates 
Fathers Mothers 
Total number of parents n=180 n=128 
Died after examinations n= 5 ( 2.8%) n=18 (14.1%) 
No permission n=10 ( 5.6%) n= 6 ( 4.7%) 
Unknown date of birth n=11 ( 6.1%) n=12 ( 9.4%) 
Causes of death to be obtained* n=153 (87.4%) n=92 (83.6%) 
No of death certificate not found* n=32 (18.3%) n=16 (14.5%) 
Registration number of death n=121 (69.1%) n=76 (69.1%) 
certificate available* 
* of the parents that died before examinations as part of the monitoring project 
Confirmation of parental history of myocardial infarction by the parents 
We also tried to verify parental histories through living parents. Fifty-nine fathers 
(24%) and 113 (47%) mothers were still alive. To optimally guarantee their privacy, 
we had send a questionnaire together with the one for the participant, and asked the 
latter to hand it over. The questionnaire was filled out and returned by 48 fathers 
(81%) and 80 mothers (71%). The main reasons for not returning the questionnaire 
were: (1) in stead of the parent the participant of the monitoring project filled out the 
questionnaire about him/herself, (2) no contact with the parent(s) (mainly for the 
fathers), (3) refusal of the participant to hand over the questionnaire because of the 
old age of his/her parent or (4) refusal of the parents. 
From the handwritings it became apparent that in most instances the 
questionnaire of the participant and the questionnaire of the living parent(s) were 
filled out by the same individual. This implies that both questionnaires have often 
been filled out by the participants together with their parent(s) or after consulting 
each other by telephone. As a result, the information given by the parents did not 
provide much extra information compared to the information provided by the 
participant him/herself. 
Reproducibility of parental history of myocardial infarction 
Although we were not able to fully validate parental history data, we were able to 
determine the reproducibility. At the time of the monitoring project, 129 participants 
had reported that their father suffered from a myocardial infarction, while 101 
participants reported a myocardial infarction of their mother. For 90 fathers and 63 
mothers the event was premature. Reproducibility of paternal and maternal history of 
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Ml was high. The general agreement exceeded 85%, while the K-statistic was 0.80 
for paternal and 0.73 for maternal history of Ml (Table 5). For a maternal Ml the 
positive agreement was somewhat lower than the negative agreement, suggesting 
that the reproducibility of positive reports was slightly worse. 
There was no difference in the performance between men and women, but 
reproducibility was lower for deceased parents (agreement 86.8% for fathers and 
79.8% for mothers, K-statistic: 0.75 and 0.62, respectively) than for those still alive 
(agreement: 96.7% and 92.9%, K-statistic: 0.93 and 0.78). 
Table 5. Reproducibility of paternal and maternal history of myocardial infarction 
Reported in the 
reproducibility study 
Yes 
No 
Unknown 
Missing 
Reported by the participant at 
Ml in father 
Yes 
117 
1 
9 
2 
No 
2 
97 
10 
3 
General agreement 
Positive agreement 
Negative agreement 
K-statistic 
88.8% 
94.4% 
92.4% 
0.80 
the time of the monitoring project 
Ml in mother 
Yes 
80 
12 
7 
2 
No 
6 
127 
4 
3 
General agreement 
Positive agreement 
Negative agreement 
K-statistic 
85.9% 
85.6% 
91.0% 
0.73 
The reproducibility of the age of the parent at the time of the event was fairly 
good. The discrepancy in reported age was two years or less for 69% of the paternal 
events and 65% of the maternal events, while the discrepancy was more than 5 
years for 8% of the paternal and 13% of the maternal events. Since for most cases 
the discrepancy in the reported age was relatively small, the reproducibility of 
parental history of premature Ml was only somewhat lower than the reproducibility of 
parental history per se (Table 6). 
The reproducibility of the classification into three parental history groups (no, one 
or two parents with a premature Ml) was evaluated as well. The general agreement 
was 75.1% and the K-statistic was 0.64. Of all participants without a parental history 
81% were similarly classified, while this was the case for 75% of those with one 
affected parent and 63% of those with two affected parents. 
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Table 6. Reproducibility of paternal and maternal history of premature* myocardial infarction 
Reported in the 
reproducibility study 
Reported by the participant at the time of the monitoring project 
Ml in father Ml in mother 
Yes No Yes No 
Yes 
No 
Unknown 
Missing 
88 2 
3 114 
8 11 
7 5 
General agreement** 
Positive agreement 
Negative agreement 
K-statistic 
85.1% 
89.8% 
91.8% 
0.73 
62 
13 
5 
7 
1 
142 
6 
5 
General agreement** 
Positive agreement 
Negative agreement 
K-statistic 
84.6% 
82.7% 
91.9% 
0.69 
* Before the age of 61 in the father and before the age of 66 in the mother. ** If the difference in the 
reported age was two years or less, parental history of premature myocardial infarction was 
considered to be similar for the validation study and the monitoring project. 
Reproducibility and differences in risk factors according to parental history 
Participants for whom parental history of premature Ml was discordant had a 
higher mean body mass index (BMI) and lower HDL-cholesterol levels, compared to 
participants for whom parental history was concordant (BMI: 26.4 versus 24.9 kg/m2 
p<0.01, HDL-cholesterol: 1.13 versus 1.23 mmol/l, p<0.05). Other CHD risk factors 
were not significantly different (data not shown). To evaluate the effect of possible 
misclassification due to the imperfect reproducibility of parental history, we 
determined differences in risk factors between parental history groups before and 
after exclusion of subjects for whom parental history was discordant (Table 7). 
Participants with a parental history of Ml had significantly higher total cholesterol 
levels compared with participants without a parental history. No statistically 
significant differences in other risk factors were observed. Exclusion of participants 
for whom parental history was discordant did not result in major alterations in our 
findings. The difference in total cholesterol levels between participants without a 
parental history and those with one affected parent became somewhat more 
pronounced, but the difference with those with two affected parents became 
somewhat smaller. Also the differences in the percentage of alcohol consumers and 
physically inactive subjects became somewhat more pronounced, but statistical 
significance was still not reached. These results suggest that if misclassification due 
to imperfect reproducibility of parental history affected the results, it will have been 
an underestimation of true effects. 
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Table 7. Differences in coronary risk factors according to parental history of premature* 
myocardial infarction 
All participants 
Age 
Body Mass Index (kg/m2) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Total cholesterol (mmol/l) 
HDL-cholesterol (mmol/l) 
Current smokers (%) 
Alcohol consumers (%) 
Physically inactive (%) 
After exclusion* 
Age 
Body Mass Index (kg/m2) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Total cholesterol (mmol/l) 
HDL-cholesterol (mmol/l) 
Current smokers (%) 
Alcohol consumers (%) 
Physically inactive (%) 
Premature 
Neither parent 
n=89 
43.2 ±11.6 
25.5 ± 3.9 
118.8 ±15.3 
75.6 ± 9.9 
5.23 ± 0.97 
1.19 ±0.31 
40.5 
62.9 
37.1 
n=72 
42.6 ± 11.8 
24.9 ± 3.7 
119.3 ±15.7 
75.8 ±10.1 
5.17 ±0.90 
1.20 ± 0.32 
38.9 
68.1 
37.5 
* myocardial infarction in 
One parent 
n=111 
42.7 ± 9.2 
25.1 ± 3.0 
119.5 ±12.7 
77.0 ± 8.3 
5.77 ±1.21 
1.22 ± 0.33 
43.2 
68.5 
38.7 
n=83 
41.9 ±8.8 
24.9 ± 2.8 
118.5 ±13.6 
76.7 ± 8.7 
5.83 ± 1.27 
1.25 ± 0.33 
42.2 
62.7 
38.6 
Both Parents 
n=41 
40.9 ± 8.6 
25.4 ± 3.9 
123.0 ±15.7 
77.4 ±10.9 
5.62 ±1.18 
1.18 ±0.33 
39.0 
53.7 
41.5 
n=26 
40.9 ±7.1 
24.9 ± 3.7 
123.8 ±16.0 
77.3 ±10.4 
5.44 ± 1.06 
1.23 ±0.33 
42.3 
50.0 
50.0 
p-value 
.48 
.76 
.29 
.45 
.0035 
.81 
.87 
.23 
.89 
.76 
.99 
.28 
.76 
.0013 
.68 
.91 
.26 
.51 
* Before the age of 61 in the father and before the age of 66 in the mother, f After exclusion of 
participants for whom parental history of premature myocardial infarction was discordant. BP: Blood 
pressure. Alcohol consumers: drinking more than 1 alcoholic beverage per week. Physically inactive: 
reporting little leisure time physical activity. 
Discussion 
Reproducibility of parental history of myocardial infarction, as assessed in the 
Monitoring Project on Cardiovascular Disease Risk Factors, was good. The 
reproducibility of premature Ml was only somewhat lower, while 75% of the 
participants were classified into the same category of parental history (no, one and 
two affected parents). For most coronary risk factors misclassification due to 
imperfect reproducibility has not biased their associations with parental history of 
premature Ml. For some risk factors it may, however, have led to an underestimation 
of true effects (bias towards the null). Validation of parental history through general 
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practitioners and causes of death was seriously hampered by the limited information 
that could be obtained. 
In the present study, the necessary information to fully validate the parental 
history of Ml could not be obtained. Several others have also attempted to validate 
family history through medical records and/or death certificates.1475,76868992 Most of 
these studies, however, have only provided partial insights. Some confined 
themselves to the verification of positive reports, therefore lacking the false-negative 
reports. In other studies, verification was limited to living next-of kin or the 
verification with death certificates. Doing so, one misses out on fatal Mi's or, in the 
other case, on non-fatal Mi's in subjects who died of non-coronary causes. For these 
reasons, we tried to validate negative as well as positive reports and wanted to use 
information on both death certificates and general practitioners for deceased 
parents. As has been described in the results section, however, it was very difficult 
to obtain the necessary information. In a considerable number of cases the parent's 
general practitioner was retired. For others the medical records were destroyed 
since he/she died more than 10 years ago, which is the official term that medical 
records should be retained. Full information (registration number of death certificate 
and information from the GP) was only available for 15% of the deceased parents. 
For this reason, it seemed not worthwhile to obtain causes of death. Although some 
other investigators were able to obtain only as much as 22% of the death 
certificates, they solely relied hereon for the validation of family history.8992 However, 
the main reason for the failure to obtain death certificates was a lack of, or 
inaccuracies in, necessary information, such as date of birth or place of death. It is 
conceivable that participants who cannot recall their parent's date of birth or other 
necessary information are also less aware of the occurrence of a myocardial 
infarction in their parents. Therefore, validation based on such a limited number of all 
deceased relatives probably results in an overestimation of the validity of self-
reported information. 
Although we were not able to determine the validity of our family history data, we 
were able to determine its reproducibility. The general agreement exceeded 85%, 
while the lowest K-statistics was 0.62 (reproducibility of maternal history in case the 
mother was deceased). Seventy-five percent of the participants were classified into 
the same parental history group according to the monitoring project and the 
reproducibility study. Although the general agreement decreased with the number of 
affected parents (from 81% for subjects without a parental history to 63% for those 
with two affected parents), these differences do not unambiguously mean that 
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participants with two affected parents are less able to give reliable information about 
their family history. The difference is at least in part artificial due to the fact that the 
number of questions that had to be answered - and therefore the chance of making 
mistakes - increased with the increasing number of affected parents. 
Although the reproducibility was high, it might have been somewhat 
underestimated since parental history was considered to be discordant when data 
were missing in the reproducibility study. On the other hand, reproducibility may 
have been overestimated since participants had a higher educational level 
compared to subjects without questionnaire information, and they were more aware 
of their CHD risk (as illustrated by the higher percentage treated for cardiac 
complaints). To our knowledge, reproducibility of family history was evaluated in only 
two other reports.9394 The test-retest correlation for family history of a heart attack in 
the study of Smith and colleagues93 was in agreement with our findings (r=0.90). In 
the other study94 reproducibility of family history of CHD in general was determined, 
but not specified for a family history of Ml. One should keep in mind that a high 
reproducibility does not imply that only little misclassification according to family 
history could have occurred. Probably, some participants reported a parental Ml on 
both occasions while in fact something else happened (for example a cardiac arrest 
or stroke), or vice versa. To evaluate how many subjects were forced into the 'Yes' 
or the 'No' category at baseline examinations, while in fact they were uncertain 
about the exact condition of their parents, 'unknown' was added as a response 
category in the reproducibility study. For the rest, questions about parental history 
were similar as in the monitoring project. Nineteen participants (7.9%) reported in 
the reproducibility study that they did not know whether a myocardial infarction had 
occurred in their father. About half of them reported 'Yes' at baseline examinations. 
Fewer participants (4.6%) reported 'unknown' with respect to the occurrence of a 
myocardial infarction in their mother (n=11), and seven of them (64%) reported 'Yes' 
before. These findings illustrate that 'unknown' does not by definition mean 'No'. As 
a consequence, including subjects that report 'unknown' into the group that reported 
no family history7690, will result in misclassification and a decrease in the reliability of 
studies on family history and disease risk. 
Remarkably, quite a large number (n=6, 67%) of the participants who reported a 
paternal history at baseline examinations, but 'unknown' in the reproducibility study, 
answered to another question in the questionnaire - one about their father's cause of 
death - that their father had died because of a myocardial infarction. Additionally, 
some participants who's parental history was discordant due to missing values or 
contradictory answers, reported that their father died of a myocardial infarction. 
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Taken this information into account, the general agreement increased from 88.8% to 
91.3%, while the K-statistic increased from 0.80 to 0.84. When such information was 
taken into account for maternal history, the general agreement increased from 
85.9% to 88.0%, while the K-statistic increased from 0.73 to 0.77, mainly due to an 
increase in the positive agreement (from 85.6 to 88.5%). 
In conclusion, reproducibility of parental myocardial infarction as assessed in the 
Monitoring Project on Cardiovascular Disease Risk Factors was good. For most 
coronary risk factors misclassification as a result of imperfect reproducibility did not 
bias the association with parental history of premature myocardial infarction. 
However, for some other risk factors it may have led to an underestimation of the 
true effect. Information was too limited to fully evaluate the validity of parental 
history. If one is planning to validate family histories, the necessary information 
should preferably be obtained simultaneously with its assessment. 
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PARENTAL HISTORY OF MYOCARDIAL INFARCTION: 
LIPID TRAITS, GENE POLYMORPHISMS AND LIFESTYLE 
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Abstract 
To investigate the relation between parental history of myocardial infarction (Ml), lipid 
traits and gene polymorphisms involved in lipid metabolism, we examined Dutch men and 
women, who were selected from a large population-based study. Subjects who's father 
(n=112), mother (n=115) or both parents (n=115) suffered from a premature Ml presented 
with significantly higher apolipoprotein (apo) B levels than subjects without a parental history 
(n=114). Genetic analyses revealed that the apo E4 isoform and the D9N mutation in 
lipoprotein lipase (LPL) were more frequent among subjects with a parental history (14.9% 
versus 8.3% and 5.3% versus 0%, respectively; p<0.05). A similar trend was found for the 
LPL N291S mutation. By contrast, other gene polymorphisms proved to be non-informative, 
i.e. LPL S447X, and polymorphisms at the cholesteryl ester transfer protein (TaqlB) and apo 
CHI (Sstl) loci. Body mass index and lifestyle could not explain differences in apo B levels 
between parental history groups. However, in subjects with two affected parents, the higher 
frequency of apo E4 accounted for most (± 50%) of their higher apo B levels. In contrast, 
part of the higher apo B levels in subjects with one affected parent could be explained by the 
higher frequency of LPL mutations (D9N or N291S). 
In conclusion, our results demonstrate that plasma levels of apo B are positively 
associated with a parental history of premature myocardial infarction. This association can 
be partly explained by the presence of the unfavorable apo E4 isoform and the adverse 
effects of two LPL gene mutations (D9N and N291S). 
Introduction 
A family history of coronary heart disease (CHD) is generally accepted to be 
associated with an increased risk for this disorder.12 It is conceivable that this 
association is partly mediated through genetic and environmental factors that affect 
lipid metabolism which are shared by family members. Elevated total cholesterol 
levels and reduced levels of HDL-cholesterol are among the major risk factors for 
CHD.3540 About 40-50% of the inter-individual variation in these lipid traits can be 
explained by differences in genetic background.100 Furthermore, their levels are 
influenced by body mass index101 and lifestyle factors such as smoking102, physical 
activity103 and alcohol consumption.104 
Numerous studies have shown an association between family history of CHD and 
unfavorable lipid and lipoprotein levels8485,105, but we are aware of few investigations 
that evaluated the association between family history and gene polymorphisms that 
affect lipid metabolism.106109 The distribution of several polymorphisms (i.e. the 
apolipoprotein (apo) E polymorphism106110, the apo B Xbal polymorphism109 and the 
S447X mutation in lipoprotein lipase (LPL)111) was found to be dependent on family 
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history status. Tiret and colleagues110 reported that most of the differences in apo B 
levels between young students with a paternal history of myocardial infarction and 
those without such a history was explained by the apo E polymorphism. However, in 
a study among individuals with the most common apo E3E3 genotype, those with a 
family history still had higher apo B levels than those without a family history.106 
Therefore, other genetic factors as well as lifestyle-related factors, such as smoking, 
alcohol consumption and body mass index, possibly account for some of the 
differences in lipid traits between individuals with and without a family history. 
However, the extent to which genetic and lifestyle factors account for associations 
between family history and lipid traits has never been studied using a multivariate 
approach. Therefore, we evaluated the associations of genetic factors, lifestyle-
related factors and lipid traits with parental history of premature myocardial infarction 
(Ml) in a population-based sample (n=456) of Dutch men and women. We had the 
opportunity to study six known polymorphisms in four candidate genes involved in 
lipid metabolism (i.e. Apo E phenotype, LPL N291S, LPL D9N, LPL S447X, CETP 
TaqlB and apo Clll Sstl). 
Methods 
Population 
Subjects were selected from the participants of the Cardiovascular Disease Risk 
Factor Monitoring Project in the Netherlands.95 More than 36,000 men and women, 
20-59 years of age, were examined between 1987 and 1991 at the Municipal Health 
Centers in three Dutch towns (Amsterdam, Doetinchem and Maastricht). A detailed 
description of the examinations is previously published.95 In brief, the examination 
included a physical examination and a self-administered questionnaire, while non-
fasting blood samples were obtained in EDTA-coated vacutainer tubes. After 
fractionation into plasma, erythrocytes and leukocytes, blood samples were stored at 
-20°C. All participants gave their written informed consent. 
Only subjects of Dutch nationality with stored blood samples and a known 
parental history (n=33,884) were eligible for the present study. Parental history of 
premature Ml was considered to be positive if the participant reported a myocardial 
infarction in his/her father before the age of 61 or in his/her mother before the age of 
66. For the remaining participants parental history was considered to be negative. 
From the participants who reported that both parents were affected (n=185), 53 men 
and 62 women were randomly selected, reflecting the gender distribution in this 
group. From the participants who reported that solely the father (n=3,274) or solely 
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the mother (n=1,157) was affected and from the subjects without a parental history, 
another 345 (3x115) subjects were selected. The four groups were matched for 
gender, age (within 5 years) and town of investigation. 
Data collection 
We used data that were collected as part of the monitoring project. Trained 
technicians who were all instructed by the same physician conducted the 
measurements. Height (m) and weight (kg) were measured after participants 
emptied their pockets and removed their shoes. Body mass index (BMI) was 
calculated as weight/height2. Using a random zero sphygmomanometer, systolic and 
diastolic blood pressure were measured twice on the left arm, while the subject was 
in a sitting position. We used the mean of the two measurements in the analyses. 
Hypertension was defined as a systolic blood pressure > 160 mmHg and/or a 
diastolic blood pressure > 95 mmHg and/or the use of anti-hypertensive 
medication.112 
The questionnaire provided information about the presence and (parental) history 
of cardiovascular diseases, history of other diseases, current medication, alcohol 
consumption, current cigarette smoking, and physical activity level. Subjects were 
considered to be on a cholesterol lowering diet when they reported to use a diet 
restricted in energy, fat or cholesterol or the use of a diet enriched in 
polyunsaturated fatty acids. Whether the diet was prescribed by a physician/dietitian 
or was used on own initiative was not taken into account. Subjects were asked how 
they rated their physical activity level during leisure time (little exercise/ exercise for 
at least 4 hours a week/ regular exercise/ regular strenuous exercise). Subjects were 
considered to be physically inactive when they reported little exercise, while the 
remainder was considered to be physically active. 
Laboratory analyses 
As part of the monitoring project plasma total- and HDL-cholesterol were 
enzymatically determined using a Boehringer test kit, within three weeks after 
storage of the samples.96 HDL-cholesterol was determined after precipitation of apo 
B containing lipoproteins with magnesium phosphotungstate.97 Cholesterol 
measurements were performed at the Clinical Chemistry Laboratory of the University 
Hospital 'Dijkzigt' in Rotterdam, the Lipid Reference Laboratory for standardized 
cholesterol determinations in the Netherlands. 
For the present study, additional laboratory analyses were carried out in blood 
samples that were continuously stored at -20°C for 3-7 years. For four subjects no 
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additional analyses were available. Non-fasting triglycerides were measured 
enzymatically using a Boehringer test-kit (GPO-PAP kit no. 701904), while apo B 
concentrations were measured by an immunonephelometric assay.'13 Plasma Lp(a) 
concentrations were measured using a bi-site "sandwich" ELISA1'4, and apo E 
phenotypes were determined by isoelectric focusing of delipidated plasma followed 
by immunoblotting.115 For 384 of the 456 subjects genomic DNA was successfully 
extracted from frozen buffy coats.116 The 72 subjects for whom DNA-extraction failed 
did not differ from the other participants in parental history, or any of the other 
variables relevant to the present study. We had the opportunity to determine three 
mutations in the LPL gene (N291S, D9N and S447X) and two restriction fragment 
length polymorphisms (CETP TaqlB and apo Clll Sstl). Genotypes were determined 
after PCR amplification of the relevant DNA sequences and restriction analyses as 
described previously.53116119 Because of failure to amplify the target sequences for 
some DNA samples, genotypes were missing for an additional number of subjects 
(N291S: n=17, D9N: n=5, S447X: n=2, CETP TaqlB: n=19 and apo Clll Sstl: n=6). 
Statistical analyses 
Analyses were performed with SAS Statistical software (version 6.12, SAS 
Institute, Cary, NC). Triglyceride levels were log-transformed to obtain a normal 
distribution. The association between parental history and variables of interest were 
tested in three ways: 1) we compared differences between the four parental history 
groups, 2) we pooled all subjects with a parental history and compared them to 
those without such a history and 3) we compared the group with two affected 
parents with the group without a parental history. We used analysis of variance or a 
t-test for continuous variables and a x2-test or Fisher's exact test for dichotomous 
variables. Furthermore, we evaluated to what extent BMI, lifestyle factors and gene 
polymorphisms accounted for differences in lipid and (apo)lipoprotein levels 
according to family history. For that, we calculated the change in the sum of squares 
for parental history caused by the introduction of co-variables (i.e. BMI, lifestyle 
factors and gene polymorphisms) into the model. 
Results 
General description of the study population 
The four parental history groups were well matched for age, gender and town of 
investigation (Table 1). More subjects with a parental history of premature Ml 
reported that they were treated by a physician for heart conditions or that they used 
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a cholesterol-lowering diet as compared to subjects without such a history. The 
differences were most pronounced for the group with two affected parents. Only a 
small number of subjects reported a myocardial infarction (n=8) or a stroke (n=6), 
and they mainly (n=7 and n=6, respectively) occurred in the group with a parental 
history. Two subjects, both with a parental history of Ml, reported diabetes mellitus. 
Although both systolic and diastolic blood pressure were only marginally higher 
among subjects with two affected parents, the percentage of hypertensive subjects 
among them was significantly increased. This difference could not be explained by a 
higher percentage of treated hypertensives. 
Parental history and lipid traits 
Subjects with a parental history of premature Ml presented with higher total 
cholesterol and apo B levels compared to those without a parental history (Table 2). 
Differences in HDL-cholesterol and triglyceride levels between the four groups were 
not statistically significant, but their levels seemed to be somewhat less favorable in 
those with two affected parents compared to subjects without a parental history. 
Furthermore, a higher percentage of the subjects with solely an affected father 
presented with elevated Lp(a) levels (>30 mg/dl), but this was not observed for 
subjects with solely an affected mother or two affected parents. 
Parental history, BMI, lifestyle factors and polymorphisms 
None of the lifestyle factors nor BMI were significantly associated with parental 
history of premature Ml (Table 3). In contrast, the distribution of some of the 
polymorphisms among subjects with a parental history differed from the distribution 
among subjects without a parental history. There were more carriers of the apo E4 
isoform among those with a parental history of premature Ml, especially among 
subjects with two affected parents (Table 4). Moreover, while no carriers of the LPL 
D9N mutation were found in the subjects without a parental history, the prevalence 
varied from 4-7% in the groups with a parental history (Table 5). Also the LPL 
N291S mutation tended to be more prevalent among those with a parental history, 
but statistical significance was not reached. For the other gene polymorphisms (i.e. 
LPL S447X, CETP TaqlB and apo Clll Sstl) differences between the groups were 
smaller and not statistically significant. 
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Table 4. Apolipoprotein E phenotypes and isoform frequencies according to parental history 
of premature* myocardial infarction 
Apo E phenotype 
E2E2 
E2E3 
E2E4 
E3E3 
E4E3 
E4E4 
Apo E isoforms 
E2 
E3 
E4 
Negative 
n=114 
0 
12.3 
0.9 
71.1 
15.8 
0 
0.066 
0.851 
0.083 
Parental History 
Positive 
Father 
n=112 
1.8 
7.1 
2.7 
63.4 
24.1 
0.9 
0.067 
0.790 
0.143 
, affected parent 
Mother 
n=115 
0 
8.7 
2.6 
65.2 
22.6 
0.9 
0.057 
0.809 
0.135 
Both 
n=115 
0.9 
7.8 
4.4 
61.7 
20.9 
4.4 
0.070 
0.761 
0.170 
P-valuef 
1 2 
.19 .11 
.22 .039 
3 
.033 
.019 
* < 60 years in men and < 65 years in women, t 1) comparison between the four parental history 
groups, 2) comparison of all subjects with a parental history pooled together with subjects without such 
a history and 3) comparison of subjects with two affected parents with subjects without a parental 
history. 
Do lifestyle and gene polymorphisms explain differences in apo B levels? 
We evaluated to what extent BMI, lifestyle factors and genetic factors explained 
the differences in apo B levels between the parental history groups. Only subjects 
without missing data (n=341) could be included in these analyses. BMI and lifestyle 
factors could explain only a small part of the differences in plasma apo B levels 
between individuals with and those without a family history (Table 6). In contrast, the 
apo E polymorphisms accounted for a little more as 50% of the higher apo B levels 
in those with two affected parents as compared to those without a parental history. 
Further adjustment for the LPL N291S and D9N mutations demonstrated that these 
two polymorphism explained an additional 15% of the differences, which were now 
no longer statistically significant. In contrast, the apo E polymorphism did not 
account for the higher apo B levels in subjects with one affected parent. In these 
subjects, it was merely the higher percentage of carriers of the LPL D9N and N291S 
mutations that accounted for some, but not all, of the differences. After adjustments, 
individuals with one affected parent still had higher apo B levels compared to those 
without a parental history. The other three polymorphisms that we studied (LPL 
S447X, CETP TaqlB and apo Oil) Sstl) explained less than 10% of the differences. 
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Table 5. Variation in the gene coding for Lipoprotein Lipase (LPL), apolipoprotein CM, and 
Cholesteryl Ester Transfer Protein (CETP) according to parental history of premature* 
myocardial infarction 
LPL (% carriers) 
N291S 
D9N 
S447X 
Apo CHI Sstl 
S2 carriers (%) 
CETP TaqlB 
B2B2 genotype (%) 
Negative 
n=88-92 
2.2 
0 
25.0 
23.1 
21.6 
Parental history 
Positive 
Father 
n=90-95 
4.4 
4.3 
22.1 
21.3 
17.4 
, affected 
Mother 
n=94-99 
7.5 
7.1 
20.2 
22.5 
16.8 
parent 
Both 
n=90-96 
7.5 
4.2 
17.7 
19.0 
15.6 
1 
.31 
.058 
.43 
.91 
.74 
P-valuet 
2 
.18 
.027 
.31 
.29 
.66 
3 
.17 
.12 
.22 
.49 
.30 
Numbers vary due to failure to amplify the target sequences for some DNA samples. * < 60 years in 
men and < 65 years in women, t 1) comparison between the four parental history groups, 2) 
comparison of all subjects with a parental history pooled together with subjects without such a history 
and 3) comparison of subjects with two affected parents with subjects without a parental history. 
Discussion 
We observed that adults of Dutch descent with a parental history of premature 
myocardial infarction (Ml) had higher levels of total cholesterol and apo B as 
compared to those without such a history. These differences could be partly 
explained by variation at the apo E (apo E4 isoform) and LPL gene loci (D9N and 
N291S mutation). No significant differences were found in BMI and lifestyle factors 
as well as the frequencies of the LPL S447X mutation and both the CETP TaqlB and 
apo Clll Sstl polymorphisms. 
In the present study, parental history was determined based on self reported data. 
In general the validity of such data is fairly good.75 The reproducibility of our parental 
history data, as determined in a subsample of participants in the monitoring project, 
was also good. Seventy-five percent of the subjects were similarly classified 
according to both inquiries, while only 7% of the subjects were in another parental 
history group. For the remaining 18% of the subjects (n=16) parental history was 
unknown in the reproducibility study. Reproducibility was quite similar for each 
parental history group and not related to plasma total and HDL-cholesterol levels. 
For a small number of subjects who were studied in the present study (n=104) the 
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reproducibility of parental history of Ml was known. Differences between the parental 
history groups in plasma lipids and lipoproteins and genotype frequencies remained 
similar, or became slightly more pronounced, after exclusion of those individuals for 
whom parental history of premature Ml was discordant or missing. Therefore, we 
find it unlikely that the use of self-reported family histories has biased our results. 
Table 6. Extent to which differences in apo B levels according to parental history of 
premature* myocardial infarction are explained by body mass index, lifestyle factors and 
gene polymorphisms. 
No versus one affected parent 
Crude 
After adjustment for: 
BMI and lifestyle* 
+ Apo E polymorphism 
+ LPLD9NandN291S 
+ LPL S447X, CETP TaqlB, apo 
No versus two affected parents 
Crude 
After adjustment for: 
BMI and lifestyle* 
+ Apo E polymorphism 
+ LPLD9NandN291S 
+ LPL S447X, CETP TaqlB, apo 
Clll Sstl 
CI 11 Sstl 
P-value for 
difference 
.008 
.006 
.006 
.017 
.025 
.023 
.018 
.097 
.17 
.21 
Explained by covariatest 
total 
10% 
12% 
37% 
45% 
1% 
57% 
71% 
79% 
separate 
contribution 
10% 
2% 
25% 
8% 
1% 
56% 
14% 
8% 
Only individuals without any missing values (n=341) are included in the analyses. BMI: Body mass 
index. LPL: Lipoprotein Lipase. CETP: Cholesteryl Ester Transfer Protein, t Calculated from the 
change in sum of squares for parental history of premature myocardial infarction caused by the 
introduction of covariates in the model. £ Smoking, number of cigarettes per day, alcohol consumption, 
number of alcoholic beverages per week, physical inactivity. 
Family history of coronary heart disease has been associated with differences in 
lipids and lipoproteins, but not for all lipid traits the results have been consistent. The 
most consistent finding is a higher level of total cholesterol, LDL-cholesterol or apo B 
among those with a family history.84,85,105 These results are in accordance with our 
findings, in that subjects with a parental history of premature Ml presented with 
higher levels of total cholesterol and especially with higher apo B levels. The latter is 
in line with results of Lamarche and colleagues, who showed that, among metabolic 
variables, apo B was the strongest correlate of ischemic heart disease.'20 Also 
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elevated Lp(a) levels have been associated with an increase in CHD risk.63 Although 
as much as 90% of its levels are genetically determined64, we did not find consistent 
differences in Lp(a) levels between the parental history groups. However, we 
measured Lp(a) levels in plasma samples that were stored for several years. 
Although the mean storage time of the samples was similar for each parental history 
group, a genotype dependent fall in Lp(a) levels over time, as observed by 
Kronenberg and colleagues, may have resulted in false lower Lp(a) levels in the 
groups with a parental history.121 We can therefore not exclude the possibility that a 
parental history of premature Ml is associated with higher Lp(a) levels. 
Since the association between family history and CHD becomes more 
pronounced when more family members are affected90, we hypothesized that 
differences in plasma lipid and lipoprotein levels would be largest for subjects with 
two affected parents. Interestingly, total cholesterol and apo B levels were even 
slightly lower compared to those in subjects with only one affected parent. In an 
attempt to explain this finding, we investigated whether subjects with two affected 
parents had a healthier lifestyle, since they may have been more aware of their CHD 
risk. However, BMI, smoking habits, alcohol consumption and physical activity levels 
were not significantly different from those observed in subjects with only one 
affected parent. Moreover, total cholesterol and apo B levels remained lower after 
exclusion of all subjects who reported the use of a cholesterol-lowering diet. Thirdly, 
none of the subjects reported the use of lipid lowering medication. Finally, it is 
possible that more individuals with two affected parents, especially those with one or 
more risk factors, refused or were unable to participate in the Cardiovascular 
Disease Risk Factor Monitoring Project due to illness or death. However, the number 
of subjects with two affected parents were as expected from the overall prevalence 
of a paternal and maternal history of premature Ml. Taken together, we do not have 
a clear explanation for the slightly lower total cholesterol and apo B levels in subjects 
with two affected parents. 
We have tried to get more insight into factors that underlie the higher levels of apo 
B among those subjects with a parental history of premature Ml. It became apparent 
that BMI and lifestyle factors, i.e. cigarette smoking, alcohol consumption and 
physical activity, played only a minor role. In the European Atherosclerosis Research 
Study (EARS) higher apo B levels in young men and women with a paternal history 
could largely be explained by a higher frequency of the apo E4 isoform and a lower 
frequency of the E2 isoform among them.110 In the present study, the frequency of 
the E4 isoform was elevated among subjects with a parental history of premature Ml. 
The apo E polymorphism could explain a significant part (about 50%) of the higher 
62 Chapter 4 
apo B levels in subjects with two affected parents, but not in those with only one 
affected parent. In the latter group, some, but not all, of the differences in apo B 
levels could be explained by the higher frequency of two LPL mutations (N291S and 
D9N). It is unlikely that these two mutations also account for some of the higher apo 
B levels among EARS participants with a paternal history of Ml. In EARS no 
differences in the frequencies of the LPL N291S and D9N mutation according to 
parental history could be detected.122 Moreover, these LPL mutations were 
associated with plasma triglyceride levels, not with plasma total cholesterol and apo 
B.'22 However, in our sample as well as other - highly selected - study populations of 
Dutch descent, carriers of the LPL N291S or D9N mutation had elevated total 
cholesterol or apo B levels.123125 The discrepancies between EARS and our study 
may therefore be related to differences in the genetic and environmental background 
of the study populations. Additionally, different definitions for family history were 
used. In EARS family history was based only on premature paternal but not on 
maternal myocardial infarctions. 
After adjustment for BMI, lifestyle and the genetic factors that we studied, 
subjects with one affected parent still had higher plasma apo B levels than subjects 
without a parental history of premature myocardial infarction. Since we had the 
possibility to evaluate only a small number of genetic factors, other unmeasured 
gene variants are possibly responsible for the remaining differences in plasma apo B 
levels. The apo E polymorphism explains about 10-15% of the inter-individual 
variation in plasma apo B levels.126 Until now, no other common polymorphisms is 
described which explains such a large part of the inter-individual variation in apo B. 
Therefore, it is not easy to predict which other genes or genotypes may account for 
the remaining higher apo B levels in subjects with a parental history of premature Ml. 
A recently described common mutation in the gene coding for microsomal 
triglyceride transfer protein127 may, however, be a likely candidate. 
Besides lipids and lipoproteins, other risk factors may be responsible for the 
increased risk in subjects with a family history of CHD. Therefore, gene variations 
that affect these other risk factors may also be associated with a family history of Ml. 
In this respect, we made an interesting observation. The difference in the apo E4 
isoform frequency between parental history groups remained statistically significant 
after adjustment for apo B levels. This implies that the increased risk of CHD in E4-
carriers might not only be mediated through its effects on lipid metabolism. It has, for 
example, been demonstrated that apo E has antioxidant activity but that it is less for 
the apo E4 isoform, compared to the other common isoforms.128 Additionally, apo E 
plays roles in tissue regeneration, immunoregulation and cell growth and 
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differentiation129 suggesting that the apo E polymorphism may also affect CHD risk 
through these mechanisms. We further observed that in our sample the percentage 
of hypertensives was significantly higher among subjects with two affected parents 
compared to those without a parental history of Ml. Therefore, gene polymorphisms 
involved in blood pressure regulation may be differently distributed over the parental 
history groups. 
In conclusion, our results showed that plasma levels of total cholesterol and 
especially apo B are higher in subjects with a parental history of premature 
myocardial infarction, as compared to those without such a history. While BMI and 
lifestyle factors seem to play a minor role, some genetic factors underlie the higher 
apo B levels in individuals with a parental history of premature Ml. The apo E 
polymorphism, the LPL D9N and the LPL N291S mutations could explain some, but 
not all, of the differences in plasma apo B levels. Other factors must therefore be 
responsible for some of the higher apo B levels in subjects with a parental history of 
premature myocardial infarction. 
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Abstract 
To elucidate the role of modifiable factors and the apolipoprotein E polymorphism in 
explaining lipid profiles reflecting low, average and high risk for coronary heart disease, we 
selected subjects from a large population-based study. Subjects with low total cholesterol 
(TC) (< 15th percentile) and high HDL-cholesterol levels (> 85th percentile) were randomly 
selected (n=99) and represent subjects with a low risk lipid profile. Additionally, 95 subjects 
with total and HDL-cholesterol levels in the 15% around the population-median (median risk 
lipid profile) and 100 subjects with high TC (> 85th percentile) and low HDL-cholesterol 
levels (<15th percentile) (high risk lipid profile) were selected. Compared with E3E3 
subjects, the likelihood for a low risk lipid profile was considerably higher (odds ratio 14.3; 
2.6-79) in female, but not in male E2-carriers (1.5; 0.3-6.7). Smoking and alcohol 
consumption were independently associated with a low risk lipid profile in both genders, 
physical inactivity only in women. The odds ratio for a high risk lipid profile was elevated in 
male E4-carriers (4.9; 1.1-23) only. In addition to the E4 isoform, smoking and physical 
inactivity, overweight was the main determinant for a high risk lipid profile (odds ratio 16.8; 
3.4-82). Male overweight E4-carriers had a 50 times higher likelihood of a high risk lipid 
profile than E3E3 men of normal weight. In women, only overweight was independently 
associated with a high risk lipid profile. 
Our results suggest that both modifiable factors and the apolipoprotein E polymorphism 
contribute to a lipid profile, reflecting low, average and high risk for coronary heart disease, 
but effects may be gender-specific. 
Introduction 
Elevated levels of total- and low density lipoprotein (LDL) cholesterol and low 
levels of high density lipoprotein (HDL) cholesterol are important risk factors for 
coronary heart disease (CHD).130 Their plasma levels are determined by modifiable 
as well as genetic factors. Modifiable determinants that are positively associated 
with total- and LDL-cholesterol levels are body mass index (BMI), dietary saturated 
fat, cholesterol, and cigarette smoking.102131133 Alcohol consumption and physical 
activity are positively associated with HDL-cholesterol103134"136, while smoking and BMI 
are inversely associated.102137 
Numerous studies have shown that the Apo E polymorphism is a major genetic 
factor influencing total and LDL-cholesterol levels, explaining about 7% of their 
interindividual variation in the general population.129138 The e2 allele is associated 
with reduced total and LDL-cholesterol, and Apo B levels and higher levels of Apo E, 
while the opposite is true for the e4 allele.129138139 In individuals with 
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hypercholesterolemia a higher prevalence of the e4 allele is demonstrated138, while in 
hypocholesterolemic subjects the e2 allele frequency was about four times higher 
than in normolipidemic controls.140 
Most studies have estimated the effect of the Apo E polymorphism after 
adjustment of the lipid levels for covariables. Little is known about the importance of 
the Apo E polymorphism compared with modifiable determinants of extreme lipid 
profiles, reflecting low or high CHD risk. Furthermore, very few studies have 
addressed the issue of interaction between modifiable factors and the Apo E 
polymorphism, the results were inconclusive.141145 
To elucidate how environment and genes interact in determining the individual 
susceptibility to multifactorial diseases is one of the major challenges of genetic 
epidemiology. The identification of such gene-environment interactions may provide 
better insight into the mechanisms involved in gene regulation and may help to focus 
intervention strategies on target subgroups. 
We therefore evaluated both modifiable factors and the Apo E polymorphism and 
their interaction in subjects with lipid profiles reflecting a low, average and high risk 
for CHD selected from participants of a large screening project of cardiovascular risk 
factors in the Netherlands.95 
Methods 
Population 
Subjects were selected from the population of the Cardiovascular Disease Risk 
Factor Monitoring Project, a screening project for cardiovascular disease risk factors 
in the Netherlands, carried out between 1987 and 1991.95 More than 36,000 men 
and women, 20-59 years of age, were examined at the Municipal Health Offices in 
three towns: Amsterdam, the country capital in the west, Doetinchem in a rural area 
in the east and Maastricht in the south. 
Three groups of subjects were selected to represent individuals with a low, 
average and high risk for CHD according to their age and gender adjusted total- and 
HDL-cholesterol levels. Only subjects of Dutch nationality and who did not use 
cholesterol lowering drugs (n=32,473) were eligible for the present study. From the 
subjects with high total cholesterol levels (>85th percentile) and low HDL-cholesterol 
levels (<15th percentile) (n=534) 38 men, 38 premenopausal and 38 
postmenopausal women were randomly selected. This group is referred to as 
subjects with a high risk lipid profile. Subjects with a median risk lipid profile (n=114) 
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were selected from the 716 subjects with both total and HDL-cholesterol levels in the 
15% around the median (42.5-57.5th percentile). Another 114 subjects were 
selected from subjects with low total cholesterol levels (<15th percentile) and high 
HDL-cholesterol levels (>85th percentile) (n=893) and represent subjects with a low 
risk lipid profile. Groups were matched for age (within 5 years), gender and 
menopausal status. 
Data collection 
The examination included anthropometric measurements, blood sampling and a 
self-administered questionnaire. Height and weight were measured by trained 
technicians who were instructed by the same physician. BMI was calculated as 
weight (kg)/height2 (m). Non-fasting blood samples were obtained in EDTA-coated 
vacutainer tubes. Plasma was stored at -20°C. An informed-consent form was 
completed, agreeing the use of stored blood samples for further scientific research. 
The questionnaire provided information about the presence and (family) history of 
cardiovascular diseases, history of hypertension, hypercholesterolemia and other 
diseases, current medication, alcohol consumption, cigarette smoking, physical 
activity and, for women, reproductive history. Usual dietary intake was assessed by 
including a short (70 food items) self-administered semi-quantitative food frequency 
questionnaire.'46 Cholesterol intake and dietary fat composition were calculated 
using the computerized version of the Netherlands food table (NEVO).147 
Women who reported that they no longer menstruated because of the 
menopause were classified as postmenopausal. Other women were classified as 
premenopausal. Overweight was defined as BMI > 25 kg/m2.148 Alcohol consumption 
was measured in glasses/day and categorized into 3 classes: low (< one 
glass/week), moderate (one glass/week to three (men) or two (women) glasses/day) 
and high (> three (men) and > two (women) glasses/day). Subjects who reported 
little physical activity during leisure time were classified as physically inactive. 
Laboratory measurements 
Within 3 weeks after plasma storage, total- and HDL-cholesterol were determined. 
Total cholesterol was determined enzymatically using a Boehringer test-kit.96 HDL-
cholesterol was determined after precipitation of apo B containing lipoproteins with 
magnesium phosphotungstate.97 Cholesterol measurements were performed at the 
Clinical Chemistry Laboratory of the University Hospital 'Dijkzigt' in Rotterdam, the 
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Lipid Reference Laboratory for standardized cholesterol determinations in the 
Netherlands. 
In subjects selected for the present study non-fasting triglyceride concentrations 
and apolipoprotein levels were measured. The storage time of the plasma samples 
was 3-7 years. Triglycerides were measured enzymatically using a Boehringer test-
kit (GPO-PAP kit no. 701904). Apo B concentrations were measured by an 
immunonephelometric assay (INA) as described by Rosseneu et al.'13, while plasma 
Apo E levels were determined by enzyme-linked immunosorbent assay (ELISA).149 
Apo E phenotypes were determined by isoelectric focusing of delipidated plasma 
followed by immunoblotting using a polyclonal goat anti-human apo E antiserum as 
first antibody, as previously described by Havekes et al.'16 Plasma Lp(a) 
concentrations were measured using a bi-site 'sandwich' ELISA.114 
Statistical analyses 
Additional information revealed that the menopausal status of 24 women, who 
initially had been regarded as premenopausal, in fact was not known due to 
gynecological surgery. They were excluded from analyses because the type of 
operation (hysterectomy and/or oophorectomy) was not known, and therefore 
hormonal status could not be determined. Redefining the lower, median and upper 
15% of the total- and HDL-cholesterol distribution, using this additional information, 
resulted in the exclusion of an additional 18 subjects, since they no longer met the 
selection criteria. Another six subjects were excluded because no apo E phenotype 
or triglyceride levels were available, leaving 294 subjects (110 men, 74 pre- and 112 
postmenopausal women) for statistical analyses (mean age 45.6 + 10.8). Analysis 
was carried out using the Statistical Analysis System (SAS version 6.10, SAS 
Institute, Cary, NC), separately for men and women, with adjustment for matching 
criteria (age and menopausal status in women). P-values less than 0.05 were 
considered statistically significant. 
Triglyceride and apo E values were log-transformed to improve normality. Allele 
frequencies were estimated by gene counting. Differences between the three groups 
in lipid traits and modifiable factors were determined by analysis of variance for 
continuous variables and logistic regression for categorical variables. Differences in 
apo E allele frequencies and phenotype distributions were determined using a %2-
test, while differences in Lp(a) levels were tested using a non-parametric (Kruskall-
Wallis) test. 
Since very few subjects had the E2E2 (n=7) or E4E4 phenotype (n=3), subjects 
were regrouped into E2-carriers (E2E2 and E3E2 phenotype), subjects with the 
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E3E3 phenotype and E4-carriers (E4E3 and E4E4 phenotype). Subjects with the 
E4E2 phenotype (n=4) could not be assigned to any of the groups and were 
therefore excluded from further analyses. 
Odds ratio's for a low and high risk lipid profile in E2- and E4-carriers compared 
with subjects with the E3E3 phenotype were calculated simultaneously with odds 
ratio's for modifiable factors (overweight, alcohol consumption, smoking and physical 
inactivity) from a multivariate model using logistic regression. The group with a 
median risk lipid profile was taken as control group. Odds ratios for a low and high 
risk lipid profile were also calculated for the combined effect of the modifiable factors 
and the Apo E polymorphism. 
Results 
Table 1. Matching criteria, lipids (mmol/l) and apolipoproteins (mg/dl) in men and women 
selected according to both total and HDL-cholesterol levels. 
Lipid profile 
low risk median risk high risk test" 
MEN n=38 n=37 n=35 
Age (years) 42.7 ± 9.3 42.8 ± 9.4 42.3 ± 9.9 
Total cholesterol 4.34 ±0.49 5.57 ±0.38 7.60 ±0.79 
HDL-cholesterol 1.65 ±0.18 1.10 ±0.03 0.74 ± 0.07 
Triglycerides" 0.87 ± 0.54 1.82 ±0.77 4.39 ±2.17 
ApoB 76.0 ±18.6 130.4 ±18.7 181.9 ±38.1 
ApoEa 2.6 ±0.9 3.2 ±1.2 5.9 ± 3.0 
Lp(a)c 12.4 ±17.7 16.5 ±19.9 11.7 ±21.5 NS 
WOMEN n=61 n=58 n=65 
Age (years) 47.3 ±11.2 47.7 ±11.7 47.2 ±10.7 
Postmenopausal 62.3% 65.5% 55.4% 
Total cholesterol 4.42 ±0.67 5.79 ±0.62 7.68 ±0.86 
HDL-cholesterol 1.87 ±0.20 1.34 ±0.03 0.94 ±0.09 
Triglycerides8 0.89 ± 0.34 1.37 ± 0.51 2.92 ± 1.44 
ApoB 74.9 ±25.1 127.4 ±18.3 199.7 ±37.1 
ApoEa 3.5 ±1.5 3.2 ±1.3 4.9 ± 2.0 
Lp(a)c 14.5 ± 19.3 18.3 ± 23.9 15.8 ± 18.8 NS 
a. Log-transformed values are used in analyses, but arithmetic means are presented, b. Adjusted for 
age and menopausal status, c. Non-parametric test (Kruskall-Wallis). * p < 0.0001. Values are 
presented as mean ± SD. NS: Not significant. 
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In the selected population, Apo B levels rose gradually when the lipid profile 
deteriorated (Table 1). In subjects with a high risk lipid profile not only apo B levels 
but also triglyceride concentrations and apo E levels were elevated, especially in 
men. This suggests that VLDL and triglyceride-rich remnant particles might 
accumulate in the high risk groups. No significant differences in Lp(a) levels were 
observed. 
Table 2. Modifiable factors according to low, median or high risk lipid profiles. 
Lipid profile 
MEN 
BMI (kg/m2) 
Smokers (%) 
Alcohol intake (%) 
Low 
Moderate 
High 
Physically inactive (%) 
Fat intake (en%)a 
Total 
Saturated 
Cholesterol (mg/d)a 
WOMEN 
BMI (kg/m2) 
Smokers (%) 
Alcohol intake (%) 
Low 
Moderate 
High 
Physically inactive (%) 
Fat intake (en%)a 
Total 
Saturated 
Cholesterol (mg/d)a 
low risk 
n=38 
23.8 ± 2.4 
21.1 
13.2 
68.4 
18.4 
23.7 
39.1 ±4 .1 
16.0 ± 2 . 9 
339 ± 93 
n=61 
23.7 ±3 .1 
32.8 
37.7 
47.5 
14.8 
24.6 
40.5 ± 5.4 
16.0 ±2 .4 
273 ± 83 
median risk 
n=37 
24.9 ± 3.2 
43.2 
27.0 
64.9 
8.1 
18.9 
39.1 ± 5.2 
15.0 ±2 .6 
303 ± 74 
n=58 
25.7 ± 4.5 
44.8 
58.6 
34.5 
6.9 
41.4 
40.7 ± 5.4 
15.9 ±2 .1 
259 ± 73 
high risk 
n=35 
27.7 ± 3.0 
71.4 
28.6 
57.1 
14.3 
48.6 
38.9 ± 3.8 
15.8 ±2 .5 
337 ± 94 
n=65 
27.7 ± 5.0 
56.9 
69.2 
29.2 
1.5 
46.2 
41.4 ± 5 . 0 
16.5 ± 2 . 8 
276 ± 56 
test* 
*** 
*** 
NS 
* 
NS 
NS 
NS 
*** 
** 
*** 
** 
NS 
NS 
NS 
Values are presented as mean ± SD. NS: not significant, a. n=28, 32 and 32 for men with a low, 
medium and high risk lipid profile, respectively and n=34, 40 and 45 for women with a low, medium 
and high risk lipid profile, respectively, b. Adjusted for age. * p<005, ** p<0.01, *** p< 0.0001. 
In both men and women large differences in BMI, smoking habits and physical 
activity were found between the three groups (Table 2). These modifiable factors 
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were positively associated with deteriorating lipid profiles. The inverse association 
with alcohol consumption was only significant in women. Despite these large 
differences in modifiable factors, differences in all lipid values remained highly 
significant (p<0.0001) after adjustment for these same variables. Dietary factors did 
not seem to contribute to a large extent to extreme lipid profiles in this population. 
The intake of total and saturated fat as well as cholesterol intake did not differ 
between the groups (Table 2). 
Table 3. Apolipoprotein E phenotype and allele frequencies in according to low, median and 
high risk lipid profiles. 
MEN 
Phenotype (% (n))* 
E2/2 
E3/2 
E3E3 
E4/2 
E4E3 
E4E4 
Allele frequencies** 
e2 
e3 
e4 
WOMEN 
Phenotype (% (n))* 
E2/2 
E3/2 
E3E3 
E4/2 
E4E3 
E4E4 
Allele frequencies" 
e2 
e3 
e4 
low risk 
n=38 
5.3 (2) 
13.2 (5) 
68.4 (26) 
2.6 (1) 
10.5 (4) 
0.0 (0) 
0.132 
0.803 
0.066 
n=61 
4.9 (3) 
19.7 (12) 
59.0 (36) 
1.6 (1) 
14.8 (9) 
0.0 (0) 
0.156 
0.762 
0.082 
Lipid profile 
median risk 
n=37 
0.0 
10.8 
64.9 
0.0 
24.3 
0.0 
(0) 
(4) 
(24) 
(0) 
(9) 
(0) 
0.054 
0.824 
0.122 
n=58 
0.0 
3.5 
70.7 
1.7 
22.4 
1.7 
(0) 
(2) 
(41) 
(1) 
(13) 
(D 
0.026 
0.836 
0.138 
high risk 
n=35 
5.7 (2) 
2.9 (1) 
48.6 (17) 
2.9 (1) 
37.1 (13) 
2.9 (1) 
0.086 
0.686 
0.229 
n=65 
0.0 (0) 
4.6 (3) 
69.2 (45) 
0.0 (0) 
24.6 (16) 
1.5 (1) 
0.023 
0.839 
0.139 
* p<0.05 in women, ** p<0.05 in men, p<0.0001 in women. x2-test. 
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The apo E allele frequency distribution also differed significantly between the 
groups (Table 3). In men with a low risk lipid profile a higher frequency of the e2 
allele was observed than in the two other groups. In the group with a high risk lipid 
profile, two subjects had the E2E2 phenotype. Both men had very high total 
cholesterol levels (> 8 mmol/l) and hypertriglyceridemia (> 5 mmol/l), suggesting the 
presence of type III hyperlipoproteinemia. The frequency of the e4 allele gradually 
increased with lipid profiles reflecting increasing risk for CHD (Table 3). 
In women, apo E phenotype and allele frequency distributions were comparable 
between those with a median and those with a high risk lipid profile (Table 3). 
Subjects with a low risk lipid profile, on the contrary, were characterized by a much 
higher frequency of E2-carriers, while the frequency of the e4 allele was slightly 
lower. 
In Tables 4 and 5 results of multivariate analyses are shown. In female E2-
carriers the odds ratio for a low risk lipid profile, compared with E3E3 subjects, was 
considerably higher, than in male E2-carriers. In both men and women, smoking 
reduced and alcohol consumption increased the odds for a low risk lipid profile. 
Additionally, physical inactivity was independently associated with a reduced odds 
for a low risk lipid profile in women, while in men the association with overweight 
was borderline significant (p=0.053). 
Table 4. Multiple adjusted3 odds ratios for a low or high risk lipid profile according to apo E 
phenotype and modifiable factors in men. 
Apo E polymorphism 
E3E3 (reference) 
E2-isoform 
E4-isoform 
Overweight 
Smoking 
Alcohol consumption 
Low (reference) 
Moderate 
High 
Physical inactivity 
Low risk 
OR 
1.00 
1.46 
0.38 
0.30 
0.15 
1.00 
2.46 
17.80 
1.81 
lipid profile 
95% CI 
-
(0.32-6.74) 
(0.09-1.71) 
(0.09-1.01) 
(0.04-0.58) 
-
(0.63-9.58) 
(2.17-146.2) 
(0.50-6.61) 
High risk lipid profile 
OR 
1.00 
1.62 
4.94 
16.81 
6.81 
1.00 
1.10 
0.53 
5.24 
95% CI 
-
(0.19-13.6) 
(1.06-23.1) 
(3.43-82.4) 
(1.59-29.1) 
-
(0.23-5.27) 
(0.06-4.62) 
(1.30-21.1) 
95% CI: 95%-confidence interval, a. Apo E polymorphism, modifiable factors and matching criteria 
(age) were simultaneously included as independent variables in the model. 
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The odds ratio for a high risk lipid profile was only elevated for male E4-carriers, 
but not in female E4-carriers. The association of both the apo E2 and E4 isoform 
with lipid profiles did not differ statistically significant according to gender. In men 
smoking, physical inactivity and, especially, overweight were independently 
associated with a high risk lipid profile in addition to the E4 isoform (Table 4). In 
women, the only risk factor independently associated with a high risk lipid profile was 
overweight (Table 5). Exclusion of the few subjects with the E2E2 (n=7) or E4E4 
(n=3) phenotype did not significantly alter the results. Odds ratios from the 
multivariate model were comparable to those from the model including these 
subjects, except that for female E2-carriers the chance of a low risk lipid profile was 
slightly reduced (9.26 vs. 14.3). 
Table 5. Multiple adjusted3 odds ratio's for a low or high risk lipid profile according to apo E 
phenotype and modifiable factors in women. 
Apo E polymorphism 
E3E3 (reference) 
E2-isoform 
E4-isoform 
Overweight 
Smoking 
Alcohol consumption 
Low (reference) 
Moderate 
High 
Physical inactivity 
Low Risk lipid profile 
OR 
1.00 
14.30 
0.75 
0.43 
0.35 
1.00 
3.30 
5.79 
0.25 
95% CI 
-
(2.58-79.3) 
(0.26-2.17) 
(0.16-1.13) 
(0.13-0.96) 
-
(1.30-8.39) 
(1.20-28.0) 
(0.09-0.69) 
High Risk lipid profile 
OR 
1.00 
0.87 
1.29 
2.78 
1.91 
1.00 
0.84 
0.20 
1.19 
95% CI 
-
(0.13-5.95) 
(0.53-3.16) 
(1.21-6.42) 
(0.88-4.14) 
-
(0.36-1.97) 
(0.02-2.01) 
(0.54-2.66) 
95% CI: 95%-confidence interval, a. Apo E polymorphism, modifiable factors and matching criteria 
(age and menopausal status) were simultaneously included as independent variables in the model. 
We also tried to determine the interaction between the apo E polymorphism and 
modifiable factors on the chance of a low or high risk lipid profile. Subdivision of the 
subjects according to apo E phenotype and the level of modifiable factors, however, 
often resulted in very small numbers. Therefore, interaction terms were never 
statistically significant and it was hard to compare odds ratios according to 
phenotype because of the large confidence intervals. Surprising, however, was that 
in male subjects with a high risk lipid profile, overweight E4-carriers were 
overrepresented (n=12). They had a 50 (OR: 50, 95% CI: 4.6-545) times higher 
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associated with a high risk lipid profile in men but not in women. Results from the 
Framingham Offspring Study showed that the effect of the apo E polymorphism on 
plasma lipids was largest in postmenopausal women.155 The authors suggested that 
the drop in plasma estrogens after menopause might explain their results. Even 
though in the present study the E2 isoform was associated with a low risk lipid profile 
in both pre- and postmenopausal women, sex-hormones might partly explain the 
male-female difference in the effect of Apo E2 and as such can not be excluded. 
The difference in mean apo B levels between subjects with a low and subjects with a 
median risk lipid profile was comparable for men and women (54.4 and 52.5 mg/dl, 
respectively). Therefore the larger effect of the e2 allele in women cannot be 
accounted for by a larger difference in LDL-cholesterol between the two groups. 
Despite the different study design, our data support the finding that the effect of the 
e2 allele on LDL-cholesterol is larger in women compared with men.110,155"158 Most men 
and women with a high risk lipid profile were characterized by high triglyceride 
levels. It has been shown before that the Apo E polymorphism was associated with 
total and VLDL triglycerides in men, but not in women.158159 
Our results suggest that both modifiable factors and the apo E polymorphism 
contribute to having a lipid profile, reflecting low, average and high risk for coronary 
heart disease. In women a favorable effect of the e2 allele was found, while in men 
the E4 isoform was associated with a high risk lipid profile. 
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Abstract 
To elucidate how the apolipoprotein (apo) E polymorphism and modifiable factors 
interact in explaining plasma lipid and apolipoprotein levels, we studied 1448 young adults 
(18 to 26 years old), participating in the European Atherosclerosis Research Study (EARS). 
Venous blood was collected after an overnight fast. Modifiable factors, e.g. body mass 
index (BMI), waist-to-hip ratio (WHR), tobacco and alcohol consumption, and physical 
activity, were determined by using standardized protocols. Associations of modifiable 
factors with apo E levels were homogeneous across apo E phenotypes. In contrast, 
correlations of BMI with total cholesterol and apo B levels, as well as correlations between 
WHR and apo B, were significantly (p<.05 to p<.01) stronger in E2-carriers than in subjects 
with other phenotypes. Total cholesterol and apo B levels were comparable in E2-carriers in 
the upper tertile of BMI or WHR to those in E3E3 subjects, suggesting that the lowering 
effect of the e2 allele was no longer present. The inverse association between the plasma 
cholesteryl linoleate-to-oleate ratio, a marker for the dietary polyunsaturated-to-saturated 
fatty acid ratio, and triglycerides was also stronger in E2-carriers (-0.33 versus -0.17 in 
E3E3 and -0.24 in E4-carriers). Associations with other modifiable factors were notably 
consistent across apo E phenotypes. Gender and modifiable factors explained three times 
more (31%) of the interindividual variation in apo B levels in E2-carriers than in E3E3 
subjects (9%) or E4-carriers (14%), mainly due to a larger variance explained by BMI. 
Our results suggest that the apo E polymorphism acts in a relatively uniform manner, 
independently of lifestyle. However, the associations of adiposity to total cholesterol and 
apo B levels appear to be stronger in apo E2-carriers. 
Introduction 
Apolipoprotein E is a structural component of VLDL and HDL. The protein is 
polymorphic, with three common isoforms found in the general population, coded for 
by three codominant alleles (e2, e3, e4). Numerous studies have shown that the apo 
E polymorphism is associated with plasma total and LDL-cholesterol, as well as with 
plasma apo E and apo B concentrations. In the population at large, the e2 allele is 
associated with lowered levels of apo B, total cholesterol, and LDL-cholesterol, while 
the opposite is true for the e4 allele.129138 A meta-analysis combining the data of 45 
population samples clearly demonstrated that e2 and e4 alleles are both associated 
with elevated concentrations of triglycerides.160 
Apo E allele frequencies vary widely across populations around the world16''62, 
and even across relatively close populations such as the European.'10'62163 
Notwithstanding these variations, the allele effects on lipid levels are remarkably 
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consistent across populations.110'61163 This consistency suggests that the apo E 
polymorphism acts in a relatively uniform manner, despite differences in genetic 
background and environment. However, this does not preclude a more subtle 
modulation of apo E effects by modifiable factors, which would not be well 
accounted for by interpopulation comparisons. Such a modulation is suggested, in 
particular, by intervention studies showing that the response of plasma lipids to 
dietary change is not uniform across apo E phenotypes.'64168 
Very few studies have addressed the issue of the interaction between modifiable 
factors and apo E phenotype effects on lipids. One of the reasons might be that very 
large sample sizes are required for having an acceptable power of detecting such 
interactions. It has been suggested that apo E genotypes might modify the 
relationship of measures of obesity and fat distribution142'43, smoking and alcohol 
consumption'41 and physical activity169 to lipids. 
EARS is a large multicenter study of biological, lifestyle, and genetic risk factors 
for coronary heart disease, carried out in young adults from 11 countries throughout 
Europe. In an earlier paper110, we described the association of the apo E 
polymorphism with lipids and apolipoproteins. Associations with plasma total and 
LDL-cholesterol, triglycerides, apo B, and apo E levels were consistent with the now 
well-identified effects of e2 and e4 alleles on these traits. These effects exhibited a 
great consistency among the different European populations, although there was a 
clear-cut North-to-South opposite gradient in the e2 and e4 allele frequencies. The 
large number of subjects participating in EARS allowed us to further elucidate 
whether the apo E locus interacts with environmental factors. 
Therefore the aim of the present study was to investigate whether the effects of 
modifiable factors, e.g. obesity, fat distribution, dietary fat composition, smoking, 
alcohol consumption, and physical activity on plasma total cholesterol, triglyceride, 
apo B and apo E levels were modulated by the apo E polymorphism. 
Methods 
Study Population 
A detailed description of EARS is given elsewhere.107 Briefly, 1994 male and 
female students, aged between 18 and 26 years, from 14 university populations in 
11 European countries have been studied. Students whose father had a verified 
myocardial infarction before the age of 55 were recruited and represent cases 
(n=682). Two age- and sex-matched control subjects were recruited by computer 
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selection from the same university population (n=1312). Students were grouped into 
five regions on the basis of geography, language, and age-standardized mortality 
rates170: Finland (Oulu and Helsinki), Great Britain (Glasgow and Bristol), Northern 
Europe (Goteborg, Aarhus and Hamburg), Middle Europe (Ghent, Innsbruck and 
Zurich) and Southern Europe (Bordeaux, Barcelona, Reus and Naples). 
Venous blood was collected after an overnight fast. Height, weight, and waist and 
hip circumferences were measured, and BMI (weight in kilograms divided by height 
in meters squared) and WHR were calculated. Details of lifestyle, e.g. smoking 
habits, alcohol consumption and physical activity were determined with standardized 
questionnaires and protocols.'07 
Laboratory analyses 
Cholesterol and triglyceride concentrations were measured according to the Lipid 
Research Clinic's Manual of Laboratory Operations, standardized according to the 
Centers for Disease Control and Prevention, Atlanta, GA. Apo B levels were 
measured by immunonephelometry on a Behring BNA nephelometer. Apo E levels 
were measured by ELISA according to published procedures.149 Apo E phenotyping 
was performed by isoelectric focusing of delipidated plasma followed by 
immunoblotting.115171 The composition of cholesteryl esters in plasma was 
determined by reversed-phase high-performance liquid chromatography as 
described previously.172 Four major components were determined: cholesteryl 
palmitate (16:0), oleate (18:1), linoleate (18:2), and arachidonate (20:4). The L/O 
ratio was calculated as a marker for the P/S ratio.173 
Statistical analysis 
Only subjects for whom all lipid and modifiable factors and the apo E phenotype 
were available (n=1795) were included in statistical analyses. Additionally, women 
taking oral contraceptives (n=321) were excluded because of the large effect on lipid 
parameters studied. Since very few subjects had the E2E2 (n=12) or E4E4 
phenotype (n=31), regrouping of the subjects into three groups was performed: 
carriers of the e2 allele (E2E2 and E3E2 phenotypes), subjects with the E3E3 
phenotype, and E4-carriers (E4E3 and E4E4 phenotypes). Subjects with the E4E2 
phenotype (n=26) could not be assigned to any of the groups and were therefore 
excluded, leaving 1448 subjects. All analyses were carried out using the SAS 
System (version 6.09, SAS Institute, Cary, NC). 
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Although in EARS a large number of lipids and apolipoproteins were measured, 
we decided to focus only on those traits for which there was no controversy about 
the influence of the apo E polymorphism, to limit the possibility of finding spurious 
interactions. Given the strong correlation between LDL-cholesterol and apo B levels, 
LDL-cholesterol was omitted because it was not directly measured but assessed by 
Friedewald's formula. Since in our earlier paper'10 apo E allele effects had been 
shown to be very homogeneous across regions and among cases and controls, we 
analyzed pooled data with adjustment for region and case/control status. An 
additional adjustment was performed on for age and, depending on the analysis, 
gender. Triglycerides and apo E levels were log transformed to improve normality 
for statistical testing. 
Phenotype-specific associations of continuous modifiable factors with lipid and 
apolipoprotein levels were determined by partial Pearson correlation coefficients. 
For physical activity, Spearman's correlation coefficients were determined. The 
homogeneity of associations of modifiable variables with lipid and apolipoprotein 
levels across apo E phenotypes was tested by analysis of variance, including E2 
and E4*lifestyle interaction terms in the model. The E3E3 phenotype was taken as 
the reference category. 
Finally, multivariate regression analysis was conducted in each apo E phenotype 
group, with lipid and apolipoprotein levels successively taken as the dependent 
variable, and modifiable factors and gender as independent variables. In each apo E 
phenotype group, the proportion of variance (Ft) attributable to gender and all 
modifiable factors combined was calculated as the ratio of the sum of squares due 
to these factors to the age-, region- and case/control status-adjusted total sum of 
squares. 
Results 
Associations of the apo E polymorphism with total cholesterol, triglyceride, apo E, 
and apo B levels were as expected (Table 1). The apo E polymorphism was not 
associated with any of the modifiable factors studied, e.g. indices for obesity and fat 
distribution, tobacco and alcohol consumption, physical activity, and the L/O ratio, 
used as a marker of the P/S ratio of the diet (Table 1). Ranges in modifiable factors 
were slightly smaller in E2-carriers than in E3E3 subjects or E4-carriers (data not 
shown). 
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Table 1. Lipid and apolipoprotein levels and modifiable factors according to apo E 
phenotype in young adults (EARS) 
Lipid traits 
Total cholesterol (mmol/l) 
Triglycerides (mmol/l)* 
Apo E (mg/dl)* 
Apo B (mg/dl) 
Modifiable factors 
Body Mass Index (kg/m2) 
Waist-to-Hip Ratio 
Tobacco (gram/day) 
Alcohol (ml/day) 
L/O ratio 
Physical activity (%) 
Low 
Moderate 
Heavy 
E2-carriers 
n=152 
4.07 (0.06) 
0.89 (0.03) 
4.9(0.1) 
74.1 (1.7) 
21.8(0.2) 
0.800 (0.004) 
3.3 (0.5) 
15.2(1.3) 
3.05 (0.05) 
11.1 
82.4 
6.5 
Apo E phenotype 
E3E3 
n=915 
4.38 (0.03) 
0.82(0.01) 
3.4 (0.0) 
85.6 (0.7) 
22.1 (0.1) 
0.803 (0.002) 
2.5 (0.2) 
14.9(0.5) 
3.08 (0.02) 
10.8 
80.0 
9.2 
E4-carriers 
n=381 
4.62 (0.04)t 
0.90 (0.02)t 
2.7 (0.1 ) t 
94.4 (0.1 ) t 
22.0(0.1) 
0.802 (0.003) 
2.6 (0.3) 
14.4(0.8) 
3.11 (0.03) 
8.4 
84.7 
6.9 
Values are given as mean (SEM) adjusted for age, gender, case/control status, and region. * Log-
transformed values are used in analyses, but untransformed values are presented, t p<0.001 for the 
comparison between phenotypes. 
Correlations of plasma lipid and apolipoprotein levels with modifiable factors 
according to apo E phenotype are shown in Table 2. The apo E polymorphism did 
not alter correlations between modifiable factors and apo E levels. In contrast, 
correlations of BMI and WHR with total cholesterol and apo B levels were stronger 
in subjects with the e2 allele than in subjects with the E3E3 phenotype, whereas E4-
carriers did not differ from E3E3 subjects. For the correlation between WHR and 
total cholesterol levels, however, the interaction term did not reach statistical 
significance. The correlation between tobacco consumption and apo B levels was 
also higher in E2-carriers (p=.053). The e2 allele modified the association between 
triglyceride concentrations and the L/O ratio in a similar way, increasing the inverse 
correlation between these two variables. All associations with alcohol consumption 
and physical activity were homogeneous among the apo E phenotype groups. 
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Table 2. Apo E phenotype-specific correlation coefficients of lipids and apolipoproteins with 
modifiable factors in young adults (EARS) 
Cholesterol level 
BMI 
WHR 
Tobacco 
Alcohol 
Physical activity 
L/O ratio 
Triglyceride level (log) 
BMI 
WHR 
Tobacco 
Alcohol 
Physical activity 
L/O ratio 
Apo E level (log) 
BMI 
WHR 
Tobacco 
Alcohol 
Physical activity 
L/O ratio 
Apo B level 
BMI 
WHR 
Tobacco 
Alcohol 
Physical activity 
L/O ratio 
E2 carrier 
n=152 
0.31 § 
0.14 
0.09 
0.06 
-0.01 
0.09 
0.19t 
0.19t 
0.25$ 
0.03 
-0.10 
-0.33§ 
0.06 
-0.01 
-0.16 
-0.12 
-0.00 
0.02 
0.43§ 
0.211 
0.26* 
-0.02 
-0.09 
0.02 
Apo E phenotype 
E3E3 
n=915 
0.16§ 
0.03 
0.03 
0.09$ 
0.01 
-0.14§ 
0.22§ 
0.13§ 
0.13§ 
0.10$ 
-0.09$ 
-0.17§ 
0.06 
-0.10 
0.00 
0.03 
-0.00 
-0.02 
0.23§ 
0.07$ 
0.08$ 
0.07| 
-0.03 
-0.13§ 
E4 carrier 
n=381 
0.18§ 
-0.00 
0.09 
0.11t 
0.05 
-0.1 ot 
0.20§ 
0.10 
0.11f 
0.1 ot 
-0.00 
-0.24§ 
0.11$ 
-0.10 
-0.06 
0.04 
0.09 
-0.03 
0.26§ 
-0.00 
0.11$ 
0.1 ot 
0.01 
-0.13t 
Homogeneity of 
associati 
E2 
p<.05 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
p=.007 
NS 
NS 
NS 
NS 
NS 
NS 
p<.001 
p=.012 
NS 
NS 
NS 
NS 
on* 
E4 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS indicates nonsignificant. For physical activity Spearman's correlation coefficients are calculated. 
Correlations are adjusted for age, case/control status, region, and gender. WHR is also adjusted for 
BMI. * Interactions of E2 (E4 respectively) and modifiable factors on lipid levels were tested with E3E3 
as the reference, t p<0.05, $ p<0.01, § p<0.001 
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The stronger association of BMI and WHR with apo B levels in E2-carriers was 
demonstrated in both men and women (significance of E2 interaction terms : p<.05 
in both genders). Three-way interaction terms with gender were not statistically 
significant. The correlations of Apo B with BMI were 0.48 and 0.39 in female and 
male E2-carriers, respectively, and the correlations with WHR were 0.27 and 0.16, 
respectively. By contrast, the interaction between the e2 allele and BMI and WHR on 
total cholesterol, as well as the interaction between the e2 allele and the L/O ratio on 
triglyceride concentrations was significant only in women (p<.01). In male subjects 
the correlations were quite similar among the three apo E phenotype groups. 
However, in neither case did the three-way interaction term with gender reach 
significance. Interaction effects did not differ significantly according to case/control 
status and region. 
The stronger correlations of BMI and WHR with total cholesterol and apo B levels 
in E2-carriers suggested that an increase in these modifiable factors resulted in a 
larger rise in the levels in these subjects than in those with other phenotypes. A 
similar conclusion can be drawn for the relationship between the L/O ratio and 
plasma triglyceride concentrations. To further elucidate these interactions, we 
determined mean total cholesterol, apo B, and triglyceride levels according to 
gender-specific tertiles of BMI, WHR and L/O ratio after stratification by apo E 
phenotype (Figs 1 through 3). The lowering effect of the e2 allele on total cholesterol 
and apo B levels was much less pronounced in the upper tertiles of BMI and WHR, 
so much that the levels in E2-carriers belonging to the upper fertile of BMI were 
comparable to those in E3E3 subjects (Figs 1 and 2). 
Plasma triglyceride concentrations decreased according to tertiles of the L/O ratio 
(Fig 3). Triglyceride concentrations were most elevated in E2-carriers in the lowest 
tertile, suggesting that the e2 allele exhibits its triglyceride-raising effect mainly when 
a diet high in saturated and low in polyunsaturated fat is consumed. 
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Figure 1. Mean plasma total cholesterol levels according to tertiles of BMI and WHR, 
stratified by apo E phenotype. Means are adjusted for age, gender, region, and 
case/control status. 
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Figure 2. Plasma apo B levels according to tertiles of BMI and WHR, stratified by apo 
E phenotype. Means are adjusted for age, gender, region, and case/control status. 
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Figure 3. Mean plasma triglyceride concentrations according to tertiles of cholesteryl 
ester linoleate (18:2)-to-oleate (18:1) ratio, stratified by apo E phenotype. Means are 
adjusted for age, gender, region, and case/control status. 
In multivariate regression analysis, the interactions demonstrated in univariate 
analyses remained statistically significant. In E2-carriers, 31.4% of the interindividual 
variation in apo B levels could be explained by gender, BMI, WHR, tobacco and 
alcohol consumption, physical activity, and the L/O ratio (Table 3). In E3E3 subjects, 
this proportion was only 9.2%, a proportion quite similar to that observed in E4-
carriers (13.6%). The higher Ft in E2 carriers was mostly explained by a larger 
effect of BMI on apo B in this phenotype group. For total cholesterol levels, 
congruent results were found. In contrast, the proportion of apo E and triglyceride 
variance explained by gender and modifiable factors was fairly similar in the three 
phenotype groups. 
Table 3. Percentage of interindividual variance in lipids and apolipoproteins explained by 
gender and modifiable factors according to Apo E phenotype in young adults (EARS) 
Apo E phenotype 
Total cholesterol (mmol/l) 
Apo B (mg/dl) 
Apo E (mg/dl) 
Triglycerides (mmol/l) 
E2 carrier 
n=152 
15.0 
31.4 
9.2 
24.0 
E3E3 
n=915 
5.6 
9.2 
6.8 
15.2 
E4 carrier 
n=381 
5.8 
13.6 
4.2 
17.6 
Adjusted for age, case/control status and region. 
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Discussion 
One of the major challenges of genetic epidemiology is to try to elucidate how 
environment and genes interact in determining individual susceptibility to 
multifactorial diseases. Most of the susceptibility genes to multifactorial diseases are 
frequent polymorphisms that, taken in the population at large, have a rather low 
impact at the individual level. However, in specific subgroups, genetic effects might 
amplify effects of lifestyle factors. One example is the possible modulation by 
alcohol intake of the cholesteryl ester transfer protein gene effect on HDL and the 
risk of myocardial infarction.174 Another example is the interaction between smoking 
habits and polymorphisms of the (3-fibrinogen gene on plasma fibrinogen.175,176 The 
identification of such gene-environment interactions is crucial, since besides 
providing us a better understanding of the mechanisms involved in gene regulation, 
it may help to focus intervention strategies on target subgroups of the population. 
While the effects of the apo E polymorphism on lipids have been extensively 
studied in various populations, only few studies have investigated interactions with 
environmental factors, and never in such a large sample as the present one. In the 
present study associations between modifiable factors (e.g. BMI, WHR, tobacco and 
alcohol consumption, and physical activity) and plasma apo E levels, studied in 
young adults from 11 countries throughout Europe, were nonsignificant and notably 
similar across apo E phenotypes. In contrast, a stronger effect of BMI and WHR on 
total cholesterol and apo B levels was demonstrated in E2-carriers than in those 
with the E3E3 phenotype. Multivariate analysis indicated that the modifiable factors 
explained about three times more of the interindividual variance in total cholesterol 
and apo B levels in E2-carriers than in other subjects, but this was mainly due to the 
larger contribution of BMI to the variability of these levels. Results for LDL-
cholesterol paralleled those found for apo B levels, but these results were not 
shown, because LDL-cholesterol levels were calculated and not measured directly. 
The fact that BMI emerged among all the factors studied is not unexpected, since 
the apo E polymorphism primarily affects lipid metabolism, and adiposity is a major 
metabolic factor. On the other hand, it is possible that other lifestyle factors, such as 
smoking, may not have yet exhibited their full effect on lipids, since subjects 
participating in EARS were relatively young (18 to 26 years). Although the 
interaction term did not reach statistical significance, we demonstrated that the 
association between tobacco consumption and apo B levels was also stronger in 
E2-carriers. When studying older subjects, who have longer lifetime risk-factor 
exposure, differences according to phenotypes may become more pronounced. 
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The deviation of the E2-carriers from the other apo E phenotype groups is in 
accordance with results of Reilly et al.143 showing that the heterogeneity of 
regression of several lipids and apolipoproteins to concomitants was mostly due to 
differences between the e32 and e33 genotypes. In their study, associations of 
triglyceride, total cholesterol, and HDL-cholesterol levels with weight and WHR were 
stronger in women with the E3E2 than in women with the E3E3 phenotype. In men, 
on the contrary, associations of WHR with the same lipid parameters were weaker in 
subjects with the E3E2 phenotype. In contrast to our results, associations with apo 
B levels were not different between phenotypes. Some of the interactions in the 
present study, e.g. the interaction of the apo e2 allele with BMI and WHR on total 
cholesterol levels and with the L/O ratio on triglyceride concentrations, were also 
restricted to women. These results suggest that sex-specific factors (e.g. hormonal 
factors) act as important regulators on these complex metabolic pathways. 
A large study in children aged 8 to 16 years also demonstrated stronger 
correlations between adiposity and apo B levels in E2-carriers.'44 In a small study in 
obese women, both the e2 and e4 allele altered the relationships between body 
fatness indices and plasma lipoproteins, but in contrast to the present study, no 
correlations were found between adiposity and apo B levels in E3E2 subjects.'42 
The stronger correlation between adiposity measures demonstrated in our study 
and in the study of Srinivasan et al.144 suggests that weight loss, aimed at lowering 
apo B or LDL-cholesterol levels, might be more effective in subjects carrying the e2 
allele. A study of Muls et al.'77, however, demonstrated no differences in the effect of 
weight loss on lipid levels according to apo E phenotype. Results of another study 
suggested that weight gain was associated with a larger increase in triglyceride and 
P-lipoprotein concentrations not in E2-carriers but in E4-carriers.'78 
Several experimental studies demonstrated higher cholesterol responses to a 
dietary regimen reducing the amount of dietary fat in subjects with the E4E3 or 
E4E4 phenotype'64168, while others failed to do so.179180 It was also suggested that the 
apo E polymorphism did not have any major effect on the response of lipid levels to 
increased dietary cholesterol.'81 In our study we found that the association of the L/O 
ratio, a marker for the dietary P/S ratio173, with plasma triglyceride concentrations 
was more marked in E2-carriers. A recent observational study published by Marshall 
et al.182 demonstrated that the association between dietary cholesterol and plasma 
LDL-cholesterol was strongest in E2-carriers. These results are at variance with the 
results from experimental studies. When showing modulation of dietary responses 
by the apo E polymorphism, it is rather the e4 allele that deviates. This discrepancy 
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might, on the one hand, reflect differences between the effect of normal dietary fatty 
acid intake and the effect of a lipid-lowering diet. Lipid concentrations are more 
variable after a change in dietary saturated fat or cholesterol.181 The observational 
data presented here may better represent the effects of long-term dietary 
adaptation. On the other hand, plasma cholesteryl esters only partly reflect the fatty 
acid composition of the diet.173183184 EARS II, recently carried out with a similar design 
as the study described here and including oral glucose and fat tolerance tests, will 
allow us to study more precisely the effect of the apo E polymorphism on dietary 
responses. 
The E2 isoprotein has defective receptor binding-affinity.185 Differences in binding 
affinity of the apo E isoforms for the remnant (apo B/E) receptor and the LDL-
receptor will result in differences in in vivo clearance rates and may therefore 
underlie the reported differences in (apo)lipoprotein levels according to apo E 
genotypes.185186 Obesity and abdominal fat accumulation result in a higher VLDL 
secretion and consequently higher LDL-cholesterol levels.187 Despite the 
upregulation of the LDL-receptor in E2-carriers, the diminished receptor-binding 
capacity of the E2 isoform might result in a slower clearance of excess VLDL 
secreted and therefore result in a stronger rise in LDL particles with increasing 
adiposity in E2-carriers. This might explain the stronger correlations with total 
cholesterol and apo B levels demonstrated in E2-carriers than in individuals with 
other apo E phenotypes. On the other hand, the BMI*E2 interaction could reflect a 
gene-gene interaction with some other gene involved in lipolysis. The lipoprotein 
lipase gene is mentioned as a candidate gene for obesity and it has been suggested 
that the N291S mutation of the lipoprotein lipase gene might interact with the e2 
allele to predispose to hyperlipidemia.117 In the same line of evidence, the 
postheparin plasma lipoprotein lipase activity has been shown to be related to 
plasma triglyceride and apo B levels only in E2-carriers.'88 
In conclusion, this large study among healthy European students showed that the 
apo E polymorphism did not modify effects of modifiable factors on plasma apo E 
concentrations and had little influence on the effects on triglyceride concentrations. 
Therefore, the apo E isoforms seems to act in a relatively uniform manner, 
independently of lifestyle. However, the association of adiposity with total cholesterol 
and apo B levels appears to be altered in apo E2-carriers. The identification of 
gene-environment interactions may help to focus intervention strategies on target 
subgroups in the population. 
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THE APOLIPOPROTEIN E POLYMORPHISM MODIFIES 
ASSOCIATIONS BETWEEN LIPID TRAITS AND OTHER RISK 
FACTORS FOR CORONARY HEART DISEASE 
Based on: Boer JMA, Feskens EJM, Havekes LM, Schouten EG, Seidell JC, Kromhout D. The 
apolipoprotein E polymorphism modifies associations between lipid traits and other risk factors for 
coronary heart disease. Submitted for publication. 
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Abstract 
It remains unclear whether the apolipoprotein (apo) E polymorphism modulates 
associations between lipid levels and other risk factors for coronary heart disease. To further 
elucidate this, we determined apo E phenotype-specific associations of total and HDL-
cholesterol, apo B and triglyceride levels with other risk factors for coronary heart disease 
(age, body mass index, smoking, alcohol consumption, physical activity) in a population-
based sample of 446 Dutch men and women. Both apo E2 and apo E4 significantly 
modulated some of these associations. The positive association of total cholesterol and apo 
B with overweight was absent in E2-carriers, while the association with age in males and 
with smoking in women was more pronounced in this group. In E4-carriers, associations of 
BMI with triglycerides in women and of alcohol consumption with lipid traits in men were less 
pronounced than in other phenotypes. The apo E polymorphism did not modulate 
associations of physical activity with lipid traits. Our results confirm that the apolipoprotein E 
polymorphism modulates associations between lipid traits and other risk factors for coronary 
heart disease. Several - mostly methodological - reasons may explain some of the 
discrepancies in the results of different studies. 
Introduction 
One of the major challenges of genetic epidemiology is to elucidate how genes 
and environment interact in determining individual susceptibility to multifactorial 
diseases. Most of these susceptibility genes are frequent polymorphisms that have a 
rather low impact at the individual level. Genetic subgroups may, however, be more 
susceptible to effects of other factors, such as lifestyle. The identification of such 
gene-environment interactions might provide a better understanding of mechanisms 
involved in lipid metabolism and may help to identify subgroups in the population to 
whom prevention strategies may be focused. 
The common apolipoprotein (apo) E polymorphism is a major genetic factor 
influencing plasma lipid levels.129,381S0 Three common isoforms are found in the 
general population, coded for by three codominant alleles. Compared to the most 
common e3 allele, the e2 allele is associated with reduced levels of apo B, total and 
LDL-cholesterol and elevated apo E levels, while the opposite is true for the e4 
allele.129138 Both alleles are associated with higher triglyceride concentrations.160 
Whether the apo E polymorphism modulates the cross-sectional association 
between lipid traits and other risk factors for coronary heart disease has been the 
subject of several publications141'45169189191, but the magnitude and direction of the 
interaction was not always described, and the results were inconclusive. It has, for 
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example, been suggested that the effect of the apo E polymorphism attenuates with 
age189,190, while, in contrast, results from Reilly et al.143 suggest that associations of 
the polymorphism with lipid levels may get stronger with age. 
Few studies investigated the interaction between the apo E polymorphism and 
measures of adiposity.142145'91 In E2-carriers compared to E3E3 subjects, 
associations of body fatness with some, but not all, lipid traits were stronger144145, 
weaker142 or even inverse.143 
Even fewer studies tried to elucidate whether the apo E polymorphism modulates 
associations between lipid levels and smoking141,143,145, alcohol consumption141145 or 
physical activity.145169 In an early study of Roberston et al.141 the association between 
smoking and VLDL-cholesterol was found in male E4-carriers, but not in female E4-
carriers nor in other phenotypes. In the European Atherosclerosis Research Study 
(EARS), in contrast, it was apo E2, not apo E4, that modulated the association of 
smoking with apo B levels.145 Inconsistencies are further illustrated by the finding that 
associations of alcohol consumption with LDL- and HDL-cholesterof41 as well as the 
association of physical activity with LDL-cholesterof69 were modulated by apo E2 in 
some studies, while others did not find any interaction between the apo E 
polymorphism and alcohol consumption or physical activity.145191 
From this short summary of the literature it is obvious that it remains to be clarified 
whether and how the apo E polymorphism modulates the association between lipid 
traits and other risk factors for coronary heart disease. Therefore, we investigated 
apo E phenotype-specific associations of lipid levels with age, body mass index, 
cigarette smoking, alcohol consumption and physical activity in a population-based 
sample of 446 Dutch men and women. Furthermore, we summarized possible 
explanations for the inconsistencies between different studies. 
Methods 
Subjects 
Subjects were selected from participants of the Cardiovascular Disease Risk 
Factor Monitoring Project, a large monitoring project for cardiovascular risk factors 
carried out in the Netherlands.95 More than 36,000 men and women, 20-59 years of 
age, were examined between 1987 and 1991 at the Municipal Health Centers in 
three Dutch towns (Amsterdam, Doetinchem and Maastricht). Our subsample was 
originally selected to study associations between parental history of premature 
myocardial infarction and variation in genes involved in lipid metabolism. Only 
participants of Dutch nationality, with stored blood samples and a known parental 
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history were eligible (n=33,884). Parental history was considered to be positive if the 
participant reported a myocardial infarction in his/her father before the age of 61 
(n=3,274), in his/her mother before the age of 66 (n=1,157) or in both (n=185). For 
the remaining subjects family history was considered to be negative. From each of 
the four resulting groups 115 men and women were randomly selected, matched for 
sex, age (within 5 years) and town of investigation. 
Examinations 
A detailed description of the data collection of the Cardiovascular Disease Risk 
Factor Monitoring project is previously reported.95 In brief, the examination included 
anthropometric measurements, blood sampling and a self-administered 
questionnaire. Height (m) and weight (kg) were measured and body mass index 
(BMI) was calculated as weight/height2. Overweight was defined as a BMI above 25 
kg/m2.148 Non-fasting blood samples were obtained in EDTA-coated vacutainer tubes. 
After fractionation into plasma, erythrocytes and white blood cells, the samples were 
stored at -20°C. An informed-consent form was completed, agreeing the use of 
stored blood samples for scientific research. The questionnaire provided information 
about the presence and (parental) history of cardiovascular diseases, history of 
other diseases, current medication, alcohol consumption, current cigarette smoking, 
and physical activity. Subjects who consumed equal or more than the median 
number of alcoholic consumptions per week (i.e. 10 beverages for men and 1 
beverage for women) were defined as regular alcohol consumers. Participants were 
asked how they rated their physical activity during leisure time (little exercise/ 
exercise for at least 4 hours a week/ regular exercise/ regular strenuous exercise). 
They were considered to be physically inactive when they reported little exercise, the 
remainder was considered to be physically active. 
Laboratory analyses 
Within three weeks after storage plasma total- and HDL-cholesterol were 
determined enzymatically using a Boehringer test kit.96 HDL-cholesterol was 
determined after precipitation of apo B containing lipoproteins with magnesium 
phosphotungstate.97 Cholesterol measurements were performed at the Clinical 
Chemistry Laboratory of the University Hospital 'Dijkzigt' in Rotterdam, the Lipid 
Reference Laboratory for standardized cholesterol determinations in the 
Netherlands. 
For the present study, additional laboratory analyses were carried out in plasma 
samples that were stored continuously at -20°C for 3-7 years. Non-fasting 
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triglycerides were measured enzymatically using a Boehringer test-kit (GPO-PAP kit 
no. 701904), while apo B concentrations were measured by an 
immunonephelometric assay.113 Apo E phenotypes were determined by isoelectric 
focusing of delipidated plasma followed by immunoblotting as previously described 
by Havekes et al.'15 Apo E phenotype was not available for two subjects. 
Statistical analyses 
The effect of apo E phenotype on lipid levels did not differ substantially between 
subjects with a positive or negative parental history of myocardial infarction (data not 
shown). Moreover, except for slightly higher apo B levels in subjects with a parental 
history, lipid traits were comparable across parental history groups. Therefore all 
subjects were pooled for the analyses presented in this paper. Since very few 
subjects had the E2E2 (n=3) or E4E4 phenotype (n=7), subjects were regrouped 
into E2-carriers (E2E2 and E3E2 phenotype), E3E3 subjects, and E4-carriers (E4E3 
and E4E4 phenotype). Subjects with the E4E2 phenotype (n=12) could theoretically 
be assigned to two groups and were therefore excluded, leaving data of 446 
subjects for analyses. 
All analyses were performed with SAS statistical software (SAS version 6.11, SAS 
Institute, Cary, NC), separately for men and women. Triglyceride levels were log-
transformed to improve normality for statistical testing. Adjusted differences between 
the three apo E phenotype groups in lipid traits and other continuous risk factors 
(e.g. age and BMI) were tested using analysis of co-variance. Adjustment was made 
for parental history and matching criteria, e.g. age and town of investigation. 
Adjusted differences in categorical variables (cigarette smoking, alcohol 
consumption and physical activity) were tested using logistic regression. 
Phenotype-specific associations of lipids and apo B with the above mentioned 
other risk factors were determined by regression analysis. To determine whether 
apo E phenotype significantly modulated the associations, E2*- and E4*risk factor 
product terms were included in the model. The E3E3 phenotype was taken as the 
reference. In addition to the adjustment for parental history and matching criteria, 
adjustments were made for the other risk factors than the one under study, e.g. age 
was adjusted for BMI, smoking, alcohol consumption and physical activity. 
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Results 
In both men and women age, BMI and the percentage of smokers, regular alcohol 
consumers and inactive subjects did not differ significantly between E2-carriers, 
E3E3 subjects and E4-carriers (Table 1). 
Table 1. Selected characteristics according to apo E phenotype and gender. 
MEN 
Age (years) 
Body Mass Index (kg/m2) 
Overweight 
Current smokers 
Regular alcohol consumers 
Physically inactive 
WOMEN 
Age (years) 
Body Mass Index (kg/m2) 
Overweight 
Current smokers 
Regular alcohol consumers 
Physically inactive 
E2-carriers 
n=21 
40.4 ±6.1 
25.3 ± 2.2 
47.6 
42.9 
52.4 
38.1 
n=24 
38.1 ± 9.1 
25.1 ± 3.2 
45.8 
37.5 
45.8 
50.0 
Apo E phenotype 
E3E3 
n=139 
40.6 ± 8.4 
25.7 ± 2.7 
59.0 
45.3 
52.5 
38.1 
n=159 
41.0 ±9.5 
25.0 ±4.1 
41.5 
46.5 
48.4 
47.8 
E4-carriers 
n=46 
40.8 ± 8.2 
25.7 ± 3.2 
54.4 
30.4 
52.2 
43.5 
n=57 
41.4 ±9.2 
25.1 ± 5.0 
42.1 
45.6 
52.6 
36.8 
test* 
.98 
.84 
.27 
.13 
.98 
.67 
.27 
.86 
.97 
.84 
.86 
.25 
Values are presented as means ± SD (continuous variables) or percentages (dichotomous variables). 
Overweight: Body mass index > 25 kg/nf. Regular alcohol consumers: consuming equal or more than 
the median number of alcoholic consumptions per week (i.e. > 10 beverages for men, > 1 beverage for 
women). Physically inactive: reporting little exercise during leisure time. * P-value, adjusted for age, 
town of investigation and parental history of myocardial infarction. 
Lipid levels according to apo E phenotype are shown in Table 2. Both male and 
female E2-carriers had lower levels of total cholesterol and apo B compared to E3E3 
subjects, while the levels were higher in female E4-carriers only (Table 2). In men 
the difference in total cholesterol levels between the groups did not reach statistical 
significance. No clear differences were found for HDL-cholesterol and triglyceride 
levels. 
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Table 2. 
gender. 
Lipids and apolipoprotein 
E2 
B (mean 
•carriers 
± SD) according to 
Apo E phenotype 
E3E3 
apo 
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E phenotype and 
E4-carriers test* 
MEN n=21 n=139 n=46 
Total cholesterol (mmol/l) 5.42 ± 1.24 5.76 ±1.12 5.59 ± 0.97 .25 
HDL-cholesterol (mmol/l) 1.11 ± 0.27 1.06 ± 0.24 1.06 ± 0.23 .80 
Triglycerides (mmol/l) 2.02 ± 0.96 1.94 ±1.41 1.81 ±1.11 .48 
Apolipoprotein B (mg/dl) 116.3 ± 37.4 138.9 ± 37.9 140.0 ± 35.8 .02 
WOMEN n=24 n=159 n=57 
Total cholesterol (mmol/l) 5.07 ± 1.07 5.46 ± 1.08 5.83 ± 1.06 .02 
HDL-cholesterol (mmol/l) 1.41 ± 0.25 1.35 ± 0.31 1.33 ± 0.32 .51 
Triglycerides (mmol/l) 1.16 ±0.51 1.23 ±0.67 1.47 ±0.99 .18 
Apolipoprotein B (mg/dl) 102.0 ±29.2 118.4 ± 34.7 132.3 ±29.6 .002 
For triglycerides log transformed values were used for statistical testing, but untransformed values are 
presented. * P-value, adjusted for age, town of investigation and parental history of myocardial 
infarction. 
Table 3 shows the associations of age and BMI with lipid traits stratified by apo E 
phenotype. Total cholesterol and triglyceride levels were more strongly associated 
with age in male E2-carriers than in the groups with other phenotypes (apo E2*age 
interaction: p=0.05 and p=0.04, respectively). In women, in contrast, associations of 
age with total cholesterol and triglycerides were comparable between the 
phenotypes, but age was positively associated with HDL-cholesterol levels in E4-
carriers only (apo E4*age: p=0.08). The Apo E polymorphism did not modulate the 
association of age with apo B levels (Table 3). 
The apo E polymorphism also significantly (p=0.03) modulated the association 
between BMI and apo B levels in men (Table 3). The positive association that was 
found in E3E3 subjects and E4-carriers was absent in E2-carriers. For total 
cholesterol in men and both total cholesterol and apo B levels in women, similar 
results were found, but interaction terms were not statistically significant. 
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Table 3. Apo E phenotype-specific regression coefficients* (SE) of age and BMI with lipids 
(mmol/l) and apolipoproteins (mg/dl). 
Men 
Women 
AGE (YEARS) 
Men 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
Women 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
BMI (KG/M2) 
Men 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
Women 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
E2-
0.14 
0.01 
0.05 
4.1 
0.02 
0.00 
0.01 
0.1 
-0.01 
-0.07 
0.14 
-3.3 
-0.03 
-0.02 
0.08 
-1.1 
carriers 
n=21 
1=24 
(0.04)* 
(0.01) 
(0.02)t 
(1-5) t 
(0.02) 
(0.01) 
(0.01) 
(0.6) 
(0.11) 
(0.02)* 
(0.06)t 
(3.6) 
(0.06) 
(0.02) 
(0.03)t 
(1.8) 
Apo E phenotype 
[ 
n 
n 
0.04 
-0.00 
0.01 
0.9 
0.05 
0.00 
0.01 
0.9 
0.08 
-0.02 
0.08 
3.9 
0.04 
-0.02 
0.04 
2.2 
E3E3 
=139 
=159 
(0.01)* 
(0.00) 
(0.01 )f 
(0.4) t 
(0.01 )§ 
(0.00) 
(0.00)* 
(0.3) * 
(0.03)f 
(0.01 )§ 
(0.02)§ 
(1-1) § 
(0.02)t 
(0.01 )§ 
(0.01 )§ 
(0.6) § 
E4-
0.02 
-0.01 
0.01 
1.3 
0.06 
0.01 
0.01 
1.1 
0.10 
-0.01 
0.06 
3.3 
0.05 
-0.01 
0.02 
1.8 
carriers 
n=46 
n=57 
(0.02) 
(0.00) 
(0.01) 
(0.6) t 
(0.01 )§ 
(0.00)t 
(0.01) 
(0.4) t 
(0.05)t 
(0.01) 
(0.03)t 
(1-5) t 
(0.03) 
(0.01) 
(0.01) 
(0-8) t 
Interac 
E2 
.05 
.37 
.04 
.26 
.21 
.78 
.77 
.24 
.17 
.21 
.82 
.03 
.15 
.74 
.91 
.11 
tionH 
E4 
.42 
.95 
.51 
.91 
.69 
.08 
.49 
.91 
.85 
.45 
.71 
.99 
.83 
.14 
.05 
.70 
For triglycerides regression coefficients of log transformed values are presented. * Regression 
coefficients are adjusted for town of investigation, parental history of myocardial infarction and the 
other risk factors than the one under study, e.g. age is adjusted for BMI, smoking, alcohol 
consumption and physical activity. | P-value of the interaction is given. Interactions of apo E2 (E4 
respectively) with age and BMI factors were tested with E3E3 as the reference, t P <0.05, $ p<0.01, § 
p<0.001 
106 Chapter 7 
A. MEN 
^ - 7 - i 
1 6 -
£ 5-
2
 4 -
4> H 0) n 
5 2-o 
"5 1 -
o 
•- 0 J 
p=.87 
5,44 ^ Q 
S Norma I weight •Overweigh 
p=.049 
5,54 BHi l 
t 
p=.10 
5.10 BCT 
E2-carriers E3E3 E4-carriers 
A p o E P h e n o t y p e 
Interaction: E2 p=.22, E4 p=.54 
B. WOMEN 
I Normal weight • Overweight 
z? 7 p=.002 
E2-carriers E3E3 
Apo E Phenotype 
E4-carriers 
Interaction: E2 p=.012, E4 p=.65 
Figure 1. Mean total cholesterol levels (mmol/l) according to overweight (BMI > 25 
kg/m2), stratified by apo E phenotype in men (a) and women (b). P-values are adjusted 
for age, parental history of myocardial infarction, town of investigation, smoking, alcohol 
consumption and physical inactivity. 
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Figure 2. Mean apo B levels (mg/dl) according to overweight (BMI > 25 kg/m2), 
stratified by apo E phenotype in men (a) and women (b). P-values are adjusted for age, 
parental history of myocardial infarction, town of investigation, smoking, alcohol 
consumption and physical inactivity. 
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To study this possible interaction further we divided subjects according to 
overweight. The results were in accord with the results on a continuous scale. Both 
in men and women no significant differences in total cholesterol and apo B levels 
were found between E2-carriers with and E2-carriers without overweight, while 
overweight was associated with higher levels in E3E3 subjects and E4-carriers (Fig. 
1 and 2). In women, the association between BMI and triglycerides was attenuated 
in E4-carriers (Apo E4*BMI: p=0.05). 
Regression coefficients presented in table 4 represent differences in lipid traits 
between subjects with and without a lifestyle factor (e.g. smoking, alcohol 
consumption and physical inactivity). In men, only smoking E4-carriers had 
significantly (p<0.05) higher total cholesterol and apo B levels than non-smokers 
(Table 4), but the apo E4*smoking interaction terms were not statistically significant. 
In women, smoking E2-carriers, but not E3E3 subjects or E4-carriers, had higher 
total cholesterol and apo B levels than their non-smoking counterparts (E2*smoking: 
p<0.05), resulting in similar levels for smoking E2-carriers and smoking E3E3 
women. 
Apo E4 modulated the association of regular alcohol consumption with some, but 
not all, lipid traits in men, but not in women (Table 4). In men with the E2E2, E3E2 or 
E3E3 phenotype total cholesterol, triglyceride and apo B levels were higher in those 
who regularly consumed alcohol, while in E4-carriers this association was absent. 
The apo E polymorphism did not significantly modulate the association between 
physical activity and lipid traits. 
Discussion 
In the present study both apo E2 and apo E4 modulated associations between 
lipid traits and other risk factors, e.g. age, BMI, smoking and alcohol consumption. 
The positive association of total cholesterol and apo B levels with overweight was 
absent in E2-carriers, while the association with age in men and with smoking in 
women was more pronounced in this group. In E4-carriers, associations of BMI with 
triglyceride levels in women and of alcohol consumption with lipid traits in men were 
less pronounced than in other phenotypes. The apo E polymorphism did not 
modulate associations of lipid traits with physical activity. 
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Table 4. Apo E phenotype-specific regression coefficients* (SE) of smoking, alcohol 
consumption and physical activity with lipids (mmol/l) and apolipoproteins (mg/dl). 
Men/Women 
CURRENT SMOKING 
Men 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
Women 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
E2-carriers 
n=21/n=24 
0.37 
-0.08 
0.37 
30.6 
1.06 
-0.05 
0.38 
27.1 
ALCOHOL CONSUMPTION 
Men 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
Women 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
0.89 
-0.11 
0.47 
19.9 
-0.66 
0.14 
-0.09 
-23.2 
PHYSICAL INACTIVITY 
Men 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
Women 
Total cholesterol 
HDL-cholesterol 
Triglycerides 
Apolipoprotein B 
0.83 
0.14 
-0.10 
7.5 
-0.36 
-0.19 
-0.40 
-8.3 
(0.71) 
(0.13) 
(0.38) 
(24.1) 
(0.37)t 
(0.13) 
(0.21) 
(11.4)t 
(0.48) 
(0.09) 
(0.26) 
(16.6) 
(0.37) 
(0.13) 
(0.20) 
(11.3) 
(0.51) 
(0.09) 
(0.27) 
(17.5) 
(0.44) 
(0.15) 
(0.24) 
(13.4) 
Apo E 
1 
phenotype 
E3E3 
n=139/n=159 
0.09 
-0.12 
0.07 
9.4 
0.27 
-0.02 
0.04 
6.1 
0.46 
0.09 
0.21 
12.1 
-0.16 
0.13 
-0.05 
-4.8 
0.11 
-0.06 
0.10 
7.3 
0.14 
-0.05 
0.15 
5.5 
(0.18) 
(0.04)* 
(0.09) 
(5.8) 
(0.16) 
(0.05) 
(0.07) 
(5.1) 
(0.18)t 
(0.04)t 
(0.09)t 
(5.6) t 
(0.16) 
(0.05)1: 
(0.07) 
(5.1) 
(0.18) 
(0.04) 
(0.09) 
(5.8) 
(0.16) 
(0.05) 
(0.07)f 
(5.2) 
E4-carriers 
n=46/n=57 
0.67 
-0.12 
0.08 
20.5 
0.22 
-0.11 
0.18 
6.2 
-0.03 
0.10 
-0.16 
-7.4 
-0.26 
0.14 
-0.25 
-14.6 
-0.03 
-0.06 
0.12 
1.9 
-0.27 
0.01 
-0.03 
-4.5 
(0.31 ) t 
(0.07) 
(0.21) 
(10.0)f 
(0.25) 
(0.08) 
(0.14) 
(7.2) 
(0.28) 
(0.06) 
(0.19) 
(9.2) 
(0.26) 
(0.09) 
(0.14) 
(7.4) 
(0.30) 
(0.07) 
(0.20) 
(9.8) 
(0.27) 
(0.09) 
(0.15) 
(7.6) 
Interac 
E2 
.70 
.88 
.79 
.84 
.02 
.74 
.41 
.04 
.21 
.24 
.45 
.20 
.77 
.70 
.55 
.68 
.50 
.78 
.48 
.20 
.82 
.89 
.40 
.99 
tionf 
E4 
.13 
.93 
.89 
.28 
.66 
.17 
.43 
.76 
.10 
.56 
.05 
.04 
.62 
.96 
.40 
.28 
.94 
.96 
.98 
.99 
.17 
.54 
.09 
.25 
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Footnote belonging to table 4: Alcohol consumption: drinking equal or more than the median 
number of alcoholic consumptions per week (i.e. > 10 beverages for men and > 1 beverage for 
women). Physical inactivity: reporting little exercise during leisure time. For triglycerides regression 
coefficients for log transformed values are presented. * Regression coefficients are adjusted for town 
of investigation, parental history of myocardial infarction and the other risk factors than the one under 
study, e.g. smoking is adjusted for age, BMI, alcohol consumption and physical activity. H P-value of 
the interaction is given. Interactions of apo E2 (E4 respectively) with smoking, drinking and physical 
inactivity were tested with E3E3 as the reference, t p <0.05, X p<0.01, § p<0.001 
The stronger association of age with total cholesterol and triglyceride levels in 
male E2-carriers suggests that differences between apo E2-carriers and E3E3 
subjects might become smaller at older ages, at least in men. A longitudinal study in 
men by Jarvik and co-workers190 demonstrated that the effect of the apo E 
phenotype on total cholesterol and triglyceride levels indeed attenuates with age, but 
this was due to a smaller effect of apo E4. In a sample of multigeneration pedigrees, 
the difference in apo E levels between apo E phenotypes was smaller in older than 
in younger men and women.'89 In contrast, the results in a subgroup selected from 
the same study population, e.g. the unrelated individuals, suggested that the effect 
of the apo E polymorphism on lipid levels may be larger at older ages.143 Therefore, 
more longitudinal studies are needed to evaluate whether the effect of the apo E 
polymorphism is age-dependent. 
In the present study, no associations of BMI with total cholesterol and apo B 
levels were found in E2-carriers, while in the other phenotype groups they were 
positive. Only in women, BMI was not associated with triglyceride levels in E4-
carriers. Our results are in accordance with the results of a study in a small sample 
of obese women.142 In another study, associations with total cholesterol levels were 
not only less pronounced, but even inverse in female E2-carriers, while no 
interaction in male participants was found.143 In the European Atherosclerosis 
Research Study (EARS) and the Bogalusa Heart Study, in contrast, associations 
with total or LDL-cholesterol and apo B levels were stronger in E2-carriers.144145 One 
important difference of the latter two studies is that the participants were not adults, 
but children and young adults. BMI may be correlated with lean as well as fat 
mass.192 It has been demonstrated that correlations of BMI with body fat percentage 
are high in persons aged 26-55, but much lower in younger persons.193 Therefore, 
more subjects with a high BMI, but low fat percentage and high muscle mass, might 
be classified as overweight in EARS and the Bogalusa Heart Study. As a result, 
associations between BMI and lipids in these studies might in larger part represent 
associations between lipids and fat-free mass. This may account for some of the 
discrepancy between the studies in adult and younger populations. 
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Our results showed that smoking significantly increased apo B and total 
cholesterol levels in female E2-carriers, but not in E3E3 women. The levels in 
smoking E2-carriers were even comparable to those in E3E3 women and E4-
carriers. In EARS also a stronger effect of smoking on apo B levels was found in E2-
carriers.145 These findings suggest that a favorable genetic predisposition can be 
completely overruled by an unhealthy lifestyle (e.g. smoking). Others could, 
however, not find such an interaction between apo E2 and smoking in men or 
, . , „ „ , „ „ 141,143 
women. 
It remains unclear whether the apo E polymorphism modulates associations 
between lipid levels and alcohol consumption or physical activity. In the 
Cardiovascular Risk in Young Finns Study, the effect of physical activity on serum 
total and LDL-cholesterol varied with apo E phenotype in men, but not in women.169 
These results could not be reproduced in EARS145 and the present study, where no 
interaction was found. The apo E polymorphism also did not modulate associations 
of alcohol consumption with lipid traits in EARS145 and a study of Salah et al.'91, while 
apo E2 modulated the association with LDL-cholesterol in men and with HDL3-
cholesterol in women in another study.'41 In the present study, the association of 
alcohol with apo B and triglyceride levels was absent in male E4-carriers, while it 
was positive in other phenotypes. In women associations with alcohol consumption 
were weak in all phenotypes, probably because of the lower alcohol intake in 
women. 
Some methodological explanations could be given for the lack of consistency in 
the results of various studies. First of all, the study samples differed considerably. 
Both children, young adults, adults, obese and non-obese subjects have been 
studied. Lipid levels are determined by a complex interaction of genes and 
environmental factors, including lifestyle. Therefore, differences in genetic and 
environmental background between the study populations might influence the 
associations found. In the present study, subjects with a positive parental history of 
myocardial infarction were overrepresented. Discrepancies between EARS and our 
study cannot completely be explained by this overrepresentation, however, because 
in EARS analyses were carried out on a sample that was pooled for paternal history. 
But it can be argued that the frequency of other genes involved in lipid metabolism 
might be higher in our sample than in the general population. The interactions of apo 
E2 with BMI and smoking could thus reflect interactions with some other gene. 
Variation in the gene coding for lipoprotein lipase, for example, interacts with BMI in 
determining lipid levels122123194, while the effect of a RFLP in the CETP gene is 
modified by smoking.81195 Frequencies for the LPL N291S and D9N mutations and for 
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the CETP TaqlB RFLP did, however, not deviate from frequencies found in other 
Caucasian populations, and were comparable across the apo E phenotype groups 
(data not shown). 
Another difference between studies is that genders and genotypes have been 
pooled in some studies, not in others. It has been demonstrated that the effect of 
apo E2 is larger in women than in men.196 Some of the interactions in the present 
study were also gender-specific, illustrating the importance of gender specific, e.g. 
hormonal factors as important regulators of the complex pathways of lipid 
metabolism. To avoid loss of power we decided to pool phenotypes. Doing so was 
justified by the finding that exclusion of subjects with the E2E2 and E4E4 phenotype 
did not change our results. 
A third methodological reason for discrepancies in the results of various studies 
can be found in the fact that ranges in risk factors as well as lipid traits were not 
similar across studies. This range might affect the regression coefficients found (with 
a wide range an association can be picked up more easily). This can lead to 
different results across studies, but might also influence apo E*risk factor 
interactions when ranges in risk factors differ according to apo E phenotype. 
However, in the present study, mean risk factor levels were comparable between the 
apo E phenotypes. Moreover, excluding subjects to get exact the same range of risk 
factors per apo E phenotype group did not considerably influence our results. 
Finally, because of small numbers, especially in the group of E2-carriers, it cannot 
be excluded that our results and those of other studies, are the result of chance 
alone. 
Obviously, also true biological mechanisms may underlie the interactions between 
the apo E polymorphism and the other risk factors. Apo E2 has a reduced capacity 
to bind to the remnant and LDL-receptor. As a consequence, the delivery of 
cholesterol to the liver is reduced, causing an upregulation of the LDL-receptor. The 
net result is reduced plasma levels of total and LDL-cholesterol.186 Fat accumulation 
results in an increase in VLDL-secretion from the liver, and subsequently to higher 
LDL-cholesterol levels.101 Most of the subjects in our study were only moderately 
overweight, and therefore the increase in VLDL-secretion will be relatively small. It 
can be hypothesized that, because of the upregulation of the LDL-receptor, E2-
carriers are better capable to cope with these - only moderately - increased amounts 
of VLDL than subjects with other phenotypes. This might explain why overweight E2-
carriers had total cholesterol and apo B levels that were comparable to those found 
in E2-carriers with normal weight. Smoking also increases VLDL-secretion77, but the 
effect of smoking was more pronounced in E2-carriers. This indicates that other 
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mechanisms must be responsible for this interaction. These mechanisms require 
further study. 
Differences in metabolism between apo E4 and apo E3 could be partly 
responsible for the altered associations between BMI and triglycerides and of 
alcohol consumption with lipid traits in E4-carriers. Apo E4 cannot make complexes 
with apo All, so it dissociates from HDL easily and has a preference for VLDL, 
resulting in a differential distribution of apo E3 and apo E4 among lipoprotein 
particles.197 
Our results confirm that the apolipoprotein E polymorphism modulates 
associations between lipid traits and other risk factors for coronary heart disease, 
e.g. age, BMI, smoking and alcohol consumption. Differences in study populations 
and their genetic and environmental background may account for some of the 
discrepancies in published results, but also more methodological reasons could be 
given. 
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Chapter 8 
PHYSICAL ACTIVITY MODULATES THE EFFECT OF A 
LIPOPROTEIN LIPASE MUTATION (D9N) ON PLASMA LIPIDS AND 
LIPOPROTEINS 
Based on: Boer JMA, Kuivenhoven JA, Feskens EJM, Schouten EG, Havekes LM, Seidell JC, 
Kastelein JJP, Kromhout D. Physical activity modulates the effect of a lipoprotein lipase mutation 
(D9N) on plasma lipids and lipoproteins. Submitted for publication. 
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Abstract 
We investigated interactions between a common mutation (D9N) in the LPL gene and 
physical activity as well as other lifestyle factors on lipid traits in a population-based sample 
of Dutch men and women (n=379). We used questionnaire information to classify physical 
activity, alcohol consumption and smoking habits, while overweight was defined as a body 
mass index > 25 kg/m2. Non-fasting blood samples were obtained, and used for the 
determination of lipid traits and the LPL D9N genotype. Four percent of the subjects (n=15) 
carried the D9N mutation. They presented with higher levels of total cholesterol, 
apolipoprotein (apo) B and - to a lesser extent - triglycerides compared to non-carriers. 
While no interactions with overweight, alcohol consumption and smoking were found, a 
strong interaction between the D9N mutation and physical activity became apparent. 
Physically inactive carriers of the D9N mutation (n=5) had considerably higher total 
cholesterol (+2 mmol/l, p<0.0001) and apo B levels (+63 mg/dl, p<0.0001) compared to non-
carriers of this mutation, whereas their HDL-cholesterol concentrations were lower (-0.22 
mmol/l, p<0.05). This was not the case for physically active carriers of this mutation (n=10). 
In conclusion, a common variant of the LPL gene (D9N) adversely affects plasma lipid 
and lipoprotein profiles. However, the unfavorable consequences may be counteracted by 
physical activity. 
Introduction 
Elevated plasma levels of total cholesterol35198, triglycerides36 and reduced HDL-
cholesterol concentrations40 are important risk factors for coronary heart disease. 
Their levels are modulated by genetic and environmental factors and by their 
interaction. Variation in the gene coding for lipoprotein lipase (LPL) - a key enzyme 
in the metabolism of triglyceride-rich lipoproteins'" - is likely to contribute to 
interindividual differences in plasma lipid and lipoprotein levels. Recently, a common 
functional mutation in the LPL gene (D9N) was reported to be associated with low 
HDL-cholesterol and high triglyceride levels (reviewed in 51). 
Some investigators reported that elevations in triglyceride concentrations were 
more pronounced in carriers of the D9N mutation with high body mass.194200 It is 
conceivable that other lifestyle-related factors, such as physical activity and alcohol 
intake also modify the effect of LPL mutations on lipid levels since these factors are 
known to influence LPL activity itself.201,202 But, to our knowledge, there are no reports 
on whether physical activity and alcohol consumption, or other factors, such as 
smoking, modulate the effect of the D9N mutation on lipoprotein metabolism. Such 
knowledge, however, may provide a better understanding of complex gene-
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environment interactions. Moreover, it may help us to improve risk prediction and 
strategies for prevention in subgroups of the population that are susceptible to 
coronary heart disease. 
We therefore evaluated the interaction of the D9N mutation in the LPL gene with 
physical activity, overweight, smoking and alcohol consumption on lipid and 
lipoprotein levels in a population-based sample of Dutch men and women. In this 
paper, we describe the identification of a strong interaction between the D9N 
mutation and physical activity. 
Methods 
Population 
Subjects were selected from participants of the Cardiovascular Disease Risk 
Factor Monitoring Project in the Netherlands.95 More than 36.000 men and women, 
20-59 years of age, were examined between 1987 and 1991 at the Municipal Health 
Centers in three Dutch towns (Amsterdam, Doetinchem and Maastricht). The 
subsample under investigation was originally selected to study associations between 
parental history of premature myocardial infarction and variation in genes involved in 
lipid metabolism. Only subjects with stored blood samples, of Dutch nationality and a 
known parental history were eligible (n=33,884). Parental history of myocardial 
infarction was considered to be positive if the participant reported a myocardial 
infarction in his/her father before the age of 61 (n=3,274), in his/her mother before 
the age of 66 (n=1,157) or both (n=185). For the remaining subjects parental history 
was considered to be negative. From each of the four resulting groups, 115 men and 
women were randomly selected, and matched for gender, age (within 5 years) and 
town of investigation. 
Examinations 
For the present study we used data that were collected as part of the 
Cardiovascular Disease Risk Factor Monitoring Project. A detailed description of this 
project is previously reported.95 In brief, the examination included anthropometric 
measurements, blood sampling and a self-administered questionnaire. Height (m) 
and weight (kg) were measured and Body Mass Index (BMI) was calculated as 
weight/height2. Overweight was defined as a BMI above 25 kg/m2.148 Non-fasting 
blood samples were obtained in EDTA-coated vacutainer tubes. After fractionation 
into plasma, erythrocytes and white blood cells, samples were stored at -20°C. An 
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informed-consent form was completed, agreeing to the use of stored blood samples 
for scientific research. 
The questionnaire provided information about the presence and (parental) history 
of cardiovascular diseases, history of other diseases, current medication, alcohol 
consumption, current cigarette smoking, and physical activity. Subjects who 
consumed equal or more than the calculated median number of alcoholic 
consumptions per week (i.e. 10 beverages for men, and 1 beverage for women) 
were defined as regular alcohol consumers. Subjects were asked how they rated 
their physical activity during leisure time (little exercise/ exercise for at least 4 hours 
a week/ regular exercise/ regular strenuous exercise). Subjects were considered to 
be physically inactive when they reported little exercise, while the remainder was 
considered to be physically active. 
Laboratory analyses 
Plasma total- and HDL-cholesterol were enzymatically determined using a 
Boehringer test kit.96 HDL-cholesterol was determined after precipitation of 
apolipoprotein (apo) B containing lipoproteins with magnesium phosphotungstate.97 
Cholesterol measurements were performed at the Clinical Chemistry Laboratory of 
the University Hospital 'Dijkzigt' in Rotterdam, the Lipid Reference Laboratory for 
standardized cholesterol determinations in the Netherlands. 
For the present study, additional laboratory analyses were carried out on blood 
samples that were stored for 3-7 years. Triglycerides were measured enzymatically 
using a Boehringer test-kit (GPO-PAP kit no. 701904). Apo B concentrations were 
measured by an immunonephelometric assay (INA).113 For 384 of the 460 subjects 
genomic DNA was successfully extracted from frozen buffy coats.116 The 76 subjects 
for whom DNA extraction failed did not differ from the other participants in family 
history, or any of the other variables relevant to the present study. The D9N 
mutation in the LPL gene was detected as described previously.118 Due to failure to 
amplify the target sequence for some samples, genotypes were missing for another 
five subjects. 
Statistical analyses 
The D9N mutation was not present in subjects without a parental history of 
myocardial infarction, but allele frequencies were not significantly different between 
subgroups of parental history, e.g. father (0.027), mother (0.035) or both (0.021). 
Exclusion of subjects without a parental history did not change our results. This 
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allowed us to pool all subjects. One subject was found to be homozygous for the 
D9N mutation. This subject was pooled with heterozygous subjects. 
Analyses were performed with SAS Statistical software (SAS version 6.11, SAS 
Institute, Cary, NC). Triglyceride levels were log-transformed to obtain a normal 
distribution. Differences in continuous variables between carriers and non-carriers of 
the D9N mutation were tested by analysis of variance, while analysis of co-variance 
was used to adjust for parental history and matching criteria, i.e. age, gender and 
town of investigation. Adjusted differences in dichotomous variables were tested 
using logistic regression. 
To evaluate whether the effect of the LPL D9N mutation on lipid traits was 
homogeneous across strata of lifestyle-related factors, i.e. physical activity, 
overweight, smoking and alcohol consumption, we used analysis of co-variance 
including interaction terms (genotype*risk factor) in the model. Using the same 
model, adjusted means were determined for lipid traits for each genotype by risk 
factor stratum. A t-test was used to evaluate whether the adjusted means differed 
between genotypes in subgroups with and without the risk factor. In addition to the 
adjustment for parental history and matching criteria, adjustments were made for the 
other risk factors, e.g. the results for physical activity were adjusted for smoking 
status, alcohol consumption (number of alcoholic beverages per day) and body 
mass index. 
Table 1. General characteristics and selected lifestyle-related factors according to the D9N 
mutation in lipoprotein lipase 
Men/Women 
Age (years) 
Body Mass Index (kg/m2) 
Overweight 
Current smokers 
Regular alcohol consumption 
Physically inactive 
Non-carriers 
n=364 
158/206 
41.0 ±9.1 
25.4 ± 3.8 
48.4(176) 
44.8(163) 
51.7(188) 
44.8(163) 
Carriers 
n=15 
9/6 
39.8 ± 9.1 
24.9 ± 3.3 
53.3 (8) 
46.7 (7) 
46.7 (7) 
33.3 (5) 
p-value* 
.4 
.6 
.6 
.8 
.9 
.7 
.3 
Values are presented as means ± SD (continuous variables) or % (n) (dichotomous variables). 
Regular alcohol consumption: consuming equal or more than the calculated median number of 
alcoholic consumptions per week (i.e. > 10 beverages for men, > 1 beverage for women). Physically 
inactive: reporting little leisure time exercise. * Adjusted for age (except for age itself), gender (except 
for gender itself), town of investigation and parental history of myocardial infarction. 
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Results 
Four percent (n=15) of the subjects were found to be carrier of the D9N mutation. 
Table 1 shows some of their general characteristics and the selected lifestyle-related 
factors compared to those in non-carriers of the D9N mutation. No significant 
differences between the groups were detected. 
However, carriers of the D9N mutation presented with significantly higher levels of 
total cholesterol, triglycerides and apo B and non-significantly lower HDL-cholesterol 
concentrations (Table 2). The difference in triglyceride concentrations between 
carriers and non-carriers was no longer statistically significant after adjustment for 
age and matching-criteria. 
Table 2. Lipid traits (means ± SD) according to the D9N mutation in lipoprotein lipase 
Total cholesterol (mmol/l) 
HDL-cholesterol (mmol/l) 
Triglycerides (mmol/l) 
Apolipoprotein B (mg/dl) 
Non-carriers 
n=364 
5.54 ±1.07 
1.23 ± 0.32 
1.57± 1.11 
126.6 ±36.8 
Carriers 
n=15 
6.48 ± 1.57 
1.14 ±0.43 
2.04 ±1.22 
157.1 ±48.5 
p-value 
Crude Adj* 
.0004 .0006 
.19 .85 
.045 .18 
.0006 .006 
Values are presented as means ± SD. * Adjusted for age, gender, town and parental history of 
myocardial infarction. 
We explored whether the effect of the D9N mutation was modulated by 
overweight, cigarette smoking and alcohol consumption, but found no interactions. 
The effect on lipid levels was, however, substantially modulated by physical activity. 
Physically inactive carriers of the D9N mutation had considerably higher total 
cholesterol (2.05 mmol/l p<0.0001) and apo B levels (63.4 mg/dl, p<0.0001) 
compared to non-carriers (Fig 1). In contrast, carriers of the D9N mutation who were 
physically active had similar total cholesterol and apo B levels as compared to non-
carriers. Similarly, HDL-cholesterol levels were significantly (p=0.047) lower in 
inactive, but not in physically active carriers of the D9N mutation compared to non-
carriers (Fig 2). 
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Figure 1. Adjusted total cholesterol (upper panel) and apolipoprotein B (lower panel) 
levels according to the D9N mutation in lipoprotein lipase and physical activity level. 
Values are presented as adjusted means (SE). Physically inactive: reporting little leisure 
time exercise. Adjustments were made for age, gender, town of investigation, parental 
history of myocardial infarction, body mass index, smoking status, and alcohol consumption 
(number of alcoholic beverages per day). Physically active: non-carriers n=201, carriers 
n=10. Physically inactive: non-carriers n=163, carriers n=5. 
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Figure 2. HDL-cholesterol levels according to the D9N mutation in lipoprotein lipase 
and physical activity level. Values are presented as adjusted means (SE). Physically 
inactive: reporting little leisure time exercise. Adjustments were made for age, gender, town 
of investigation, parental history of myocardial infarction, body mass index, smoking status, 
and alcohol consumption (number of alcoholic beverages per day). Physically active: non-
carriers n=201, carriers n=10. Physically inactive: non-carriers n=163, carriers n=5. 
Table 3 shows the individual levels of total cholesterol, apo B and HDL-
cholesterol in physically active and inactive carriers of the D9N mutation. For all 
physically inactive carriers of the D9N mutation total cholesterol levels exceeded 7 
mmol/l, whereas apo B levels exceeded 175 mg/dl. Total cholesterol and apo B 
levels were lower in all but one physically active carriers of the mutation. 
Discussion 
This report describes the interaction between a common LPL gene variant (D9N) 
and environmental factors on plasma lipid and lipoprotein concentrations in a 
population-based sample of Dutch men and women. The effect of the D9N mutation 
on total and HDL-cholesterol and apo B appeared to be strongly influenced by the 
level of physical activity of the carriers of this mutation. By contrast, overweight, 
smoking and alcohol consumption did not modulate the effect of this LPL gene 
defect. 
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Table 3. Individual plasma levels of total cholesterol, apolipoprotein B and HDL-cholesterol 
in physically active and physically inactive carriers of the LPL D9N mutation 
Observation no 
Physically active 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Physically inactive 
11 
12 
13 
14 
15 
Total cholesterol 
(mmol/l) 
3.60 
4.55 
5.46 
5.55 
5.67 
5.90 
6.02 
6.04 
6.19 
9.29 
7.03 
7.35 
7.53 
7.87 
9.13 
Apolipoprotein B 
(mg/dl) 
79 
89 
154 
133 
121 
142 
121 
143 
129 
213 
175 
227 
183 
225 
222 
HDL-cholesterol 
(mmol/l) 
1.09 
1.08 
0.84 
1.22 
1.47 
1.40 
2.28 
1.14 
1.46 
0.78 
1.32 
0.70 
1.01 
0.82 
0.47 
Individuals are ordered according to plasma total cholesterol levels 
For physically inactive carriers of the LPL D9N mutation mean total cholesterol 
levels were about 2 mmol/l higher than for non-carriers. By contrast, for carriers of 
this mutation who were physically active this difference was much smaller (0.4 
mmol/l). Taken that an increase in total cholesterol of 2 mmol/l corresponds to a 
considerable increase (40-50%) in long-term coronary heart disease mortality198203, 
our results suggest that a genetic predisposition for unfavorable lipid levels and 
consequently coronary heart disease might be counteracted by components of a 
healthy lifestyle, in this case physical activity. However, larger scale association 
studies and intervention studies are needed to confirm this hypothesis. 
Our finding that only physically inactive carriers of the LPL N9 allele have 
unfavorable lipid levels is plausible. The D9N mutation appears to be associated 
with a modest decrease in LPL activity - possibly due to a reduced secretion of the 
enzyme from parenchymal cells204 - which consequently results in an impaired 
hydrolysis of triglyceride-rich lipoproteins. It is conceivable that an increase in LPL 
activity due to exercise202 compensates for this reduced activity of the D9N variant, 
resulting in normal lipolytic activity in physically active carriers of the D9N mutation. 
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Besides physical inactivity, also overweight might potentiate an unfavorable effect 
of the D9N mutation. This can be illustrated by the observation that elevations in 
triglyceride levels are more pronounced in overweight carriers of the D9N 
mutation.'9420C We and others'22 did not identify such an interaction. Therefore the 
interaction with physical activity must be independent of body mass. 
In contrast to our findings, the D9N mutation did not result in higher total 
cholesterol and apo B levels in most other studies."8122'24,194205 However, our findings 
are supported by two recent studies among individuals of similar (i.e. Dutch) 
ancestry. These studies showed that in the Dutch population the D9N mutation is in 
almost complete linkage with another mutation in the LPL gene (-93T->G). The N9/-
93G haplotype resulted in both higher total cholesterol and higher LDL-cholesterol 
levels.62125 
Some methodological aspects of our study need to be discussed. Our subjects 
were selected from a large population sample, and stratified for parental history of 
myocardial infarction. This resulted in an overrepresentation of subjects with a 
positive family history. It can be argued that therefore the frequency of other gene 
mutations that adversely affect lipid metabolism is higher in our sample than in the 
general population. To test for this putative selection bias, we analysed a common 
polymorphism in the gene coding for apo E, an example of a major genetic factor 
influencing total cholesterol and apo B levels.13816' However, the apo E phenotype 
distribution did not differ from that observed in other Caucasian populations161, and 
was similar between carriers and non-carriers of the LPL D9N mutation. Moreover, 
elevations in total cholesterol and apo B concentrations in carriers of the LPL D9N 
mutation remained significant when only subjects with the most common apo E3E3 
phenotype (including n=10 D9N carriers) were studied. 
Another aspect is that non-fasting blood samples were taken in our study, while 
most other studies included fasting individuals. One of the main functions of LPL is 
to hydrolyse triglycerides in chylomicrons that are generated after a meal.199 Thus, 
the measurement of triglyceride levels after an overnight fast may not be a good 
estimate of triglyceride levels experienced throughout the day.51 Taken this, we 
argue that non-fasting triglyceride levels may be more accurate to study the effect of 
LPL mutations. 
In summary, we have shown that a common variant of the LPL gene (D9N) 
adversely affects plasma levels of total cholesterol and apo B. However, this 
unfavorable effect was only found in subjects who were inactive during leisure time 
and might therefore be counteracted by physical activity. 
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SMOKING AND ALCOHOL INTAKE MODIFY ASSOCIATIONS OF 
TWO COMMON GENE POLYMORPHISMS WITH HDL-
CHOLESTEROL AND TRIGLYCERIDES 
Based on: Boer JMA, Feskens EJM, Kuivenhoven JA, Schouten EG, Kastelein JJP, Seidell JC, 
Kromhout D. Smoking and alcohol intake modify associations of two common gene polymorphisms 
with HDL-cholesterol and triglycerides. Submitted for publication. 
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Abstract 
Interaction between genes and environment affects plasma levels of lipid traits. We 
investigated whether associations of two common gene polymorphisms (CETP TaqlB and 
apo CHI Sstl) with lipids and lipoproteins were modulated by lifestyle factors in a population-
based sample of Dutch men and women (n=384). Only among moderate alcohol 
consumers, subjects with the CETP B2B2 genotype (n=43) presented with higher mean 
HDL-cholesterol levels (1.38 mmol/l) compared to subjects with other genotypes (1.26 
mmol/l, p=0.006). Furthermore, smokers with the apo Clll S1S2 genotype (n=31) had 
somewhat lower levels of HDL-cholesterol (-0.08 mmol/l, p=0.11) and higher levels of 
triglycerides and apo B (+0.47 mmol/l and +15.6 mg/dl, respectively, p<0.02), compared to 
smokers with the S1S1 genotype. This was not observed among non-smokers. We did not 
detect any significant interactions with overweight and physical activity. Interestingly, the 
unfavorable effect of the S2 allele was especially observed among subjects whose parents 
both suffered from a premature myocardial infarction. 
Our findings suggest that moderate alcohol consumption strengthens a genetic 
predisposition for high HDL-cholesterol levels. More important, smoking may deteriorate the 
effect of a high susceptibility for unfavorable lipid levels. Our results further suggest that the 
apo Clll gene is a modifier gene that mainly affects lipid profiles of individuals susceptible for 
coronary heart disease. 
Introduction 
Low high density lipoprotein (HDL) cholesterol levels40 and high triglyceride 
levels36 are important independent risk factors for coronary heart disease. Genetic 
and environmental factors, as well as their interaction, to a large extent determine 
their levels.60 Genes that are likely to influence plasma levels of HDL-cholesterol and 
triglycerides are those encoding apolipoproteins and enzymes involved in lipoprotein 
metabolism. In this respect, common polymorphisms in the genes coding for 
lipoprotein lipase (LPL) and the cholesteryl ester transfer protein (CETP), as well as 
the apo AI-CIII-AIV gene cluster have been the subject of intensive study.51,53195206 
However, the interaction between these genes and environmental risk factors for 
coronary heart disease has been evaluated in a much smaller number of studies.60 
For example, variation in the LPL gene has been associated with higher triglyceride 
levels (reviewed in 51), but this effect was more pronounced in subjects with higher 
body mass.62 Additionally, the TaqlB polymorphism of the CETP gene has been 
associated with HDL-cholesterol levels53195, and several studies have shown an 
interaction with alcohol consumption or smoking.174195207 We are aware of only one 
report81, however, that also studied interactions with other lifestyle factors. Strikingly, 
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a large number of studies reported an association between the Sstl polymorphism of 
the apo OKI gene and hypertriglyceridemia or triglyceride levels (for a review see 206), 
but interaction was evaluated in only one report.208 
We determined polymorphisms in the LPL, CETP and apo Oil I genes in a 
population-based sample of Dutch men and women as part of a study relating 
candidate genes to parental history of premature myocardial infarction. We used this 
sample to consistently investigate whether the association between these genes and 
lipid traits was modulated by lifestyle-related factors, i.e. overweight, smoking, 
physical inactivity and alcohol consumption. Previously we have shown that the 
effect of the LPL N291S mutation in this very population sample was modulated by 
overweight123, while a strong interaction between the LPL D9N mutation and physical 
activity became apparent.209 We here describe the results of our studies regarding 
the two other polymorphisms, i.e. the TaqlB polymorphism of the CETP gene and 
the Sstl polymorphism of the Apo Clll gene. 
Methods 
Population 
Subjects were selected from the participants of the Cardiovascular Disease Risk 
Factor Monitoring Project in the Netherlands.95 More than 36,000 men and women, 
20-59 years of age, were examined between 1987 and 1991 at the Municipal Health 
Centers in three Dutch towns (Amsterdam, Doetinchem and Maastricht). The 
subsample under investigation was originally selected to study associations between 
parental history of premature myocardial infarction and variation in genes involved in 
lipid metabolism. Only participants of Dutch nationality with stored blood samples 
and a known parental history were eligible (n=33,884). Parental history was 
considered to be positive if the participant reported a premature myocardial 
infarction in his/her father (before the age of 61, n=3,274) or in his/her mother 
(before the age of 66, n=1,157) or in both (n=185). For the remaining subjects 
parental history was considered to be negative. From each of the four resulting 
groups 115 men and women were randomly selected, matched for gender, age 
(within 5 years) and town of investigation. 
Examinations 
A detailed description of the Cardiovascular Disease Risk Factor Monitoring 
Project has been previously reported.95 In brief, the examination included 
anthropometric measurements, blood sampling and a self-administered 
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questionnaire. Height (m) and weight (kg) were measured and body mass index 
(BMI) was calculated as weight/height2. Overweight was defined as a BMI above 25 
kg/m2.148 Non-fasting blood samples were obtained in EDTA-coated vacutainer tubes. 
After fractionation into plasma, erythrocytes and white blood cells, samples were 
stored at -20°C. All participants completed an informed-consent form. 
The questionnaire provided information about the presence and (parental) history 
of cardiovascular diseases, history of other diseases, current medication, alcohol 
consumption, current cigarette smoking, and physical activity. Participants who 
consumed equal or more than the calculated median number of alcoholic 
consumptions per week (i.e. 10 beverages for men, and 1 beverage for women) 
were defined as regular alcohol consumers. Participants were asked how they rated 
their physical activity during leisure time (little exercise/ exercise for at least 4 hours 
a week/ regular exercise/ regular strenuous exercise). They were considered to be 
physically inactive when they reported little exercise, while the remainder was 
considered to be physically active. 
Laboratory analyses 
As part of the monitoring project, plasma total- and HDL-cholesterol were 
enzymatically determined using a Boehringer test kit within three weeks after 
storage.96 HDL-cholesterol was determined after precipitation of apolipoprotein (apo) 
B containing lipoproteins with magnesium phosphotungstate.97 Cholesterol 
measurements were performed at the Clinical Chemistry Laboratory of the University 
Hospital 'Dijkzigt' in Rotterdam, the Lipid Reference Laboratory for standardized 
cholesterol determinations in the Netherlands. 
For the present study, additional laboratory analyses were carried out in blood 
samples that were stored continuously at -20°C for 3-7 years. Non-fasting 
triglycerides were measured enzymatically using a Boehringer test-kit (GPO-PAP kit 
no. 701904). Apo B concentrations were measured by an immunonephelometric 
assay.113 For 384 of the 460 subjects genomic DNA was successfully extracted from 
frozen buffy coats.116 The 76 subjects for whom DNA-extraction failed did not differ 
from the other participants in family history, or any of the other variables relevant to 
the present study. The TaqlB polymorphism of the CETP gene was detected with a 
PCR-based analysis (a DNA fragment of 1413 basepairs that encompasses the 
polymorphic Taql site at positions 782-785 of the CETP gene was amplified).53 The 
Sstl polymorphism of the apo Clll gene was detected as described by Hayden et 
al.116 Due to failure to amplify the target sequences for some samples (n=19 for 
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CETP TaqlB and n=6 for apo Clll Sstl) data were available for 365 and 378 
subjects, respectively. 
Statistical analyses 
Analyses were performed with SAS statistical software (version 6.12, SAS 
Institute, Cary, NC). Differences in genotype distributions and allele frequencies 
between the four parental history groups were small and not statistically significant 
(p=0.78-0.91). Therefore, we analyzed data of all subjects pooled for parental 
history, evaluated the possibility of effect modification and described it whenever it 
became apparent. 
Triglyceride levels were log-transformed to obtain a normal distribution. 
Differences in continuous variables between genotypes were tested by analysis of 
co-variance with adjustment for parental history and matching criteria, i.e. age, 
gender and town of investigation. Adjusted differences in dichotomous variables 
were tested using logistic regression. 
To evaluate whether the effect of the two polymorphisms on lipid and apo B levels 
was homogeneous across strata of lifestyle-related factors, i.e. overweight, smoking, 
alcohol consumption and physical activity, we used analysis of co-variance including 
product terms (genotype*risk factor) in the model. Since the power to detect 
interaction effects is lower than the power to detect main effects, a p-value <0.1 was 
considered to be statistically significant. Using the same model, adjusted mean lipid 
and lipoprotein levels were determined for each genotype by risk factor stratum. A t-
test was used to evaluate whether the adjusted means differed between genotypes 
in subgroups with and without the risk factor under investigation. In addition to the 
adjustment for parental history and matching criteria, adjustments were made for the 
other risk factors than the one under study, e.g. the results for smoking were 
adjusted for body mass index, alcohol consumption (number of alcoholic beverages 
per day) and physical activity. 
Results 
CETP TaqlB polymorphism 
One hundred and seventeen subjects (32%) presented with the B1B1 genotype, 
183 (50%) with the B1B2 genotype and 65 (18%) with the B2B2 genotype. 
Differences in general characteristics and lifestyle-related factors between CETP 
TaqlB genotypes were not statistically significant, except that there were significantly 
more regular alcohol consumers among subjects with the B2B2 genotype (Table 1). 
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Table 1. General characteristics and lifestyle-related variables according to CETP TaqlB 
genotype 
General characteristics 
Men 
Age (years) 
Lifestyle-related factors 
Body Mass Index (kg/m2) 
Overweight 
Current smokers 
Regular alcohol consumers 
Physically inactive 
B1B1 
n=117 
47.9 (56) 
42.0 ± 9.1 
25.5 ± 3.2 
48.7 (57) 
38.5 (45) 
46.2 (54) 
45.3 (53) 
CETP TaqlB genotype 
B1B2 
n=183 
42.6 (78) 
40.4 ± 9.3 
25.5 ± 3.9 
50.3 (92) 
45.9 (84) 
50.8 (93) 
43.7 (80) 
B2B2 
n=65 
38.5 (25) 
41.5 ±8.6 
24.6 ± 3.4 
41.5(27) 
53.9 (35) 
66.2 (43) 
41.5 (27) 
p-value* 
.44 
.19 
.16 
.37 
.11 
.029 
.90 
Values are presented as means ± SD (continuous variables) or % (n) (dichotomous variables). 
Overweight: BMI > 25 kg/m2. Regular alcohol consumers: consuming equal or more than the median 
number of alcoholic consumptions per week (i.e. > 10 beverages for men, > 1 beverage for women). 
Physically inactive: reporting little exercise during leisure time. * Adjusted for age, gender, town of 
investigation and parental history of myocardial infarction. 
They also had significantly higher HDL-cholesterol levels and non-significantly 
lower apo B levels than subjects with the B1B1 or B1B2 genotype (Table 2), and 
these differences could be partly explained by the higher percentage of regular 
alcohol consumers among them (after adjustment differences were borderline 
significant: p=0.07 and p=0.08, respectively). 
Table 2. Lipids (mmol/l) and apolipoprotein B (mg/dl) according to CETP TaqlB genotype 
Total cholesterol 
HDL-cholesterol 
Triglycerides* 
Apolipoprotein B 
B1B1 
n=117 
5.60(0.10) 
1.22 (0.03) 
1.62(0.10) 
128.2(3.2) 
CETP TaqlB genotype 
B1B2 
n=183 
5.64 (0.08) 
1.20 (0.02) 
1.61 (0.08) 
129.6(2.5) 
B2B2 
n=65 
5.46(0.13) 
1.31 (0.03) 
1.52(0.13) 
118.5(4.2) 
P-value 
.46 
.02 
.69 
.07 
Values are presented as adjusted means (SE). Adjustments are made for age, gender, town of 
investigation and parental history of myocardial infarction. * Log transformed values were used in 
analyses, but untransformed values are presented 
Since both lipid and lipoprotein levels and lifestyle-related factors were very 
similar between subjects with the B1B1 and B1B2 genotype, they were pooled for 
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analyses regarding gene-environment interaction. We evaluated whether the 
associations between the CETP TaqlB polymorphism and lipid and lipoproteins were 
modulated by overweight, smoking and physical activity, but did not find any 
statistically significant interactions. However, only among regular alcohol consumers, 
subjects with the B2B2 genotype had higher HDL-cholesterol levels compared to 
those with the B1B1 or B1B2 genotype (Fig. 1). No difference in HDL-cholesterol 
levels between genotypes was found in subjects who were not regular alcohol 
consumers. 
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Figure 1. Plasma HDL-cholesterol (mmol/l) according to CETP TaqlB genotype and 
regular alcohol consumption. Values are presented as adjusted means (SE). Adjusted for 
age, gender, town of investigation, parental history of myocardial infarction, body mass 
index, smoking and physical activity. Regular alcohol consumption: Consuming equal or 
more than the median number of alcoholic consumptions a week (> 10 beverages for men, 
> 1 beverage for women). No regular alcohol consumption: B1B1 or B1B2 n=153, B2B2 
n=22. Regular alcohol consumption: B1B1 or B1B2 n=147, B2B2 n=43. 
We further evaluated this interaction and the results are shown in Table 3. The B2B2 
genotype was significantly associated with higher HDL-cholesterol levels among 
subjects who consumed equal or more than two alcoholic beverages per day only. 
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Table 3. Plasma HDL-cholesterol 
consumption 
Number of alcoholic B1B1 
beverages per day 
level according to CETP 
CETP TaqlB genotype 
orB1B2 
TaqlB genotype 
B2B2 
and 
P-v 
135 
alcohol 
alue 
0 
< 1 
1-2 
>2 
1.12(0.03) 
1.22(0.03) 
1.23(0.03) 
1.31 (0.03) 
1.09(0.07) 
1.24(0.06) 
1.31 (0.07) 
1.52(0.06) 
.64 
.76 
.34 
.003 
Values are presented as adjusted means (SE). Adjustments are made for age, gender, town of 
investigation, parental history of myocardial infarction, body mass index, smoking status and physical 
activity. 
Apo CHI Sstl Polymorphism 
Two subjects were found to be homozygous for the rare allele (S2) of the apo Clll 
Sstl polymorphism. They were both obese (BMI > 30 kg/m2), and one of them was 
hyperlipidemic. Both subjects were excluded from further analyses. Seventy-nine 
subjects (21%) had the S1S2 genotype. They did not differ significantly from 
subjects with the S1S1 genotype for the distribution of gender, age and lifestyle-
related variables (Table 4). 
However, subjects with the S1S2 genotype who reported that both parents had 
suffered from a premature myocardial infarction had a less favorable lipid profile 
compared to those with the S1S1 genotype, characterized by significantly higher 
levels of total cholesterol, triglycerides and apo B (Table 5). No marked differences 
in lipid and lipoprotein levels between subjects with the S1S2 and S1S1 genotype 
were observed in subjects without a parental history or in those with only one 
affected parent. 
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Table 4. General characteristics and lifestyle-related variables according to Apo CHI Sstl 
genotype 
General characteristics 
Men 
Age (years) 
Lifestyle-related factors 
Body Mass Index (kg/m2) 
Overweight 
Current smokers 
Regular alcohol consumers 
Physically inactive 
Apo Clll Sstl genotype 
S1S1 
n=297 
42.4(126) 
40.5 ± 9.0 
25.2 ± 3.7 
46.1 (137) 
45.8(136) 
51.2(152) 
45.8(136) 
S1S2 
n=79 
49.4 (39) 
42.4 ± 9.3 
25.7 ± 3.7 
53.2 (42) 
39.2(31) 
53.2 (42) 
38.0 (30) 
p-value* 
.27 
.13 
.63 
.60 
.44 
.82 
.26 
Values are presented as means ± SD (continuous variables) or % (n) (dichotomous variables). 
Overweight: BMI > 25 kg/m2. Regular alcohol consumers: consuming equal or more than the median 
number of alcoholic consumptions per week (> 10 beverages for men, > 1 beverage for women). 
Physically inactive: reporting little exercise during leisure time. * Adjusted for age, gender, town of 
investigation and parental history of myocardial infarction. 
Table 5. Lipids (mmol/l) and apolipoprotein B (mg/dl) according to Apo Clll Sstl genotype 
and parental history of premature* myocardial infarction. 
Myocardial infarction in: 
Neither or one parent 
Total cholesterol 
HDL-cholesterol 
Triglycerides* 
Apolipoprotein B 
Both parents 
Total cholesterol 
HDL-cholesterol 
Triglycerides* 
Apolipoprotein B 
Apo Clll Sstl genotype 
S1S1 
n=297 
n=220 
5.61 (0.07) 
1.25 (0.02) 
1.51 (0.06) 
127.1 (2.4) 
n=77 
5.37(0.11) 
1.19(0.03) 
1.51 (0.10) 
122.6(3.9) 
S1S2 
n=79 
n=61 
5.49(0.13) 
1.26 (0.04) 
1.55(0.12) 
125.9(4.3) 
n=18 
6.22 (0.23) 
1.17(0.07) 
2.29 (0.22) 
147.0(8.0) 
P-value* 
.43 
.81 
.90 
.81 
.001 
.74 
.003 
.006 
Values are presented as adjusted means (SE). * In the father before the age of 61, in the mother 
before the age of 66. t Adjusted for age, gender, and town of investigation, t Log transformed values 
were used in analyses, but untransformed values are presented 
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We detected significant interactions between the apo Oil I Sstl polymorphism and 
smoking, but associations between genotypes and lipid traits were not modulated by 
the other lifestyle-related factors, i.e. overweight, alcohol consumption and physical 
activity. A Sstl*parental history interaction term was included in the models, to 
account for the family history-specific effect of the apo CIII Sstl polymorphism. 
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Figure 2. Plasma triglycerides (upper panel) and apolipoprotein B (lower panel) 
according to Apo Clll Sstl genotype and smoking. Values are presented as adjusted 
means (SE). Adjusted for age, gender, town of investigation, parental history of myocardial 
infarction, body mass index, alcohol consumption (number of alcoholic beverages per day), 
physical activity and Sstl*parental history interaction. Non-smokers: S1S1 n=161, S1S2 
n=48. Smokers: S1S1 n=136, S1S2 n=31. 
138 Chapter 9 
The unfavorable effect of the S2 allele on apo B and triglyceride levels was 
restricted to those who smoked (Fig. 2). Moreover, HDL-cholesterol levels were also 
lower in smoking subjects with the S1S2 genotype (Fig. 3). In contrast, for non-
smokers lipid and lipoprotein levels were virtually similar between genotypes. 
Subsequently, we excluded participants who reported that both parents had 
suffered from a premature myocardial infarction to evaluate whether this influenced 
the Sstrsmoking interactions. Results remained unchanged for HDL-cholesterol, 
while the interaction between smoking and the apo Clll Sstl polymorphism became 
less pronounced for triglycerides and apo B (p-value for interaction term: p=0.11 and 
0.13, respectively). 
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Figure 3. Plasma HDL-cholesterol according to Apo Clll Sstl genotype and cigarette 
smoking. Values are presented as adjusted means (SE). Adjusted for age, gender, town of 
investigation, parental history of myocardial infarction, body mass index, alcohol 
consumption (number of alcoholic beverages per day), physical activity and Sstrparental 
history interaction. Non smokers: S1S1 n=161, S1S2 n=48. Smokers: S1S1 n=136, S1S2 
n=31. 
Discussion 
Our results show that alcohol consumption increases the HDL-cholesterol raising 
effect of the CETP TaqlB B2 allele in a population-based sample of Dutch men and 
women. In addition, we found that the unfavorable effect of the common Sstl 
polymorphism of the apo Clll gene on lipid levels was more pronounced in smokers 
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compared to non-smokers. The associations between these polymorphisms and lipid 
and lipoprotein levels were not modulated by overweight or physical activity. 
CETP TaqlB polymorphism 
Our observation that the association between the CETP TaqlB polymorphism and 
HDL-cholesterol is affected by alcohol consumption (> 2 alcoholic beverages per 
day) is supported by findings of Fumeron et al.174 Another study reported the 
absence of such effects81, but strong evidence for the existence of this interaction 
comes from a recent intervention study of Toury and colleagues.210 Interestingly, no 
association between the CETP TaqlB polymorphism and HDL-cholesterol was found 
in Finnish alcoholics207, which may mean that this interaction is confined to moderate 
levels of alcohol intake. 
The mechanism by which moderate alcohol consumption interacts with the TaqlB 
polymorphism on plasma HDL-cholesterol levels is unclear to date. The TaqlB 
polymorphism is not likely to be a functional one and it remains uncertain whether or 
not lower transfer activity of the CETP B2 enzyme variant is responsible for the 
association with HDL-cholesterol levels.8"74 Alcohol consumption itself is known to 
reduce CETP activity and might consequently lead to higher HDL concentrations.211 
It has recently been suggested that individuals who carry the B2 allele of the CETP 
gene are more sensitive to an alcohol-induced decrease in CETP activity210, 
providing a possible explanation for our results. 
In concordance with the results reported by Fumeron et al.174, the effect of the B2 
allele on lipid levels was not modified by smoking in the present study. However, 
others have described the presence of such an interaction.81,195,207212 We have no 
clear explanation for these discrepancies, but they may be related to differences in 
ethnicity, age, gender and other characteristics of the study populations. 
Apo Clll Sstl polymorphism 
In the present study, heterozygous carriers of the S2 allele presented with higher 
levels of triglycerides, cholesterol and apo B than non-carriers, but strikingly this 
effect was only seen in subjects who reported that both parents had suffered from a 
premature myocardial infarction. In agreement with these findings, others have 
shown that although S2 allele frequencies did not differ between coronary heart 
disease patients and controls, patients with the S2 allele, but not controls, had 
higher triglyceride levels than non-carriers.2'2215 Moreover, the S2 allele has been 
associated with hypertriglyceridemia in several case-control studies206214,216217, but no 
association between the apo Clll Sstl genotype and triglyceride levels was found in 
140 Chapter 9 
a large number of healthy population samples or control groups.208212'216,218 These 
findings suggest that the apo Clll gene is a modifier gene that mainly influences lipid 
profiles in subjects who are susceptible to coronary heart disease. In this respect, 
interaction with other genes may contribute to the unfavorable lipid profile in S2-
carriers. In our sample, however, no gene-gene interaction with the apo E 
polymorphism, LPL mutations (N291S and D9N) or CETP TaqlB could be detected, 
but the number of individuals with combinations of rare alleles was small (range 2-
15) and this did not allow meaningful conclusions. It is also possible that variation in 
other genes, for example the apo B gene, interacts with the Sstl polymorphism. 
In the present study we observed that the unfavorable effect of the S2 allele on 
lipid levels was more pronounced in smokers compared to non-smokers. To our 
knowledge, this specific interaction has not been reported before. However, smoking 
modulated the effects of other polymorphisms of the apo AI-CIII-AIV gene cluster on 
plasma triglyceride and HDL-cholesterol levels50219220, supporting our observation that 
smoking does interact with the locus of this gene cluster. 
There are potential explanations for the stronger effect of the apo Clll Sstl 
polymorphism in smokers compared to non-smokers. The S2 allele is associated 
with higher apo Clll levels221 and in vitro studies showed that apo Clll inhibits LPL 
activity, thereby reducing hydrolysis of triglyceride-rich particles.222 Despite higher 
apo Clll levels, lipolysis may be sufficient to maintain normal lipid and lipoprotein 
levels in non-smoking S2-carriers. The increased VLDL-production resulting from 
smoking77, however, may overwhelm the slightly impaired lipolytic system, resulting 
in increased triglyceride and total cholesterol levels in smokers with the S1S2 
genotype. It is also suggested that the apo Clll Sstl polymorphism is linked to 
polymorphic sites in an insulin response element like region of the proximal promoter 
of the apo Clll gene.217 In this respect, Li and co-workers223 have demonstrated that 
variation in this region leads to abolition of insulin responsiveness and might 
consequently lead to overexpression of the apo Clll gene. If subjects with the S2 
allele are indeed irresponsive to the increase in insulin levels caused by smoking77, 
this might explain why especially smokers with the S1S2 genotype have elevated 
levels of triglycerides and total cholesterol. More studies are needed to corroborate 
the interaction between the apo Clll Sstl polymorphism and smoking and to 
elucidate the mechanisms that are responsible for this interaction. If the interaction is 
confirmed, refraining from smoking might prevent the development of unfavorable 
lipid profiles in S2-carriers, while smoking cessation may ameliorate lipid profiles in 
those who already smoke. 
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Our results suggest that moderate alcohol consumption might increase the effect 
of a genetic susceptibility for high HDL-cholesterol levels. More importantly, smoking 
may deteriorate the effects of a genetic predisposition to high triglyceride and 
cholesterol levels. The identification of such gene-environment interactions may help 
us to improve prevention strategies in subgroups of the population that are 
susceptible to coronary heart disease. 
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Introduction 
The objectives of the research described in this thesis were twofold. The first 
objective was to identify genetic, lifestyle and biological factors that may explain the 
association between family history of myocardial infarction (Ml) and coronary heart 
disease (CHD). The second objective was to evaluate how genes and lifestyle-
related factors interact in their effects on some of the major biological risk factors for 
coronary heart disease, i.e. lipids and (apo)lipoprotein levels. 
Many of the strengths and limitations of our studies were already discussed in the 
previous chapters. In this chapter a summary of the main findings and a more 
general reflection on issues related to our research is given. After the summary of 
the main findings, some methodological aspects of research on family history are 
discussed. Topics include, validity issues in family history - CHD research and 
testing for effect modification. Subsequently, the current state of knowledge about 
mechanisms that may underlie the family history - CHD association - based on our 
and other studies - is described. The third part of this chapter describes 
methodological issues and current insights with respect to gene-environment 
interactions in relation to lipid traits. Finally, a general conclusion and future 
directions are given. 
Main findings 
In a large Dutch cohort study, family history of myocardial infarction was 
associated with a 1.7 times higher risk for CHD death in men, while it more than 
doubled the risk in women (Chapter 2). If familial clustering of lifestyle-related risk 
factors is partly responsible for the increased risk associated with a family history, 
one would expect higher prevalences of these factors among subjects with a family 
history as compared to those without such a history. However, the results in 
chapters 2, 3 and 4 showed that differences in smoking habits, alcohol consumption 
and physical activity level according to family history of Ml were small. Also 
biological risk factors were fairly similar in subjects with and subjects without a family 
history, except for higher apo B levels and slightly higher levels of total cholesterol in 
subjects with a parental history of premature Ml (Chapter 2-4). They also presented 
somewhat more often with hypertension, especially when more than one parent was 
affected (Chapter 2 & 4). Given these small differences it was not unexpected that 
smoking habits, leisure time physical activity, body mass index, systolic blood 
pressure and serum total cholesterol levels, explained only a small part of the 
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association between family history and CHD death (Chapter 2). The marginal role of 
body mass index and lifestyle (smoking, alcohol consumption and physical activity) 
was further supported by our finding that these variables could explain only a small 
part (<10%) of the differences in plasma apo B levels according to parental history of 
premature Ml (Chapter 4). It appeared that genetic factors accounted for a 
significant part of the higher apo B levels in subjects with a parental history. Six 
genetic factors were studied: the apo E phenotype, three functional LPL mutations 
(N291S, D9N and S447X), and two restriction fragment length polymorphisms 
(CETP TaqlB and apo Clll Sstl). Despite the fact that they were all associated with 
plasma lipid and lipoprotein levels in our population-based samples (Chapter 5, 7-9, 
and ref'23), only two of them were significantly associated with parental history of 
premature Ml (Chapter 4). The apo E4 isoform and the D9N mutation in the LPL 
gene were more frequent among subjects with a parental history. For the LPL 
N291S mutation a similar trend was found. In subjects with two affected parents, the 
higher frequency of apo E4 accounted for about 50% of the higher apo B levels. Part 
of the higher apo B levels in subjects with one affected parent (about 25%) could be 
explained by the higher frequency of the two LPL mutations (D9N and N291S). 
In addition to our findings that known lifestyle and biological risk factors could not 
explain the positive association between family history and CHD death (Chapter 2), 
little support was found for the hypothesis that individuals with a family history are 
more susceptible to the effects of other risk factors on CHD. Among men, the effects 
of family history and known risk factors were additive. In women the effects of family 
history and other risk factors were more than additive, but confidence intervals for 
the proportion of cases that were due to interaction were large. However, women 
with a family history may be more susceptible to the adverse effects of smoking 
(Chapter 2). 
How gene-environment interaction affected plasma levels of lipids and 
(apo)lipoproteins was described in the second part of this thesis (Chapter 6-9). A 
significant interaction between the apo E2 isoform and body mass index was found 
in the European Atherosclerosis Research Study (EARS) (Chapter 6) as well as in a 
population-based sample of Dutch origin (Chapter 7). Surprisingly however, in EARS 
the association between BMI and apo B levels was more pronounced in apo E2-
carriers compared to subjects with other phenotypes, but in the Dutch sample the 
same association was weaker in apo E2-carriers. More consistent was the finding 
that the association between smoking and apo B levels was somewhat more 
pronounced in E2-carriers. In the Dutch sample the interaction was confined to 
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women. In Chapter 8 we described the interaction between lifestyle-related factors 
and the D9N mutation in the LPL gene. No significant interactions with overweight, 
alcohol consumption and smoking were detected, but a strong interaction with 
physical activity became apparent. In subjects who were physically active, no 
differences in lipid and lipoprotein levels were observed between carriers and non-
carriers of the mutation. In contrast, physically inactive carriers of the D9N mutation 
had much higher total cholesterol and apo B levels, and lower HDL-cholesterol 
levels as compared with physically inactive non-carriers. The adverse effect of 
another polymorphism (apo 01II Sstl) on lipid profiles seemed to be more 
pronounced in smokers than in non-smokers, while a genetic predisposition to high 
HDL-cholesterol levels was enhanced by moderate alcohol consumption (Chapter 
9). These results indicate that risk factors for CHD that are related to lifestyle might 
deteriorate the effect of a genetic predisposition to unfavorable lipid levels. Similarly, 
lifestyle-related factors might counteract or enhance the favorable effects of other 
polymorphisms. 
Family history and coronary heart disease 
In this part of the General Discussion some methodological issues regarding 
studies into the association between family history and CHD risk are first discussed. 
Subsequently, the current state of knowledge about several aspects of the 
mechanisms that may underlie this association are described. 
Methodological considerations 
Validity of self-reported family history data 
One of the criticisms on studies that relate family history to CHD or its risk factors 
is that they often use self-reported data, which may be unreliable. For the validation 
of family history of CHD death, death certificates can be used as a 'gold 
standard'.'4'768992224 In two studies8992 death certificates could be obtained for 22% of 
the relatives only, while CHD death was underreported in one study14, and 
overreported in two other studies.76224 
Most studies into the family history - CHD association, including ours (Chapter 2-
4), also included non-fatal CHD in the definition of family history. Kee and 
colleagues75 verified CHD status for living and deceased relatives, but for deceased 
relatives death certificates were used as the sole source of information. Although 
CHD mortality is high among individuals that already have non-fatal forms of this 
disease, a significant number of these individuals die of non-coronary causes.225 
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Therefore, validation of reported family history by death certificate alone, ignores 
non-fatal CHD in relatives who died of other causes. This implies that also for 
deceased relatives information from medical records should be retrieved. However, 
as described in Chapter 3, this is hard to accomplish. In our validation study, general 
practitioners were able to provide medical information for 18% of the deceased 
fathers and 25% of the deceased mothers only. Unfortunately, other researchers 
who were able to validate family history of CHD through medical records for living 
relatives and both death certificates and medical records for deceased relatives, 
verified only positive family histories.8691 Information about false-negative reports is 
lacking in these studies. 
Family history of non-fatal CHD has also been verified with the health status that 
was reported by relatives themselves.8990 However, study participants as well as their 
relatives may concordantly report the presence (or absence) of CHD, but they can 
both be wrong. Therefore, self-reports of relatives cannot be considered as a 'gold 
standard', and the true validity of the family history data cannot be obtained. 
Moreover, not much additional information is obtained when questionnaires may 
have been filled out together or after consulting each other by telephone (Chapter 
3). 
Based on the above described studies it is not possible to obtain a general 
measure for the validity of self-reported family history data. Our attempts to validate 
parental history of Ml failed, due to a lack of necessary information (Chapter 3). 
However, to get some insight into the reliability of parental history of myocardial 
infarction we determined its test-retest reproducibility. Seventy-five percent of the 
individuals were classified into the same parental history group based on the data 
that were collected as part of the Monitoring Project on Cardiovascular Disease Risk 
Factors and the data collected for the reproducibility study. For the other 25% 
percent of the subjects, family history was discordant (7%) or missing in the 
reproducibility study (18%). Also here one should keep in mind that in some 
instances family history may have been concordant, but in fact invalid. 
Validity of family history - CHD / CHD risk factor associations 
Several sources of bias exist that may have affected the validity of the observed 
associations between family history and CHD or its risk factors. First of all, invalid 
family history data will have led to misclassification of family history status. The 
general opinion is that non-differential misclassification leads to a dilution of true 
effects (bias towards the null). However, when misclassification of family history is 
differential, i.e. associated with the outcome measures, it may lead to an under-, 
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over- or even inverse estimation of the association of family history with CHD and its 
risk factors.226 In Chapter 2, the association between family history and CHD death 
would have been biased when those subjects who died of CHD were more (or less) 
likely to falsely report a family history of CHD at baseline as compared to the other 
participants (recall bias). Given the prospective nature of the study, such bias is not 
very likely. Accordingly, the cross-sectional association of family history with CHD 
and its risk factors (Chapter 2 at baseline, Chapter 3 & 4) might have been biased 
when subjects who reported a personal history of CHD-like conditions (e.g. 
myocardial infarction, treatment for heart conditions) or unfavorable risk factor levels 
are more (or less) likely to report a myocardial infarction in one of their parents. 
However, it is unclear whether the occurrence of CHD in relatives is over- or 
underreported.7576224 Moreover, it is unclear whether the degree of misclassification is 
dependent on the personal history of the respondents.75,224 
Since we do not have information on the validity of our family history data, 
judgments about the possible effects of differential misclassification on our results 
would be speculative. However, we evaluated whether a lack of reproducibility in the 
family history data might have affected our results (Chapter 3). Subjects for whom 
parental history was discordant or missing in the reproducibility study, more often 
reported treatment for cardiac complaints or a personal history of myocardial 
infarction. Therefore, the true association between parental history and clinical 
features (Chapter 4, Table 1) might have been somewhat overestimated. 
Furthermore, reproducibility was associated with BMI, HDL-cholesterol, the apo 
E4E3 phenotype and the LPL D9N mutation. Differences in genetic, lifestyle and 
biological factors between parental history groups remained similar or became 
somewhat more pronounced when only subjects for whom parental history was 
reproducible were studied (Chapter 3 & 4). These observations suggest that if 
misclassification due to imperfect reproducibility influenced our observations, it may -
at most - have led to an underestimation of the true effects. 
In addition to recall bias, non-response may have biased the results if the 
respondents differed systematically from the non-respondents. For the CB-project 
(Chapter 2) no information about non-respondents was available. However, since 
the response rate was high (70-80%)70, no major impact of non-response on the 
results is expected. In the Monitoring Project on Cardiovascular Disease Risk 
Factors, the response was much lower (45-62%), but no substantial selection with 
respect to educational level - used as a marker to evaluate potential bias - was 
observed.95 In the validation study, respondents more often reported a personal 
history of Ml, treatment for cardiac complaints and more frequent use of 
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antihypertensive medication. This may imply that participants in the study had a 
higher CHD risk than non-respondents. Since similar differences between 
responders and non-responders were observed among all parental history groups 
(no, one and two affected parents) non-response bias is unlikely. 
Testing for effect modification by family history 
One of the mechanisms underlying the family history - CHD association may be 
that individuals with a family history are more susceptible to the adverse effects of 
other risk factors on CHD (see Chapter 1 & 2). Several investigators evaluated 
whether family history modified the effect of other risk factors on CHD by including 
product terms in Cox proportional hazards or logistic regression models.9,121431 
Including product terms in these multiplicative models refers to testing whether 
relative risks associated with a given risk factor vary according to strata of family 
history. The major pitfall of testing interaction this way, i.e. on a multiplicative scale, 
is clearly illustrated by Rothman's69 example on lung cancer in relation to the 
exposure to cigarette smoke and asbestos. In his example smokers had a five times 
higher risk for lung cancer as compared with non-smokers, whether they were 
exposed to asbestos or not. Based on this information one may conclude that there 
was no interaction between smoking and asbestos exposure. However, smoking 
increased the incidence of lung cancer by 9/100.000 yr'1 in those not exposed to 
asbestos and with 45/100.000 yr1 among those who were exposed. Based on this 
information (on an additive scale), the same results lead to the opposite conclusion, 
namely that the smoking effect was clearly larger in those exposed to asbestos. In 
epidemiological research interaction should preferably be tested on an additive 
scale, which equals testing the modification of risk differences.69 We used the 
method described by Walker for this purpose.74 
One should note that in the above paragraph interaction in fact refers to effect 
measure modification, which means the presence of statistical interaction. Although 
non-additivity of effects implies the presence of some biological interaction, it gives 
no insight into the specific underlying biological mechanisms. 
Mechanisms underlying the family history - CHD association 
Explanation by familial aggregation of risk factors 
According to Perkins87 the relationship between family history and coronary heart 
disease incidence may be entirely mediated by the concomitant familial aggregation 
of known risk factors. However, in our study (Chapter 2), other prospective 
studies7'91112'14'227'228 as well as in a large number of case-control studies15293094 the 
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association hardly changed after adjustment for known risk factors, such as smoking 
status, total cholesterol, blood pressure, diabetes and relative weight. Some of the 
remaining risk may be the result of residual confounding, since risk factors were not 
always precisely measured. It is more likely, however, that the remaining excess risk 
is explained by other familial CHD risk factors that were not measured in the CB-
project and other studies. In a small study of Durrington and colleagues229, the 
difference in family history between Ml patients and controls was fully explained by 
the concurrent difference in Lp(a) levels. However, it is premature to conclude that 
Lp(a) is responsible for the remaining increase in CHD risk in individuals with a 
family history, since we (Chapter 4) and others, failed to demonstrate a strong 
association between family history and Lp(a).230"232 HDL-cholesterol, triglycerides and 
fibrinogen levels were also not significantly related to family history in our study 
{Chapter 4), suggesting a minor role for these risk factors. Indeed, in the few studies 
that adjusted the association between family history and CHD for HDL-cholesterol 
levels, the adjustment had little impact on risk estimates.2831 We are not aware of 
studies that adjusted for triglycerides, fibrinogen or other hemostatic variables. Since 
others observed that the levels of risk factors, such as Lp(a), HDL-cholesterol, 
triglycerides, and hemostatic variables, were less favorable in individuals with a 
family history,84233'236 we cannot rule out the possibility that they do account for a part 
of the remaining association between family history and CHD risk. 
Explanation by higher susceptibility to CHD risk factors 
An additional explanation for the increased risk in individuals with a family history 
might be that they are more susceptible to the effects of other risk factors on CHD. 
This hypothesis has been investigated in several studies. In general, little support is 
found for the hypothesis that subjects with a family history are more susceptible to 
the adverse effects of diabetes, high blood pressure or overweight on CHD risk 
(Chapter 2 and refs912'530). As far as we know, our study is the only one that 
evaluated this hypothesis with respect to physical activity (Chapter 2). The risk of 
CHD death in physically inactivity women with a family history was higher than 
expected from the additive effects of these two, but we cannot not exclude the 
possibility that this was a chance finding. 
Most consistent is the observation that smokers with a family history have a risk 
for coronary heart (or cardiovascular) disease that is 1.2-2.8 times higher than 
expected from the separate effects of smoking and family history (Chapter 2 and 
refs121530,3168). It is possible that a higher susceptibility to smoking in individuals with a 
family history is a reflection of gene-smoking interactions. This hypothesis is 
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supported by evidence from case-control studies showing that smoking increased 
the risk for CHD in individuals with certain genotypes, but not (or less) in individuals 
with other genotypes.83,237 
For the interaction between total cholesterol levels and family history, results have 
been less consistent. In the CB-project (Chapter 2) the risk of CHD death for women 
with hypercholesterolemia (total cholesterol > 6.5 mmol/l) and a family history was 
five times higher than expected from their separate effects. For men, no effect 
modification by family history was found. In some case-control studies the 
investigators also observed that the effect of family history in combination with 
elevated cholesterol levels was higher than expected152930, but this could not be 
confirmed in four prospective studies.9121468 Some methodological shortcomings may 
partly account for the discrepancies. In the case-control studies fatal cases of Ml 
were not included. Additionally, the case-control studies pooled men and women in 
their statistical analyses. Some of the prospective studies had shortcomings as well. 
The major problem in the Nurses Health Study9 was the use of self-reported 
hypercholesterolemia as independent variable. In the study reported by Khaw and 
Barret-Connor68, total cardiovascular death was used as outcome measure, which 
included a significant number of non-CHD deaths, especially for women (40%). 
Moreover, effect modification was usually evaluated at the multiplicative, and not at 
the - preferable - additive scale.914 Based on the here described results we cannot 
exclude the possibility that individuals with a family history are more susceptible to 
the effects of hypercholesterolemia on CHD. 
The role of genetic factors 
As was outlined in the introduction of this thesis, the association between family 
history and coronary heart disease might be mediated by genetic factors and their 
influence on biological risk factors. For example, several studies showed that the Del 
allele of an Insertion/Deletion polymorphism in the gene coding for angiotensin-
converting enzyme (ACE) was more frequent among individuals with a family 
history.238240 Although the function of ACE may suggest otherwise, there is no 
association between the ACE polymorphism and blood pressure.241 This implies that 
higher blood pressure levels among individuals with a family history12678586 nor higher 
prevalences of hypertension among individuals with two affected parents (Chapter 4) 
can be explained by this polymorphism. 
The studies described in this thesis focused on genes involved in lipid 
metabolism. Until now, studies that related polymorphisms in these genes to family 
history of CHD are scarce. For most researchers who studied this issue, the primary 
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goal was to investigate whether a given polymorphism is a major genetic 
determinant of CHD or not, irrespective of their effects on intermediate traits. They 
used healthy individuals with and without a family history to circumvent some of the 
methodological problems encountered in conventional case-control studies.242 
In contrast, the purpose of the study described in Chapter 4, was to investigate 
whether or not genetic factors accounted for differences in plasma lipid and 
lipoprotein levels between individuals with and without a family history. We had the 
opportunity to study several genetic factors (Apo E phenotype, LPL D9N, N291S 
and S447X, CETP TaqlB and apo Clll Sstl). Of these genetic factors, the apo E 
polymorphism is the most important genetic determinant of plasma total- and LDL-
cholesterol in the general population known to date, explaining up to 15% of the 
inter-individual variation in their levels.4445126157243 It is therefore not unexpected that 
this polymorphism explained a large part of the difference in apo B levels between 
subjects with and without a family history of Ml in our study (Chapter 4) and the 
European Atherosclerosis Research Study.110 However, in another study106, 
differences in apo B levels according to family history remained significant when 
data analyses were restricted to individuals with the apo E3E3 phenotype. It seems 
that additional genetic factors must account for some of the higher apo B levels 
among individuals with a family history of CHD. 
It is hard to predict which polymorphisms may be otherwise important. A recently 
detected common polymorphism in microsomal triglyceride transfer protein (MTP) 
strongly influenced LDL-cholesterol levels in healthy men and may therefore be one 
of the contributors.'27 However, we have no data on this polymorphism. We observed 
that some of the remaining association between parental history of premature Ml 
and apo B levels was mediated through the LPL D9N and N291S mutations. While 
in a study among patients with coronary atherosclerosis carriers of the LPL D9N 
mutation more often had a positive family history118, another study could not confirm 
higher carrier frequencies of the D9N and the N291S mutation among subjects with 
a family history.122 Moreover, while in some samples of Dutch ancestry plasma total 
and LDL-cholesterol levels were higher in carriers of the LPL D9N or N291S 
mutation124125, associations between these mutations and total and LDL-cholesterol 
or apo B levels were weak in other studies.62122194244 It is thus uncertain whether our 
results are generalizable to other populations, and it remains unclear to what extent 
these LPL mutations explain unfavorable lipid levels in individuals with a family 
history. 
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Summary 
Until now most of the increased CHD risk in individuals with a family history of 
coronary heart disease remains unexplained. Only a small part is mediated through 
known coronary risk factors, and total and/or LDL-cholesterol levels appear to be the 
most important among them. The contribution of lifestyle-related (i.e. modifiable) 
factors to higher apo B levels in individuals with a family history seems to be small; 
most of it seems to be genetically determined. The apo E polymorphism is probably 
one of the most important genetic factors involved. Furthermore, it seems unlikely 
that individuals with a family history are more susceptible to the adverse effects of 
major risk factors on CHD. 
Gene-environment interaction 
The second part of this thesis described studies on gene-environment interaction. 
In this part of the General Discussion some methodological issues, (general 
concepts, multiple testing and validity concerns) and the current evidence for gene-
environment interactions in relation to plasma lipid traits is discussed. 
Methodological considerations 
Concepts of gene-environment interaction 
In epidemiological research gene-environment interaction refers to the 
modification of environmental effects by a given genotype or vice versa (effect 
modification or statistical interaction). This has to be distinguished from another -
more biological - approach to gene-environment interaction, which refers to how 
environmental factors, such as diet, regulate gene expression. As described before, 
it is most appropriate to evaluate effect modification on an additive scale. In the 
studies described in this thesis (Chapter 6-9) product terms were included in 
analyses of variance models. Since these models are linear this indeed corresponds 
to testing interaction on an additive scale. 
One should keep in mind that the power to detect interaction is much lower than 
the power to detect main effects. Especially when allele frequencies are rare, large 
numbers are needed to detect small to moderate gene-environment interaction 
effects.245247 However, strong gene-environment interactions may be detected with 
much smaller numbers, as demonstrated by our finding of a significant interaction 
between the LPL D9N mutation and physical activity [Chapter 8). 
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Multiple testing 
In the research described in this thesis, interaction effects of six polymorphisms 
with four to six lifestyle-related factors were investigated for four lipid traits. It has 
been stated that the probability of at least one spurious test result is (1-(1-a)n (where 
n is the number of statistical tests and a is the probability of a spurious finding (Type 
1 error)), and that the probability of finding at least one spurious result therefore 
increases exponentially with the number of statistical tests.248 Some believe that one 
should therefore adjust for multiple testing.248 However, this exponential increase in 
the probability for at least one spurious finding only holds true under the condition 
that the dataset consists of pure random numbers. This is never the case in an 
observational study. In our study for example, we did not search for interactions 
without any prior (though global) hypothesis. Beforehand, the detection of gene-
environment interaction seemed not unlikely, since both the polymorphisms51,53,160'161, 
206.249,250
 a s w e | | a s t h e |jfesty|e_re|atec| factors77'101 ~104'136 under investigation have been 
associated with lipid levels in previous studies. The effect of some of the lifestyle 
factors is even mediated through direct effects on the factors in lipid metabolism for 
which we studied variation in the coding genes. For example, physical activity has 
an effect on LPL activity.202 
Moreover, although adjustment for multiple comparisons will indeed reduce the 
chance for a spurious finding, it will unnecessarily reduce the power to detect 
associations that are truly there. Therefore, under most circumstances, adjustment 
for multiple testing is irrelevant and inappropriate.226 251 Nevertheless we cannot rule 
out the possibility that some of the observed associations might have arisen by 
chance, so our results need confirmation. 
Representativeness of the study population 
In addition to acknowledging the possibility of chance findings we should ask 
ourselves whether the observed associations between genetic factors and lipid traits 
(and the interactions) might have been the result of methodological shortcomings. In 
the investigated populations, subjects with a family history of premature Ml were 
overrepresented. It can be argued that several gene variants that adversely affect 
lipid levels are concurrently present, especially in those individuals with a family 
history of premature CHD. More unfavorable lipid levels in individuals with a given 
genotype could therefore have arisen because of the confounding effects of other 
genotypes. In our sample, associations between lipid traits and the apo E 
phenotype, the CETP TaqlB polymorphism and the apo OlII Sstl polymorphism were 
as expected. However, plasma levels of total cholesterol and apo B were higher in 
156 Chapter 10 
carriers of the D9N mutation (Chapter 8) as well as in carriers of the N291S 
mutation123, whereas in most population based samples only higher triglyceride 
levels were observed.62122,252253 This could suggest that the selection based on 
parental history indeed caused some spurious findings. We evaluated whether 
associations may have been due to the concurrent presence of the other gene 
variants, but this was not the case. Observations in other samples from Dutch 
ancestry also support the possibility that our findings reflect true associations 
between the LPL D9N and N291S mutations and plasma levels of total cholesterol 
« « J ~r*r. D 52,124,125.254 
and apo B. 
Evidence for gene-environment interactions 
Introduction 
The importance of gene-environment interaction in the etiology of coronary heart 
disease is far and wide acknowledged.56255 However, our current knowledge with 
respect to CHD and lipid levels is limited. While, much attention has focused on the 
determination of interactions between genes and diet, little attention is given to 
factors that are not directly related to diet. Usually the role of specific gene-
environment interactions is evaluated only when earlier studies have suggested that 
such interaction might exist. Furthermore, interaction effects are usually only 
evaluated for those lipid traits that showed statistically significant main effects. Doing 
so possible gene-environment interactions may be overlooked. For example, the 
LPL D9N mutation was not associated with HDL-cholesterol in our total sample 
(Chapter 8). However, HDL-cholesterol levels were significantly lower in carriers of 
the rare allele compared with non-carriers in those that were physically inactive. The 
next paragraphs describe the available evidence for gene-environment interactions 
for the polymorphisms that were studied as part of our research. 
Apolipoprotein E polymorphism 
Of all known genetic factors, the apo E polymorphism received the most attention 
up to now. Numerous studies investigated its relation to lipid levels and coronary 
heart disease.16'256 Furthermore, several studies investigated how this polymorphism 
modified associations between lifestyle-related factors and plasma lipids and 
lipoproteins. The short review of the literature given in Chapter 7, clarified that the 
results have not been very consistent. However, if any significant interactions were 
detected, it were usually the E2-carriers (E2E2 and E2E3 phenotype) who showed 
associations between plasma lipids and lifestyle-related factors that were different 
from those observed in subjects with other phenotypes. In this respect, interactions 
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with body mass index and smoking seem to be most likely. Several studies observed 
that in apo E2-carriers associations between BMI and plasma total cholesterol 
and/or apo B levels were dissimilar from those observed in individuals with other 
phenotypes (Chapter6, 7and rets142'44). Noteworthy, in some of these studies the 
associations were stronger in E2-carriers (Chapter 6 and ref144), while in other 
studies they were weaker (Chapter 7 and refs142143). As described in chapter 7, these 
discrepancies may be related to differences in the body composition of the 
participants. Besides body mass index, smoking may interact with the apo E 
phenotype. The results described in this thesis (Chapter 6 & 7) showed that smoking 
may counteract the favorable effect of the apo E2 isoform on plasma levels of total 
cholesterol and apo B. Others, however, did not find any interaction between the 
apo E polymorphism and smoking.141143 Large population studies, are needed to 
elucidate whether these interactions are true or just chance findings. 
Mutations in lipoprotein lipase (LPL) 
In contrast to the findings for the apo E polymorphism, the observation that the 
effect of the LPL N291S mutation on triglyceride levels is most pronounced in 
individuals with a high body mass index seems highly consistent. After the initial 
finding of this interaction6162, it has been confirmed by several others.122254 Also in one 
of our samples we observed that the effect of this mutation on plasma lipid levels 
was modulated by overweight.123 
Both the LPL N291S and D9N mutation appear to be associated with modest 
(about 30%) decreases in post-heparin LPL activity.51 Because of the similar effects 
on LPL activity, one may expect that similar observation will be made for the N291S 
and the D9N mutation. Although the results of some studies suggested that the 
effect of the D9N mutation on triglyceride levels was also dependent on BMI194,200, our 
results (Chapter 8) and those of others122 could not confirm this finding. We observed 
that the effect of the D9N mutation was altered by physical activity (Chapter 8). 
Compared to non-carriers, physically inactive carriers of the D9N mutation presented 
with higher levels of total cholesterol and apo B, while their HDL-cholesterol levels 
were lower. In contrast, plasma lipid levels were normal in physically active carriers 
of the D9N mutation. To our knowledge we are the first who studied interactions with 
physical activity. Therefore, more research is needed to confirm or reject the 
hypothesis that physical activity modulates the effect of this LPL mutation. 
Apparently, the effects of the N291S and D9N mutations in the LPL gene are not 
completely similar. This is supported by results of EARS, which showed that 
postprandial lipid response was prolonged in carriers of the N291S mutation, but not 
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in carriers of the D9N mutation.122 Discordant findings for both mutations could be 
related to differences in the defects that underlie the reduced post-heparin LPL 
activities associated with the mutations. It has been suggested that the stability of 
the LPL 291S variant is decreased, leading to an increased dissociation of the active 
dimer into the inactive monomeric form of the enzyme. In contrast, the D9N 
substitution may lead to a reduced secretion of normal LPL.5' 
Cholestervl ester transfer protein (CETP) TaqlB polymorphism 
Several investigators have observed that the B2 allele of the CETP TaqlB 
polymorphism was associated with higher plasma HDL-cholesterol levels.53,249 There 
is evidence from some small studies that this effect may be restricted to non-
smokers.81,207212 However, this could not be confirmed in our study and two other -
larger - studies (Chapter 9 and refs174,257), indicating that more research is needed 
before definite conclusions can be drawn. 
Fumeron and colleagues were the first to observe that the positive association 
between the CETP B2 allele and HDL-cholesterol was restricted to those who 
consumed alcohol.174 We observed similar results. Only individuals with the B2B2 
genotype who regularly consumed alcohol had higher HDL-cholesterol levels than 
individuals with the B1B1 or B1B2 genotype. Strong support for this alcohol-
dependent effect of the B2 allele has recently been provided by an intervention 
study published by Toury et al.210 Further analyses of our data revealed that the B2 
effect on HDL-cholesterol was most pronounced in individuals who consumed two or 
more alcoholic beverages per day. In the study of Fumeron et al.174 the effect was 
apparent among those consuming 25 grams per day or more (about 2.5 glasses). 
Therefore, moderate alcohol consumption is probably sufficient to enhance the 
effect of the B2 allele. 
Apolipoprotein CHI Sstl polymorphism 
Our results demonstrated that smoking might influence the effect of the apo OlII 
Sstl polymorphism on plasma lipid levels. More specifically, lipid profiles were 
unfavorable in smoking, but not in non-smoking, carriers of the apo Oil I S2 allele. 
We are not aware of any other study that evaluated the interaction between this 
specific polymorphism and smoking. However, several studies showed that the HDL-
raising effect of a G to A transition in the promoter region of the apo Al gene was 
absent in smokers.50220 Since, the apo Al gene is located near the apo Oil I gene on 
chromosome 11258, these findings corroborate our finding that variation in this gene 
cluster interacts with smoking. However, the underlying functional defect that is 
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responsible for the effect of the apo Clll Sstl polymorphism on lipid metabolism (and 
consequently for the possible interaction with smoking) remains unknown. 
Summary 
Until now several interactions between genes and environmental factors have 
been identified that influence plasma lipid levels. However, some of these 
interactions have been consistent across populations, others have not. In genetic 
association studies, similar findings in different populations support the existence of 
strong effects.259 Taken this into account, the interaction between the N291S 
mutation and body weight as well as the interaction between the CETP TaqlB 
polymorphism and alcohol consumption, possibly reflect strong interaction effects. 
Interactions for which findings have been less consistent (apo E2*body mass index, 
LPL D9N*body mass index, apo E2*smoking and CETP TaqlB*smoking) may be 
less pronounced or dependent on the further genetic and environmental background 
of the study populations. However, one can also not exclude the possibility that 
some interactions have been found by chance alone, and do not reflect true 
interaction effects at all. This especially holds true for the interactions that were not 
investigated before, i.e. the interaction between the LPL D9N and physical activity 
as well as the interaction between the apo Clll Sstl polymorphism and smoking. 
Although these interactions can biologically be explained in a plausible way, our 
results need confirmation. 
General conclusions and future directives 
It becomes more and more clear that individuals with a family history of coronary 
heart disease are themselves at an increased risk for this disorder. When it is known 
which factors are responsible for the increased risk, preventive actions may be 
focused on these factors, especially on those that are modifiable. However, until 
now most of the increased risk remains unexplained. Only a small part is mediated 
through known CHD risk factors, and total and/or LDL-cholesterol levels appear to 
be the most important among them. The contribution of lifestyle-related (i.e. 
modifiable) factors to higher apo B levels in individuals with a family history seems to 
be small; most of it seems to be genetically determined. The apo E polymorphism is 
probably one of the most important genetic factors involved. 
In short, what we know to date about family history is: 1) most of the increased 
risk associated with family history is not mediated by the conventional risk factors, 2) 
it seems unlikely that risk factor reduction is more effective in individuals with a 
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family history than in those without a family history and 3) family history status in 
itself cannot be changed. Therefore, one may argue that information on family 
history contributes little to CHD prevention. However, the absolute risk for CHD is 
highest in individuals with both a family history and unfavorable levels of other risk 
factors. The control of risk factor levels is therefore very important in individuals with 
a family history and it is justified that family history of CHD is included as one of the 
criteria in recommendations for CHD prevention.5260 
It is generally accepted that the risk associated with a family history increases 
when only first-degree relatives are considered, when the number of affected 
relatives increases and under the circumstance that the event is premature.261 In 
guidelines for CHD prevention there is, however, no consensus about the definition 
of a positive family history. In the Dutch guidelines for the treatment of elevated 
cholesterol levels, family history is defined as the occurrence of CHD in one or more 
first degree relatives before the age of 60.260 In contrast, in the recommendations of 
the Second Joint Task Force of the European and other Societies on Coronary 
Prevention, family history is defined as the occurrence of CHD or other 
atherosclerotic vascular disease in any male relative (<55 years) or in any female 
relative (<65 years).5 Gender-specific cut-off points for the age of the relative at the 
time of the event are widely used. This choice seems to be driven by the fact that 
CHD becomes manifest at later ages in women than in men. As a consequence, for 
women coronary events may be considered as more premature than events for men 
of similar age. However, the scientific basis for such a gender-specific cut-off point is 
small. The most comprehensive study regarding this issue available until now is a 
long-term follow-up study of Swedish twins.6 The risk of CHD death was not 
increased when the co-twin died of CHD after the age of 85, while the largest risks 
were observed for twins who's co-twin died before the age of 65. In all age ranges 
results were similar for male and female co-twins, suggesting that a gender-specific 
cut-off point may not be justified. 
It may be clear, that inclusion of family history data in risk predictions and 
recommendations for the prevention of CHD will be more valuable when the most 
informative definition of premature CHD is used. Therefore, large long-term 
prospective studies are needed that provide further basis for a useful cut-off point for 
the relative's age at the time of the event. 
A significant part of the increased apo B levels in individuals with a family history 
seems to be genetically determined. Like family history, genotypes can not be 
modified. However, not only genotypes themselves, but also their interaction with 
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environmental factors, such as factors that are related to lifestyle, are important 
determinants of plasma lipid profiles and CHD risk. Several examples of gene-
environment interactions were described in this thesis. The effect of some 
polymorphisms clearly depended on the environmental background of the 
individuals. First of all, this implies that interactions with environmental (i.e. lifestyle-
related) factors should be taken into account in genetic association studies. Some of 
the inconsistencies between studies that related gene polymorphisms to plasma 
lipids and lipoproteins may be explained by the fact that gene-environment 
interaction is usually neglected. For example, no difference in triglyceride levels 
between carriers and non-carriers of the N291S mutation may be found in 
populations where the majority of the people is lean. In contrast, in more adipose 
populations a positive association may be easily detected. 
Secondly, gene-environment interaction implies that a genetic predisposition to 
unfavorable lipid profiles is not in all cases something of which the consequences 
cannot be influenced. On the contrary, its consequences may be limited by the 
modification of risk factor levels. Notwithstanding this general awareness, our 
insights into specific gene-environment interactions are fragmentary to date. With 
regard to most known genetic factors, interactions with only a few (one or two) 
lifestyle-related factors are consistently studied. Only for a few of those interactions 
enough evidence is provided, so more research is warranted. Firstly, large cross-
sectional studies are needed that will shed more light on those gene-environment 
interactions that have a significant effect on plasma lipid and lipoprotein levels. 
Secondly, intervention studies are needed to evaluate whether the unfavorable 
effects of these gene defects on lipid profiles can indeed be modified through 
changes in lifestyle (for example smoking cessation). Thirdly, studies are needed 
that relate gene-environment interactions to endpoints, such as coronary heart 
disease or myocardial infarction. 
At the time that for specific gene-environment interactions the effects on lipid 
levels and CHD risk are cleaily established, the determination of genotypes may 
become useful to improve prevention and intervention strategies for those 
subgroups in the population that are susceptible to coronary heart disease. At this 
moment there is no basis for population-wide screening. It is highly unlikely that the 
costs will counterbalance the benefits. Moreover, genetic testing is a sensitive issue 
for which there are many ethical barriers, so it should be very carefully used. More 
benefits can be expected from screening subgroups that are CHD-prone, such as 
those with a strong family history or pre-existing disease. It is therefore more likely 
that genotyping becomes useful in clinical practice. Not only it will help to reduce 
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CHD risk by better focusing preventive measures to individual needs, but also by 
establishing the correct diagnosis in a given patient (e.g. apo E genotyping for the 
confirmation of suspected type III hyperlipidemia). Additionally, evidence is emerging 
that a person's response to lipid-lowering therapy may depend on its genotype.262264 
This implies that genotyping might help in providing the most suitable therapy to an 
individual patient. 
So, in the near future the determination of genotypes may become useful in 
clinical practice. However, the main value of knowledge about gene-environment 
interactions in the general population for now and the near future is to provide more 
insight into complex mechanisms that are involved in lipid metabolism. 
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Summary 
Despite the decrease in age-adjusted coronary heart disease (CHD) mortality in 
the Netherlands since the 1970's, there is an increase in the prevalence of CHD. 
Therefore, CHD remains one of the most important public health problems. Many 
lifestyle, biological and genetic factors contribute to the development of CHD. 
Individuals with a family history of CHD have an increased risk for this disorder. 
However, the mechanisms behind the increased risk remain unclear. In particular, 
little is known about genetic factors that may play a role. This thesis (Chapter 2-5) 
describes research into parts of the mechanisms that may underlie the association 
between family history and CHD. 
Besides family history, elevated total cholesterol and triglyceride levels, and 
reduced HDL-cholesterol levels are among the major CHD risk factors. Their levels 
are influenced by genetic and environmental (lifestyle) factors. Although it is 
generally acknowledged that the interaction between these two contributes to inter-
individual variability in plasma lipid levels, little is known about specific gene-
environment interactions. Chapters 6-9 of this thesis describe research into the 
interaction between lifestyle-related factors and several common polymorphisms that 
have been associated with plasma lipid and lipoprotein levels before. 
We investigated the joint impact of a family history of myocardial infarction and 
other cardiovascular risk factors on CHD mortality in a large Dutch cohort study with 
a mean follow-up of 12 years (Chapter 2). Family history increased the risk for CHD 
death in men (RR 1.70, 95%-CI 1.26-2.30) and women (2.31, 1.21-4.41). Body mass 
index (BMI), systolic blood pressure, serum total cholesterol, smoking and physical 
activity could explain only a small part of this association. Women seemed 
somewhat more susceptible to the unfavorable effects of smoking on CHD. The risk 
in female smokers with a family history was higher (RR: 5.6, 2.3-13.7) than expected 
from the additive effects of family history and smoking (2.0). The results did not 
provide much evidence for the hypothesis that individuals with a family history are 
more susceptible to the adverse effect of other risk factors on CHD. Nevertheless, 
special attention for risk factor modification is warranted in individuals with a family 
history, since they had the highest absolute risk for CHD death when other risk 
factors were also present. 
Self-reported data for the definition of parental history of premature myocardial 
infarction (Ml) were used in the study described in Chapter 4. A study was 
conducted to evaluate both the validity and reproducibility of these data (Chapter 3). 
Questionnaires were send to individuals who had earlier provided information about 
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the occurrence of a myocardial infarction in their parents and who were willing to 
participate. These questionnaires were returned by 241 participants (50%). 
Information to validate the parental history data could be obtained from general 
practitioners for 32% of the fathers and 45% of the mothers. For 69% of the 
deceased parents the registration number of the death certificate could be obtained, 
but for only 15% of the deceased parents information from the general practitioner 
was also available. The obtained information was so limited that we did not proceed 
with the validation study. However, information on the reproducibility of parental 
history was available. For both a paternal and maternal history the general 
agreement was 85% or more, while the K-statistics were 0.80 and 0.73, respectively. 
About 75% of the participants were classified into the same parental history group 
(no, one or two parents with a premature Ml) in the original and the reproducibility 
study. A lack of reproducibility led to an underestimation of true associations 
between parental history and coronary risk factors. 
Chapter 4 describes whether lifestyle-related and genetic factors accounted for 
the association between parental history of Ml and lipid traits. Subjects (n=458) were 
selected from a large monitoring project in the Netherlands (the Cardiovascular 
Disease Risk Factor Monitoring Project). We used questionnaires to classify family 
history, physical activity, alcohol consumption and smoking habits. Height and 
weight were measured at a physical examination. Non-fasting blood samples were 
obtained, and used for the determination of lipid traits. DNA was extracted from 
frozen buffy coats for 384 subjects. Subjects who's father, mother or both parents 
suffered from a premature Ml presented with higher apolipoprotein (apo) B levels 
than subjects without a parental history. The E4 isoform of the apo E polymorphism 
was more frequent among subjects with a parental history (14.9% versus 8.3%, 
p<0.05), as was the case for the D9N mutation in lipoprotein lipase (LPL) (5.3% 
versus 0%, p<0.05). A similar trend was found for another LPL mutation (N291S). By 
contrast, other gene polymorphisms, i.e. LPL S447X, and polymorphisms at the 
cholesteryl ester transfer protein (CETP TaqlB) and apo Oil I (Sstl) loci, proved to be 
non-informative. BMI and lifestyle could not explain the association between family 
history and apo B levels. However, the association could be partly explained by the 
adverse effects of the apo E4 isoform and the two LPL mutations (D9N and N291S). 
The association of lifestyle-related factors and the apo E polymorphism with lipid 
profiles reflecting low, average and high risk for CHD was studied in another subset 
of participants in the monitoring project (Chapter 5). Subjects with low total 
cholesterol (<15th percentile) and high HDL-cholesterol levels (>85th percentile) 
were randomly selected (n=99) and represented subjects with a low risk lipid profile. 
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Additionally, 95 subjects with total and HDL-cholesterol levels in the 15% around the 
population-median (median risk lipid profile) and 100 subjects with high total 
cholesterol (>85th percentile) and low HDL-cholesterol levels (<15th percentile) 
(high risk lipid profile) were selected. The results showed that both modifiable factors 
and the apo E polymorphism contributed to the lipid profiles, but the effects were 
gender-specific. Compared with apo E3E3 subjects, the likelihood for a low risk lipid 
profile was considerably higher (odds ratio 14.3; 95%-CI 2.6-79) in female, but not 
(1.5; 0.3-6.7) in male E2-carriers (E2E2 or E2E3 phenotype). Smoking and alcohol 
consumption were independently associated with a low risk lipid profile in both 
genders, physical inactivity only in women. The odds ratio for a high risk lipid profile 
was elevated in male E4-carriers (E4E3 or E4E4 phenotype) only (4.9; 1.1-23). In 
addition to the E4 isoform, smoking and physical inactivity, overweight (BMI > 25 
kg/m2) was the main determinant for a high risk lipid profile. 
The second part of this thesis further addresses the association between genetic 
factors and lipid traits, but focuses on gene-environment interaction. How the apo E 
polymorphism and lifestyle-related factors interact in explaining plasma lipid and 
apolipoprotein levels was studied in two different populations {Chapter 6 & 7). Firstly, 
we studied 1448 young adults (18 to 26 years old) participating in the European 
Atherosclerosis Research Study (EARS) (Chapter 6). Venous blood was collected 
after an overnight fast, while BMI, waist-to-hip ratio (WHR), tobacco and alcohol 
consumption, and physical activity, were determined by using standardized 
protocols. The apo E polymorphism acted in a relatively uniform manner, mostly 
independent of lifestyle. However, correlations of BMI with total cholesterol and apo 
B levels, as well as correlations between WHR and apo B, were significantly 
stronger in E2-carriers than in subjects with other phenotypes. Total cholesterol and 
apo B levels were comparable in E2-carriers in the upper fertile of BMI or WHR to 
those in E3E3 subjects, suggesting that the lowering effect of the E2 allele was no 
longer present. 
We also determined apo E phenotype-specific associations of total and HDL-
cholesterol, apo B and triglyceride levels with other CHD risk factors in the 
population-based sample described in Chapter 4. The results are described in 
Chapter 7. Both apo E2 and apo E4 significantly modulated some of the 
associations. In contrast to the findings in EARS, the positive association of total 
cholesterol and apo B with BMI (and overweight) was absent in E2-carriers. The 
discrepancies may be related to the difference in body composition of young 
(Chapter 6) and adult (Chapter 7) individuals. The association with age in men and 
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with smoking in women was more pronounced in E2-carriers. In E4-carriers, 
associations of BMI with triglycerides in women and of alcohol consumption with lipid 
traits in men were less pronounced than in other phenotypes. These results suggest 
that the apo E polymorphism modulates some of the associations between lipid traits 
and other CHD risk factors. 
In the same sample that was used for the investigations described in Chapter 7, 
we investigated interactions between a mutation in the LPL gene (D9N) and physical 
activity as well as other lifestyle factors (Chapter 8). Four percent of the subjects 
(n=15) carried the LPL D9N mutation. They presented with higher levels of total 
cholesterol, apo B and triglycerides as compared to non-carriers. While no 
interactions with overweight, alcohol consumption and smoking were found, a strong 
interaction between the D9N mutation and physical activity became apparent. 
Physically inactive carriers of the D9N mutation (n=5) had considerably higher total 
cholesterol (+2 mmol/l, p<0.0001) and apo B levels (+63 mg/dl, p<0.0001) compared 
to non-carriers of this mutation, whereas their HDL-cholesterol concentrations were 
lower (-0.22 mmol/l, p<0.05). This was not the case for physically active carriers of 
this mutation (n=10). These results suggest that the D9N in the LPL gene adversely 
affects plasma lipid and lipoprotein profiles, but that the unfavorable consequences 
may be counteracted by physical activity. 
Chapter 9 describes whether associations of two other gene polymorphisms 
(CETP TaqlB and apo Clll Sstl) with lipids and lipoproteins were modulated by 
lifestyle-related factors. Only among moderate alcohol consumers (> 2 glasses/day), 
subjects with the CETP B2B2 genotype presented with higher mean HDL-
cholesterol levels (1.52 mmol/l) compared to subjects with other genotypes (1.31 
mmol/l, p=0.003), suggesting that moderate alcohol consumption strengthens a 
genetic predisposition for high HDL-cholesterol levels. Furthermore, smokers with 
the apo Clll S1S2 genotype had higher levels of triglycerides and apo B (+0.47 
mmol/l and +15.6 mg/dl, respectively, p<0.02) and somewhat lower levels of HDL-
cholesterol, compared to smokers with the S1S1 genotype. This was not observed 
among non-smokers. Smoking may therefore deteriorate the effect of a 
predisposition to unfavorable lipid levels. We did not detect any significant 
interactions with overweight and physical activity. Interestingly, the unfavorable 
effect of the S2 allele was especially observed among subjects whose parents both 
suffered from a premature myocardial infarction. This implies that that the apo Clll 
gene is a modifier gene that mainly affects lipid profiles of individuals susceptible for 
coronary heart disease. 
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It is concluded that individuals with a family history of coronary heart disease are 
at an increased risk for this disorder themselves. However, until now most of the 
increased risk remains unexplained. Only a small part is mediated through known 
CHD risk factors, and total and/or LDL-cholesterol levels appear to be the most 
important among them. The contribution of lifestyle-related (i.e. modifiable) factors to 
higher apo B levels (the main apolipoprotein constituent of LDL) in individuals with a 
family history seems to be small; most of it seems to be genetically determined. The 
apo E polymorphism is probably one of the most important genetic factors involved. 
Furthermore, it seems unlikely that individuals with a family history are more 
susceptible to the adverse effects of other risk factors on CHD. They may, however, 
be somewhat more susceptible to the detrimental effects of smoking. No definite 
conclusions can be drawn, since most of the studies into this hypothesis evaluated 
effect modification on a multiplicative scale, while it is more appropriate to evaluate 
effect modification on an additive scale. Nevertheless, the absolute risk for CHD is 
highest in individuals with both a family history and unfavorable levels of other risk 
factors. The control of risk factor levels is therefore very important in individuals with 
a family history. In guidelines for CHD prevention there is, however, no consensus 
about the definition of a positive family history. Moreover, our knowledge about the 
validity of self-reported family history data is fragmentary. 
A significant part of the increased apo B levels in individuals with a family history 
seems to be genetically determined. Like family history, genotypes can not be 
modified. However, the effect of some polymorphisms clearly depended on the 
environmental background of the subjects. First of all, this implies that interactions 
with environmental (i.e. lifestyle-related) factors should be taken into account in 
genetic association studies. Some of the inconsistencies between studies that 
related gene polymorphisms to plasma lipids and lipoproteins may be explained by 
the fact that gene-environment interaction is usually neglected. Secondly, the 
consequences of a genetic predisposition to unfavorable lipid profiles may be limited 
by the modification of risk factor levels. Notwithstanding this general awareness, our 
insights into specific gene-environment interactions remain fragmentary to date. At 
the time that for specific gene-environment interactions the effects on lipid levels and 
CHD risk are clearly established, the determination of genotypes may become useful 
to improve prevention and intervention strategies for those subgroups in the 
population that are susceptible to CHD. However, the main value of knowledge 
about gene-environment interactions in the general population for now and the near 
future is to provide more insight into complex mechanisms that are involved in lipid 
metabolism. 
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Sinds de jaren zeventig neemt de sterfte aan coronaire hartziekten (kortweg: 
CHZ) in Nederland af. Hoewel minder mensen sterven aan CHZ, komt de 
aandoening steeds vaker voor. CHZ blijven daarom een van de grootste problemen 
voor de volksgezondheid. Vele leefstijl-gerelateerde, biologische en genetische 
factoren bepalen de kans op het ontstaan van CHZ. Personen, waarvan familieleden 
CHZ hebben of hebben gehad (familiegeschiedenis), hebben zelf ook een verhoogd 
risico op CHZ. Welke factoren hiervoor verantwoordelijk zijn, is echter grotendeels 
onbekend. Vooral over de rol van specifieke genetische factoren is weinig bekend. 
Dit proefschrift beschrijft onderzoek naar factoren die mogelijk het verband tussen 
familiegeschiedenis en CHZ kunnen verklaren (Hoofdstuk 2-5). 
Naast familiegeschiedenis zijn verhoogde niveaus van vetten in het bloed 
(cholesterol en triglyceriden) belangrijke risicofactoren voor CHZ. Voor HDL-
cholesterol is het omgekeerde het geval; mensen met hogere niveaus hebben een 
lager risico op CHZ. Genetische en leefstijl-gerelateerde factoren be'i'nvloeden elk de 
niveaus van deze vetten. Bovendien verklaart de interactie tussen deze twee 
factoren (ofwel gen-omgevingsinteractie) een deel van de verschillen in de niveaus 
tussen personen. Ook over specifieke gen-omgevingsinteracties is nog weinig 
bekend. Onderzoek hiernaar is beschreven in de Hoofdstukken 6-9 van dit 
proefschrift. 
In de studie, die in Hoofdstuk 2 is beschreven, werd het risico om te sterven aan 
CHZ bepaald voor mensen met en mensen zonder familiegeschiedenis. Tussen 
1974 en 1980 werden bij meer dan 45000 mannen en vrouwen risicofactoren voor 
CHZ gemeten. Gemiddeld 12 jaar na dit onderzoek werd nagegaan wie in de 
tussentijd aan CHZ was overleden. Zowel mannen als vrouwen met een 
familiegeschiedenis hadden een verhoogd risico om te sterven aan CHZ (1.7-2.3 
keer hoger dan het risico voor personen zonder familiegeschiedenis). Bekende 
factoren, zoals de quetelet index (maat voor relatief lichaamsgewicht), bloeddruk, 
bloed cholesterol, roken en lichamelijke activiteit konden maar een klein deel van het 
verhoogde risico verklaren. Het risico te sterven aan CHZ was het hoogst voor 
personen met een familiegeschiedenis die ook andere risicofactoren hadden. Voor 
vrouwelijke rakers met een familiegeschiedenis was het risico zelfs hoger dan 
verwacht werd op basis van de afzonderlijke effecten van familiegeschiedenis en 
roken. Voor personen met een familiegeschiedenis is het dus extra belangrijk 
risicofactoren voor CHZ tot een minimum te beperken. 
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Gegevens over de familiegeschiedenis zijn door de deelnemers aan onze studies 
zelf gerapporteerd. Het is echter niet waarschijnlijk dat iedereen precies weet of zijn 
familieleden wel of niet een hartinfarct hebben gehad. Daarom is geprobeerd 
gegevens over het optreden van een hartinfarct bij ouders te verifieren via 
huisartsen en doodsoorzaken (Hoofdstuk 3). Voor dit onderzoek werden 
vragenlijsten verzonden aan personen, die al eerder gegevens hadden verstrekt 
over het al dan niet optreden van een hartinfarct bij nun ouders. Voor een beperkt 
aantal mensen konden we informatie over hun ouders via huisartsen vinden. Het 
was voor de huisartsen vooral moeilijk om dossiers te vinden van ouders die 
overleden waren. Ook het nummer van de overlijdensakte was maar voor een deel 
van de overleden ouders (69%) bekend. In totaal was de verkregen informatie zo 
beperkt, dat niet verder is geprobeerd de familiegeschiedenis te verifieren. Wel was 
er informatie om de reproduceerbaarheid van de familiegeschiedenis te bepalen. In 
minstens 85% van de gevallen kwam de status van de vader of moeder, zoals 
gerapporteerd in de vragenlijst overeen met de status die eerder was gerapporteerd. 
In Hoofdstuk 4 wordt beschreven of leefstijl-gerelateerde en genetische factoren 
de relatie tussen familiegeschiedenis en vetten in het bloed konden verklaren. Voor 
dit onderzoek werd een groep personen geselecteerd, die tussen 1987 en 1992 had 
deelgenomen aan het Peilstations-project. Voor dit project waren, met behulp van 
vragenlijsten en een lichamelijk onderzoek, risicofactoren voor CHZ gemeten. Ook 
was een bloedmonster afgenomen en ingevroren, welke later werd gebruikt voor de 
bepaling van vetten in het bloed, te weten: totaal cholesterol, HDL-cholesterol, 
triglyceriden en apo B (als maat voor 'slecht' (LDL) cholesterol). Het genetisch 
materiaal (DNA) werd uit witte bloedcellen gehaald en gebruikt voor het bepalen van 
de genetische code (genotype) van de deelnemers. Dit werd gedaan voor zes 
verschillende genetische factoren, waarvan bekend is dat ze de niveaus van vetten 
in het bloed be'invloeden. Personen van wie een of beide ouders een hartinfarct 
hadden gehad, hadden hogere (en dus ongunstigere) apo B waarden dan personen 
zonder familiegeschiedenis. Twee van de zes genetische factoren kwamen vaker 
voor bij personen met een familiegeschiedenis. Dit waren 'apo E4' en de 
verandering in DNA (mutatie) 'LPL D9N'. Voor de mutatie 'LPL N291S' was de trend 
vergelijkbaar. De drie overige mutaties kwamen in dezelfde mate voor bij personen 
met en personen zonder familiegeschiedenis. De hogere waarden van apo B bij 
personen met een familiegeschiedenis kon niet worden verklaard door verschillen in 
leefstijl-gerelateerde factoren. Wel kon een deel van de hogere waarden verklaard 
worden door de ongunstige effecten van 'apo E4'en de mutaties 'LPL D9N'en 'LPL 
N291S'. 
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In een andere steekproef uit de deelnemers van het Peilstationsproject werd net 
verband tussen vetten in het bloed en leefstijl-gerelateerde factoren alsmede variatie 
in het apo E gen bestudeerd (Hoofdstuk 5). Drie groepen personen werden met 
elkaar vergeleken, namelijk personen met een: 
- gunstig profiel (lage totaal cholesterol en hoge HDL-cholesterol waarden), 
- normaal profiel (gemiddelde totaal en HDL-cholesterol waarden) en 
- ongunstig profiel (hoge totaal cholesterol en lage HDL-cholesterol waarden). 
Zowel leefstijl-gerelateerde factoren als het apo E genotype verschilde tussen de 
groepen. Vrouwen met 'apo E2'hadden vaker een gunstig profiel in vergelijking met 
vrouwen met het 'apo E3E3' genotype (wat het meest voorkomt). Ook verhoogde 
lichamelijke activiteit de kans een gunstig profiel te hebben. Dit was niet het geval 
voor mannen. Zowel mannen als vrouwen die niet rookten en matig alcohol 
gebruikten hadden een hogere kans op een gunstig profiel. 
Een ongunstig profiel kwam vaker voor (4.9 keer) bij mannen met 'apo E4'. Naast 
'apo E4', was overgewicht de belangrijkste determinant van een ongunstig profiel, 
gevolgd door roken en lichamelijke inactiviteit. 
In het tweede deel van dit proefschrift wordt het verband tussen genetische 
factoren en vetten in het bloed verder beschreven, waarbij de nadruk op gen-
omgevingsinteracties is gelegd. 
De interactie tussen het apo E genotype en leefstijl-gerelateerde factoren werd 
bestudeerd in twee verschillende studies (Hoofdstuk 6 & 7). Ten eerste zijn 1448 
jong volwassenen (18-26 jaar oud) bestudeerd, die deelnamen aan een Europese 
studie - EARS genaamd (Hoofdstuk 6). Na een nacht vasten werd een bloedmonster 
afgenomen. De quetelet index, de verhouding tussen de middel- en heupomtrek 
(MHV), tabak en alcohol consumptie en lichamelijke activiteit werden bepaald 
volgens standaard methoden. Het effect van het apo E genotype op niveaus van 
vetten in het bloed was grotendeels onafhankelijk van leefstijl. Mensen met 'apo E2' 
hebben meestal lagere totaal en apo B waarden dan andere personen. Uit de EARS 
studie bleek echter dat verbanden van de quetelet index met totaal cholesterol en 
apo B alsmede verbanden tussen de MHV en apo B sterker waren bij mensen met 
'apo E2' dan bij andere personen. Daardoor was het cholesterol verlagende effect 
van 'apo E2' niet langer aantoonbaar bij personen met een hoge quetelet index of 
een hoge middel-heup verhouding. 
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In de andere studie - waarbij gebruik werd gemaakt van dezelfde gegevens als in 
hoofdstuk 4 - was het positieve verband van de quetelet index (en overgewicht) met 
totaal cholesterol en apo B niet sterker maar juist afwezig in mensen met 'apo E2' 
(Hoofdstuk 7). Het is niet duidelijk waarom de resultaten van deze twee studies zo 
verschillend zijn. Mogelijk speelt het verschil in de lichaamssamenstelling tussen 
jonge mensen (hoofdstuk 6) en volwassen mensen (hoofdstuk 7) hierbij een rol. Of 
overgewicht het effect van 'apo E2' be'fnvloedt is dus nog niet duidelijk. Wei waren 
er in beide studies aanwijzingen dat roken het gunstige effect van 'apo E2' op de 
niveaus van vetten in het bloed zou kunnen verminderen. 
Ook werden interacties tussen de mutatie 'LPL D9N en leefstijl-gerelateerde 
factoren bestudeerd (Hoofdstuk 8). Vijftien deelnemers (4%) hadden de mutatie. Zij 
hadden hogere waarden voor totaal cholesterol, apo B en triglyceriden dan 
personen die deze mutatie niet hadden. Het verband tussen de mutatie en vetten in 
het bloed was verschillend voor personen die aangaven lichamelijk actief te zijn en 
personen waarvoor dit niet het geval was. De 5 personen met de mutatie 'LPL D9N 
die lichamelijk inactief waren hadden aanmerkelijk hogere waarden voor totaal 
cholesterol en apo B dan personen zonder de mutatie. Hun HDL-cholesterol 
waarden waren lager. Dit was niet het geval voor de 10 personen met deze mutatie 
die wel lichamelijk actief waren. Lichamelijke activiteit kan dus mogelijk de 
ongunstige effecten van de mutatie 'LPL D9N teniet doen. Meer onderzoek met 
grotere aantallen is nodig om deze bevindingen te bevestigen. Voor zover bekend is 
dit namelijk het eerste onderzoek dat deze interactie aantoont. 
Hoofdstuk 9 beschrijft of de verbanden van twee andere genetische factoren 
{'CETP TaqlB en 'apo CHI SstF) met vetten in het bloed ook gemoduleerd werden 
door leefstijl-gerelateerde factoren. Alleen bij matige alcohol gebruikers, hadden 
personen met het 'CETP B2B2 genotype hogere HDL-cholesterol waarden dan de 
overige personen. Matig alcohol gebruik zou dus een genetische aanleg voor hoge 
(en dus gunstige) HDL-cholesterol niveaus kunnen versterken. Ander onderzoek 
heeft dit ook aangetoond. 
Rokers met het 'apo CHI S1S2 genotype hadden hogere waarden voor 
triglyceriden en apo B dan rokers met het 'apo CHI S1ST genotype. Dit werd niet 
gevonden bij niet-rokers. Roken zou daarom een genetische aanleg voor ongunstige 
niveaus van vetten in het bloed kunnen verergeren. Interessant was ook dat het 
ongunstige effect van 'apo CHI S1S2' alleen gevonden werd voor personen waarvan 
beide ouders een hartinfarct hadden gehad. Mogelijk be'i'nvloedt variatie in het apo 
Clll gen vooral niveaus van vetten in het bloed van personen die aanleg hebben 
voor CHZ. 
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Het beeld dat uit deze studies ontstaat is als volgt. Personen met een 
familiegeschiedenis voor CHZ hebben een verhoogd risico deze aandoening zelf 
ook te krijgen. Tot op heden blijft dit verhoogde risico onverklaard. Slechts een klein 
deel wordt verklaard door bekende risicofactoren, waarvan totaal en LDL-cholesterol 
de belangrijkste lijken te zijn. De bijdrage van leefstijl-gerelateerde factoren (die dus 
te be'i'nvloeden zijn) aan de hogere (en dus ongunstigere) apo B waarden bij 
personen met een familiegeschiedenis is waarschijnlijk klein; het leeuwendeel lijkt 
genetisch bepaald. Variatie in het 'apo E gen is waarschijnlijk een van de 
belangrijkste genetische factoren. Het moge duidelijk zijn dat het hebben van een 
familiegeschiedenis niet veranderd kan worden. Wei blijkt dat het risico om aan CHZ 
te sterven het hoogst is voor mensen met een familiegeschiedenis die ook nog 
andere risicofactoren hebben. Voor personen met een familiegeschiedenis is het 
dus zeer belangrijk risicofactoren onder controle te hebben. 
Uit ons onderzoek blijkt dat een belangrijk deel van de verhoogde apo B waarden 
bij personen met een familiegeschiedenis blijkt genetisch bepaald is. Net als 
familiegeschiedenis, kunnen genetische codes niet veranderd worden. Het effect 
van sommige genetische factoren blijkt evenwel af te hangen van leefstijl. Het 
bestaan van zulke gen-omgevingsinteracties impliceert dat een genetische aanleg 
voor ongunstige niveaus van vetten in het bloed beperkt kan worden door 
veranderingen in leefstijl. In het algemeen zijn onderzoekers zich hiervan bewust, 
maar tot nu toe zijn de inzichten in specifieke gen-omgevingsinteracties zeer 
beperkt. Tegen de tijd dat voor bepaalde gen-omgevingsinteracties de effecten op 
vetten in het bloed en het risico op CHZ duidelijk gei'dentificeerd zijn, kan het nuttig 
zijn om iemands genotype te bepalen. Preventie en interventie strategieen kunnen 
dan verbeterd worden voor personen die een aanleg hebben voor het ontwikkelen 
van CHZ. Maar zover is het nog niet. Nu en in de nabije toekomst is het inzicht 
verschaffen in de - zeer complexe - stofwisseling van cholesterol en triglyceriden de 
belangrijkste waarde van het bepalen van gen-omgevingsinteracties. 
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